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are trying to comprehend





like pouring water from stairwells.
The source of our behavior,
our thinking,
our entire mind.
A super construction, of which the blueprint we must find
to cure people who forget,
cannot speak,
are paralysed.
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I remember well the image of a real brain during a neurosurgical procedure I attended as a 
medical student. It was pulsating calmly to the rhythm of the heart, yet looking so vulnerable 
as it was exposed when the piece of skull was removed. A little scratch to this soft pink organ 
could have devastating consequences as I learned. I was intrigued by this organ. How could 
it be so powerful, controlling our entire body, yet be so prone to damage? And damage could 
occur in a vast variety of forms: from tumours to vascular damage, to trauma. Moreover, in 
contrast to for example trauma, where it is clear where the damage comes from, we often do 
not know why damage to the brain occurs in the first place. Why do some people develop 
brain tumours? Like my mom, who fortunately recovered. Why do others have extensive 
vessel disease in their brain? Why does the brain shrink so fast in some people? All these 
phenomena have devastating consequences. I fell in love with the brain, with its mystery, its 
complexity and its weaknesses.
The cover of my thesis depicts the grey matter of a normal brain with ‘resting’ microglia 
cells stained with Rio Hortega`s silver carbonate method. Microglia are the guardians that 
react to potential danger to the brain. But the question is, could they also become traitors? 
While my thesis does not specifically focus on microglia, it does attempt to answer this 
question, among others, by viewing inflammation or the immune system as a potential 
mechanism that may cause dementia or stroke.



















The brain is a fascinating and unique organ which orchestrates our entire behaviour. The 
earliest reference to the brain anywhere in human records is in an ancient Egyptian medical 
treatise called the Edwin Smith Surgical Papyrus (Figure 1).1 Since then, our understand-
ing of the brain has come a long way, however many mysteries still remain.2 One of those 
mysteries is the neural basis underlying psychiatric and neurological disease. With an ageing 
population projected to include 152 million people with dementia by 20503, along with the 
rising global burden of disability attributed to stroke4, these two diseases play a key role in 
the worldwide health burden.5
DEMENTIA: SENILE INSANITy
The word dementia derives from the Latin root demens, which means being out of one’s 
mind. The term “dementia” has been used since the 13th century, but its mention in the 
medical community was only reported in the 18th century.6 Dementia was recognized as 
having two types of brain changes. In some of these brains, numerous healed infarcts could 
be seen, which were clearly the result of arteriosclerosis; in the others, the only evident 
change was a generalized atrophy as a consequence of aging.7 Alzheimer wrote his first major 
article in 1899 on the nature of senile insanity or dementia in which he maintained that 
those cases of atrophy without recognizable infarcts also were due to vascular disease, but 
that this involved arterioles rather than arteries, so the infarcts were microscopic.8 By 1906, 
when Alzheimer’s disease (AD) was discovered, Alzheimer had moved to Munich where 
he became the chief of pathology in the lavish new institute of brain research headed by 
Emil Kraepelin, the foremost psychiatrist in the world.9 Kraepelin was an organist, believing 
that all mental disease was due to some alteration of the brain as an organ, opposing the 
Freudian concept of psychoanalysis in which mental disease was due to a conflict between 
the consciousness and subconscious mind.10 Kraepelin lay the foundation of the modern 
classification system for mental disorders, and remarkable similarities remain in the now 
widely used Diagnostic and Statistical Manual of Mental Disorders (DSM), of which the 










As far as 2,500 years ago the term apoplexia has been found in writings, meaning “struck down 
with violence”, describing a disorder in which “a person suddenly falls, without conscious-
ness or motion, retaining pulse or respiration”.11 This characteristic picture was well known 
to the ancient Greeks, and it was Hippocrates who was responsible for the first recorded 
appearance of the term “apoplexy”.12 During The Renaissance, the promotion of human 
dissection allowed society to use autopsy for forensic, health and scientific purposes, paving 
the way for modern medicine.13 During this modern era from the 17th century onwards, 
“apoplexy” began to lose its unitary (umbrella) meaning,14 marking the start of studies on 
vascular diseases of the brain or “cerebrovascular disease(s)”11, after which Cole (1689) first 
used the term “stroke”.15 This term then appeared only much later in the ICD-9 in 1968.16 
The definition of the concept by the World Health Organization (WHO) appeared soon 
after in 1971 and 1980, and more recently, a new definition was proposed by the American 
Heart Association-American Stroke Association (AHA-ASA) in 2013, incorporating clinical 
and tissue criteria.17 Stroke is nowadays widely recognized as the appearance of acute focal 
neurological symptoms or signs that result from diseases involving cerebral blood vessels.18
WHy STUDyINg DEMENTIA AND STROKE?
The etiological similarity between dementia and stroke was already suggested in Alzheimer’s 
first major article on dementia mentioned earlier, describing that those cases of atrophy 
without recognizable infarcts were due to microscopic infarcts8. This idea was further sup-
ported by Walter Alvarez, a gastroenterologist, whose interest in AD was stimulated by the 
presence of this condition in his father-in-law.7 The episodic aggravation of his father-in-law’s 
condition led him to the conclusion that these changes were the results of small episodes 
of brain damage, ultimately known as little strokes.19 Indeed, it is now recognized that all 
major dementias have a vascular component, ranging from 61% in frontotemporal dementia 
to 80% in AD.20 In fact, the presence of a vascular component doubles the probability that 
the neurodegenerative pathology will have manifested as dementia later in life.21 At the same 
time, not all dementias can be prevented by preventing stroke and there are growing genetic, 
transcriptomic and proteomic data pointing to the complexity of AD pathogenesis.22 It is 
thus essential to gain a better understanding of the underlying pathophysiology that may 

















DEMENTIA AND STROKE: AN IMMUNITy AND 
INFLAMMATION PERSPECTIVE
When Alois Alzheimer fi rst described the histopathology of AD, he noted, “Th e glia have 
developed numerous fi bers”.24 It was only in the late 1980s that scientists began to study 
this feature.25 It included the involvement of the immune system in AD, and was shown 
by the attachment of complement proteins to diseased tissue, and by the activation of cells 
associated with the immune system.26,27 Over the last 10 years, this fi eld of research saw 
a steep increase25 after the discovery of AD-associated variants in the triggering receptor 
expressed on myeloid cell 2 (TREM2) gene that is only expressed on immune cells of my-
eloid origin. Further support came from a large-scale genome-wide association study that 
identifi ed multiple additional immune risk factors28, but to date, it is still not clear whether 
immunity and infl ammation in fact lead to AD or become only present in a later stage, 
when the disease already started. In order to shed some light on this issue, chapter 2 explores 
the eff ects of the immune system on the risk of dementia using population-based data. 
Chapter 2.1 considers immune cells in relation to dementia risk. Th ese immune cells consist 
of granulocyte and platelet count as measures of the innate immune system and lymphocyte 
count as measure of the adaptive immune system. In the fi eld of cancer research it has been 
suggested that taking the ratio of these innate and adaptive immune cells results in new 
white blood-cell based infl ammatory indices as markers of low-grade infl ammation.29 Th ese 
are the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR) and 
the systemic immune-infl ammation index (SII), which are thought to better refl ect the rela-











Figure 2. White blood-cell based infl ammatory indices refl ecting the relative balance between the in-
nate and adaptive immune system: Granulocyte-to-lymphocyte ratio (GLR), the platelet-to-lympho-
cyte ratio (PLR) and the systemic immune-infl ammation index (SII).
17
 
To follow-up on the fi ndings of chapter 2.1, I performed a two-sample Mendelian random-
ization study (chapter 2.2) examining immune cells and signaling molecules in relation 
to the risk of AD and hippocampal volume. I further study whether common infectious 
diseases could be a trigger of low-grade infl ammation by studying the relation between 
Helicobacter pylori (chapter 2.3) and Herpes Simplex Virus type 1 (chapter 2.3) in relation 
to the risk of dementia.
Th e immune system is not only a potential determinant for dementia, but also for 
stroke.30 Indeed, studies have shown that gene expression changes in the peripheral blood 
and immune cells of stroke patients can serve as potential diagnostic biomarkers in acute 
stroke.31,32 Moreover, randomized clinical trials have also shown potential for anti-infl am-
matory treatment in reducing cardiovascular risk including stroke.33,34 Chapter 3 therefore 
examines immunity components, the same immune cells and derived ratios as studied in 
chapter 2.1, in relation to stroke. In chapter 3.1, I determine the association between im-
munity components and the risk of atherosclerotic cardiovascular disease, including stroke 
and coronary heart disease. I furthermore relate these immunity components to arterial 
calcifi cations as measures of subclinical atherosclerosis and examine to what extent arterial 
calcifi cations serve as a potential mediator in the relation between immunity components 
and atherosclerotic cardiovascular disease. Finally, in chapter 3.2 I examine immunity 
components with carotid atherosclerotic plaque characteristics to study whether immunity 
components relate to the plaque’s vulnerability to rupture.
BRAIN PATHOLOgy
In addition to immunity and infl ammation being potentially important factors for AD 
and stroke, Alois Alzheimer already reported early on plaques and neurofi brillary tangles, 
after which Kraepelin included AD in his book Pschiatrie.9 To date, amyloid plaques and 
neurofi brillary tangles are still considered the hallmark features of AD (Figure 3).35 Amyloid 
plaques contain toxic peptides known as β-amyloid, while neurofi brillary tangles contain 

















While in AD, extracellular deposits of polymerized β-amyloid peptides create an amyloid 
plaque, β-amyloid deposition can also occur in the vascular walls, which leads to loss of ves-
sel integrity and can result in cerebral amyloid angiopathy, a condition that increases the risk 
for stroke caused by bleeding.36 Chapter 4.1 of this thesis describes how these biomarkers of 
AD-related brain pathology as measured in plasma relate to stroke risk in the general popula-
tion. I furthermore describe the immune system as potential determinant of these markers 
(chapter 4.2) by studying their relation with immune cells. Some of these immune cells, 
the leukocytes, own a nucleus and thus contain DNA from which we can measure telomere 
length.37 As an indicator of oxidative stress and senescence, telomere length is hypothesized 
to be a biomarker of aging.38 In chapter 4.3 I study telomere length as measured from 
leukocytes as another potential biomarker of AD.
Brain hemodynamics
The brain is highly vulnerable to disturbance of its blood supply.18 Therefore, blood flow 
to the central nervous system must efficiently deliver oxygen, glucose, and other nutrients 
and remove carbon dioxide, lactic acid, and other metabolites.39 The major vessels that 
provide the brain of its blood are the carotid arteries and the vertebrobasilar arterial system 
(Figure 4).18 The brain vasculature has special anatomical and physiological properties that 
protect the brain from hypoperfusion. Autoregulation involves the alteration of small vessel 
diameters and is observed in virtually every vascular bed, but it is most pronounced in the 
brain and kidney.39 When this protective mechanism fails, ischemia could occur which may 











Figure 3. A section of a neocortex from a patient with Alzheimer’s disease treated with a silver stain. 
The tissue shows neuronal cell bodies containing neurofibrillary tangles and neuropil containing amy-
loid plaques. Modified from Principles of Neural Science.
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(<24 hours), we refer to this as a transient ischemic attack or TIA. Although most occlusive 
strokes are caused by atherosclerosis and thrombosis, there are also several other causes, 
of which subclinical hypoperfusion remains relatively unknown.40 Chapter 5 of this thesis 
is dedicated to studying measures of brain hemodynamics within the general population. 
First, I describe the association between global brain perfusion and the risk of TIA and 
ischemic stroke (chapter 5.1). In chapter 5.2, I then present thyroid function as a potential 
determinant of brain hemodynamics.
Studying the role of various etiological entities including brain pathology and brain hemo-
dynamics in dementia and stroke provides new opportunities to connect the two diseases. 
Moreover, I show that targeting immunity and infl ammation also point to new directions, 
and sheds new light on pathological and hemodynamical changes that occur in the brain. 
In chapter 6, the fi ndings described in this thesis are therefore refl ected upon from an 
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Chapter 2  
Immunity and dementia





















Background: Immunity has been suggested to be important in the pathogenesis of de-
mentia. However, the contribution of innate versus adaptive immunity in the development 
of dementia is not clear. In this study we aimed to investigate 1) the association between 
components of innate immunity (granulocytes and platelets) and adaptive immunity 
(lymphocytes) with risk of dementia and 2) the association between their derived ratios 
(granulocyte-to-lymphocyte ratio [GLR], platelet-to-lymphocyte ratio [PLR], and systemic 
immune-inflammation index [SII]), reflecting the balance between innate and adaptive im-
munity, with risk of dementia.
Methods: Blood cell counts were measured repeatedly between 2002-2015 in dementia-
free participants of the prospective population-based Rotterdam Study. Participants were 
followed-up for dementia until 1st January 2016. Joint models were used to determine the 
association between granulocyte, platelets, and lymphocyte counts, and their derived ratios 
with risk of dementia. 
Results: Of the 8313 participants (mean [standard deviation] age 61.1 [7.4] years, 56.9% 
women), 664 (8.0%) developed dementia during a median follow-up of 8.6 years. Doubling 
of granulocyte and platelet counts tended to be associated with an increased risk of demen-
tia (HR [95%CI]: 1.22 [0.89-1.67] and 1.45 [1.07-1.95], respectively). Doubling of the 
derived ratios GLR, PLR, and SII were all associated with an increased dementia risk (HR 
[95%CI]: 1.26 [1.03-1.53], 1.27 [1.05-1.53], and 1.15 [0.98-1.34], respectively). 
Conclusions: GLR, PLR, and SII are associated with an increased risk of dementia in the 
general population. This supports the role of an imbalance in the immune system towards 































Dementia poses a huge burden on societies in terms of financial costs as well as on individual 
patients and their caregivers regarding suffering and grief [1]. Dementia is a multifactorial 
disease, in which various pathologies interact during the long pre-clinical phase, ultimately 
resulting in its clinical manifestations of cognitive decline and loss of independence. While 
amyloid depositions, neuronal loss, and vascular damage have long been established as key 
pathologies underlying dementia[2], recent findings point towards a key role for the im-
mune system [3-5]. The immune system is a highly complex system involving multiple syn-
ergistic and antagonistic substrates, yet broadly can be classified into two components, i.e. 
innate immunity and adaptive immunity [6]. Innate immunity refers to immune responses 
present at birth, forming a first line of defence, whereas adaptive immunity is acquired 
during life by exposure to specific antigens [7]. High activity of innate immunity can lead to 
disrupted neuronal integrity, and ultimately in cell death [8]. Although these components 
of the immune system work closely together, adaptive immunity is considered to be more 
neuroprotective than innate immunity, presumably by stimulating phagocytosis of amyloid 
fibrils [9, 10]. 
Exact quantification of these opposing components of the immune system is challenging 
and focus of ongoing research, but recent work from the field of cancer research suggests that 
easily obtainable laboratory measurements may in fact capture their relative activity levels 
to a reliable degree [11]. Measuring granulocytes, including the most abundant subtype 
neutrophils, and platelets provides important markers of the innate immunity, whereas mea-
suring lymphocytes yields information on the adaptive immunity [12, 13]. Furthermore, 
combining these measurements into ratios, i.e. the neutrophil-to-lymphocyte ratio (NLR), 
platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), is 
thought to even better reflect the relative balance between innate and adaptive immunity 
[11, 14-16]. Previous work on the link between innate versus adaptive immunity and de-
mentia showed higher NLR and PLR in dementia patients compared to healthy individuals 
[17-19]. Yet, to really understand the role of the immune system in the risk of developing 
dementia, it is pivotal to study how these markers change during the pre-clinical phase of 
the disease. 
We thus investigated the longitudinal association of markers of the innate versus adap-
tive immune system with the risk of dementia. The underlying hypothesis was that higher 
activity of the innate versus adaptive immune system would be associated with an increased 
risk of dementia. A further methodological novelty of our study was the use of joint model-
ling that enabled us to study the longitudinal evolution of the various markers during the 




















The present study is embedded in the Rotterdam Study, a prospective population-based co-
hort study in Rotterdam, the Netherlands. The Rotterdam Study started in 1990 with 7983 
persons (response of 78%) aged ≥55 years and residing in the district Ommoord, a suburb 
of Rotterdam. This first subcohort (RS-I) was extended with a second subcohort (RS-II) in 
2000, consisting of 3011 persons (response of 67%) and with a third subcohort (RS-III) 
in 2006, composed of 3932 persons aged ≥45 years (response of 65%). The design of the 
Rotterdam Study has been described in detail previously [20]. In brief, participants were 
examined in detail at study entry and at follow-up visits every three to five years. They were 
interviewed at home by a trained research nurse, followed by two visits at the research facility 
for additional interviewing, laboratory assessments, imaging, and physical examinations.
The Rotterdam Study was approved by the Medical Ethics Committee of Erasmus Medi-
cal Center and by the board of The Netherlands Ministry of Health, Welfare, and Sports. A 
written informed consent was obtained from all participants. 
Laboratory tests for granulocytes, platelets, and lymphocytes were introduced from 
2002 onwards, corresponding with the following assessment rounds in the Rotterdam 
Study (baseline in this study): i.e. fourth round of RS-I, second round of RS-II, and first 
round of RS-III, comprising 9994 participants. From these 9994 eligible participants, we 
excluded those without complete baseline blood measurements (n=1288). Of the remaining 
participants, we excluded those with a history of dementia (n=52), participants who were 
insufficiently screened for dementia (n=62), and those without informed consent to assess 
medical records during follow-up (n=39). Lastly, we excluded participants with missing 
apolipoprotein E (APOE) genotype (n=240), resulting in 8313 participants for analysis 
(Flowchart in Figure 1).
Assessment of blood cell counts and their derived ratios
Fasting blood samples were taken during each visit at the research center with a maximum 
of three visits during follow-up. Full blood count measurements were performed using the 
COULTER® Ac·T diff2™ Hematology Analyzer (Beckman Coulter, San Diego, California, 
USA) directly after blood sample drawn. Laboratory measurements included absolute 
granulocyte, platelet, and lymphocyte counts in 109 per liter. Since neutrophil counts were 
not available, we used granulocyte count as a reliable proxy given that these are the most 
abundant subtype of neutrophils [21, 22].
The GLR and PLR were calculated as the ratio of granulocyte count to lymphocyte 
count, and as the ratio of platelet count to lymphocyte count, respectively. The SII was 































Participants were screened for dementia at baseline and subsequent center visits with the 
Mini-Mental State Examination and the Geriatric Mental Schedule organic level [23]. 
Th ose with a Mini-Mental State Examination score <26 or Geriatric Mental Schedule score 
>0 underwent further investigation and informant interview, including the Cambridge 
Examination for Mental Disorders of the Elderly. Th e entire cohort was continuously under 
surveillance for dementia through electronic linkage of the study database with medical 
records from general practitioners and the regional institute for outpatient mental health 
care. Available information on clinical neuroimaging was used when required for diag-
nosis of dementia subtype. A consensus panel led by a consultant neurologist established 
the fi nal diagnosis according to standard criteria for dementia (Diagnostic and Statistical 
Manual of Mental Disorders III-revised), Alzheimer’s disease (AD, National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association), and vascular dementia (National Institute of Neurological 
Disorders and Stroke and Association Internationale pour la Recherché et l’Enseignement en 





Figure 1 Flowchart participants for analysis association between blood cell counts and their derived ratios, 
and dementia.



















We assessed education and smoking by interview. Education level was classified into pri-
mary education, lower (lower general education, intermediate general education, or lower 
vocational education), intermediate (intermediate vocational education or higher general 
education), or higher (higher vocational education or university). Smoking status was cat-
egorized as never, former, or current smoker. Body mass index (BMI) was computed from 
measurements of height and weight (kg/m2). Diabetes mellitus was defined as use of antidia-
betic medication, fasting serum glucose level ≥7.1 mmol/L, or random serum glucose level 
≥11.1 mmol/L [24]. History of stroke was assessed by interview and verified by reviewing 
medical records [25]. APOE genotype was determined using polymerase chain reaction on 
coded DNA samples in RS-I and with a bi-allelic TaqMan assay in the two extensions (RS-II 
and RS-III) [26, 27]. APOE-ε4 carrier status was defined as carrier of one or two APOE-ε4 
alleles.
Statistical analysis
We associated the different blood cell counts and their derived ratios with the risk of all-cause 
dementia using the framework of joint models for longitudinal and survival data. In this way 
we are able to account for the endogenous nature (i.e. blood cell counts can be measured 
with error during follow-up and their values at any time point can be affected by an event 
occurring at an earlier time point) [28] and the correlations in the repeated measurements of 
granulocyte, platelet, and lymphocyte counts [29]. 
In order to normalize the skewed distribution of granulocyte, platelet, and lymphocyte 
counts, and their derived ratios we used a natural logarithmic transformation. Hazard ratios 
(HRs) with 95% confidence intervals (CIs) were obtained from the joint models using the 
piecewise-constant baseline hazard, and multiplied with log(2), providing a HR for dou-
bling of the blood cell counts and their ratios. We computed two nested models: Model I 
was adjusted for baseline age (continuous, centered as age minus mean age) and sex; Model 
II was additionally adjusted for education, smoking status, BMI (continuous), diabetes 
mellitus, history of stroke, and APOE-ε4 carrier status. For assessment of the association 
between the individual components of the ratios and dementia, we repeated analyses with 
adjustment for the baseline blood cell counts of the remaining two blood cell types (for 
instance, the association of granulocyte count with dementia was adjusted for platelet and 
lymphocyte counts). Follow-up time was used as timescale and started at the first laboratory 
assessment until date of all-cause dementia diagnosis, death, loss to follow-up, or 1st January 
2016, whichever came first. Censoring participants at date of death allowed us to compute 
cause-specific HRs.
In sensitivity analyses, we repeated all analyses using age as timescale instead of follow-up 
time to account for potential residual confounding by age and to minimize potential effects 






























that the observed effect may be driven by incident strokes that occurred before dementia 
diagnosis. Moreover, we investigated the association between the ratios and AD or vascular 
dementia separately. Lastly, we explored effect modification by stratifying by median age, 
sex, smoking status, diabetes mellitus, and APOE-ε4 carrier status. 
Multiple imputation was used for missing covariates (maximum of 0.99%), with five 
imputed datasets based on other covariates and the outcome. Rubin’s method was used for 
pooled HRs and 95% CIs [30]. Two-sided P <.05 was considered statistically significant. 
Statistical analyses were performed using the R packages ‘survival’, ‘nlme’, ‘JM’, and ‘JM-
bayes’ in RStudio Version 3.3.2 [28, 29, 31, 32].
RESULTS
Characteristics of included and excluded study participants are presented in Table 1. An 
overview of the median blood cell counts and blood cell-based ratios per assessment round 
is shown in Supplementary Table 1. Mean age of included study participants was 61.1 years 
and 56.9% were women. During a median follow-up of 8.6 years (70273 person-years), 
664 participants developed all-cause dementia (543 AD, 31 vascular dementia) with an 
incidence rate of 9.4 (95% CI, 8.7-10.2) per 1000 person-years. 
Higher levels of granulocytes reflecting higher innate immunity were associated with an 
increased risk of dementia, but only after correcting for the platelet and lymphocyte counts 
(HR for doubling granulocyte count [95% CI] = 1.33 [0.99-1.79], Table 2). Doubling of 
platelets was associated with an increased risk of dementia (HR [95% CI] = 1.48 [1.11-
1.96]). Regarding adaptive immunity, higher levels of lymphocytes were associated with a 
decreased risk of dementia (HR for doubling lymphocyte count [95% CI] = 0.80 [0.64-
0.99]).
Higher levels of GLR, PLR, and SII were associated with an increased dementia risk 
(HR [95% CI] for doubling GLR = 1.34 [1.10-1.63]; for PLR = 1.29 [1.08-1.55]; for SII 
= 1.18 [1.02-1.39], respectively [Table 2]). Risk estimates were comparable when using the 
adjusted model and when using age as timescale instead of follow-up time. 
Censoring for stroke did not meaningfully change the risk estimates (Table 3). Higher 
levels of platelets showed a slightly stronger association with AD compared with all-cause 
dementia, whilst the association with granulocytes was less pronounced for AD. Risk esti-
mates for all-cause dementia and AD were comparable for the ratios. For vascular dementia, 
risk estimates regarding the individual blood cell components and their derived ratios were 
































Age, year, mean (SD) 61.1 (7.4) 72.6 (11.8) 61.7 (8.2)
Women 4729 (56.9) 845 (65.6) 160 (66.7)
Education
Primary 908 (11.0) 233 (18.4) 25 (11.7)
Lower 3329 (40.3) 537 (42.4) 95 (44.4)
Intermediate 2429 (29.4) 336 (26.5) 57 (26.7)
Higher 1588 (19.2) 161 (12.7) 37 (17.3)
Body mass index, kg/m2, mean (SD) 27.6 (4.3) 27.6 (4.5) 28.2 (4.8)
Smoking status
Current 1595 (19.3) 308 (24.4) 57 (24.5)
Former 4191 (50.7) 550 (43.6) 106 (45.5)
Diabetes mellitus 501 (6.0) 136 (10.7) 15 (6.3)
History of stroke 305 (3.7) 54 (4.2) 11 (4.6)
APOE-ε4 carrier status 2328 (28.0) 244 (30.8)
Blood cell types, 109/L, median (IQR)
granulocytes 3.8 (1.6) 4.0 (1.7)
Platelets 263 (84) 277 (87)
Lymphocytes 2.2 (0.8) 2.3 (0.9)
Blood cell-based ratios, median (IQR)
granulocyte-to-lymphocyte ratio 1.7 (0.9) 1.7 (0.8)
Platelet-to-lymphocyte ratio 120 (55) 119 (54)
Systemic immune-inflammation 
index
455 (280) 473 (312)
Abbreviations: APOE, apolipoprotein E; IQR, interquartile ratio; N = number of participants; SD, 
standard deviation.
Values are shown before multiple imputation and therefore not always add up to 100%.
Data are presented as number (percentage) of participants unless otherwise indicated. 
# Excluded participants in this table only include those participants who were excluded due no com-






























Stratified analyses showed that the association between the ratios and dementia was par-
ticularly pronounced in participants aged below the median age of 65.4 years, women, 
and non-smokers (Figure 2). However, formal interaction terms did not reach statistical 
significance. Also, no significant effect modification was observed across different strata of 
these variables for the association between granulocyte, platelet, and lymphocyte counts, and 
risk of dementia (Figure 3).




Model I Model II
  HR (95% CI) HR (95% CI)
granulocytes 1.14 (0.87-1.50) 1.07 (0.80-1.43)
Corrected for platelets and lymphocytes 1.33 (0.99-1.79) 1.22 (0.89-1.67)
Platelets 1.48 (1.11-1.96)* 1.43 (1.08-1.90)*
Corrected for granulocytes and lymphocytes 1.48 (1.10-2.00)* 1.45 (1.07-1.95)*
Lymphocytes 0.80 (0.64-0.99)* 0.81 (0.64-1.03)
Corrected for granulocytes and platelets 0.76 (0.61-0.96)* 0.78 (0.62-1.00)
granulocyte-to-lymphocyte ratio 1.34 (1.10-1.63)* 1.26 (1.03-1.53)*
Platelet-to-lymphocyte ratio 1.29 (1.08-1.55)* 1.27 (1.05-1.53)*
Systemic immune-inflammation index 1.18 (1.02-1.39)* 1.15 (0.98-1.34)
Abbreviations: CI = confidence interval; HR = hazard ratio; n = number of incident dementia events; 
N = number of participants for analysis. Model I is adjusted for age and sex. Model II is adjusted for 
age, sex, education, smoking status, body mass index, diabetes mellitus, history of stroke, and APOE4 
ε4 carrier status.
# All types of blood cells and their derived ratios were natural logarithmic transformed.




























  HR (95% CI) HR (95% CI) HR (95% CI)
granulocytes 1.13 (0.83-1.56) 1.03 (0.75-1.42) 1.99 (0.52-7.55)
Corrected for platelets and 
lymphocytes
1.36 (0.96-1.93) 1.12 (0.79-1.58) 1.92 (0.44-8.41)
Platelets 1.45 (1.07-1.96)* 1.59 (1.17-2.17)* 3.86 (1.02-14.6)*
Corrected for granulocytes 
and lymphocytes
1.47 (1.07-2.02)* 1.63 (1.18-2.27)* 3.39 (0.84-13.7)
Lymphocytes 0.80 (0.62-1.02) 0.85 (0.66-1.10) 0.76 (0.25-2.30)
Corrected for granulocytes 
and platelets
0.76 (0.58-0.98)* 0.81 (0.62-1.06) 0.64 (0.20-2.03)
granulocyte-to-lymphocyte 
ratio
1.33 (1.07-1.65)* 1.17 (0.95-1.46) 1.85 (0.74-4.62)
Platelet-to-lymphocyte 
ratio
1.31 (1.07-1.60)* 1.30 (1.06-1.60)* 1.99 (0.82-4.81)
Systemic immune-
inflammation index
1.19 (1.01-1.41)* 1.15 (0.97-1.37) 1.77 (0.87-3.63)
Abbreviations: CI = confidence interval; HR = hazard ratio; n = number of incident dementia events; 
N = number of participants for analysis. Models are adjusted for age, sex, education, smoking status, 
body mass index, diabetes mellitus, history of stroke, and APOE4 ε4 carrier status.
# All types of blood cells and their derived ratios were natural logarithmic transformed.
† Number of participants for analysis is 8313 minus participants with a history of stroke (n=305). 































Figure 2 Forest plots of the association of the GLR, PLR, and SII, and risk of dementia. Hazard ratios are 
shown in logarithmic scale with stratification by median age, sex, smoking status, diabetes mellitus, 
and APOE-ε4 carrier status. 




Figure 3 Forest plots of the association of  granulocytes, platelets, and lymphocytes, and the risk of dementia. 
Hazard ratios are shown in logarithmic scale with stratification by median age, sex, smoking status, 
diabetes mellitus, and APOE-ε4 carrier status. Abbreviations: APOE, apolipoprotein E; n = number of 



















In this population-based study, we found that higher levels of granulocyte and platelet 
counts are related to an increased risk of dementia, whereas a higher lymphocyte count is 
associated with a decreased dementia risk. Furthermore, higher levels of their derived ratios, 
i.e. GLR, PLR, and SII are associated with an increased risk of all-cause dementia, including 
its subtype AD and even more with vascular dementia.
Activation of the immune systems can result in inflammation by production of different 
cytokines [33]. These cytokines can act as a link between the innate and the adaptive im-
mune system, having pro- or anti-inflammatory effects depending on the type of cytokine 
[34]. A recent meta-analysis of 175 studies suggests that AD is accompanied by an inflam-
matory response and that this can be reflected by a variety of systemic cytokines, for instance 
interferon-γ, interleukin(IL)-2, and in particular IL-6, of which dysregulation has been 
associated with multiple chronic inflammatory diseases [35, 36]. It is now recognized that 
systemic inflammation can trigger or exacerbate the inflammatory environment of the brain, 
thereby contributing to chronic neuroinflammation and neurodegeneration [37]. A plau-
sible explanation for the occurrence of this chronic neuroinflammation in (pre)demented 
individuals involves a disruption of a process called resolution [38]. Resolution is an active 
process that halts the acute phase of inflammation and restores tissue homeostasis. The acute 
inflammatory phase is usually initiated in response to infection, neoplasia, tissue injury, or 
other major homeostatic stressors. This phase is accompanied by the increased release of pro-
inflammatory mediators such as prostaglandins, leading to leukocyte recruitment. Normally, 
resolution would clear the recruited granulocytes [39]. However, it has been shown that 
failure of resolution, induced by any chronic inflammatory state, is associated with an over-
active innate immune system, resulting in the development of chronic inflammation, which 
could subsequently lead to AD [38, 40, 41]. Our finding that an increase in the granulocyte 
count, resulting in a higher GLR and SII, is associated with an increased risk of dementia 
could therefore support the role of insufficient resolution in the pathogenesis of dementia.
Only few studies examined the interplay between the innate and adaptive immunity 
by studying levels of these blood cell-based ratios in dementia patients. Two cross-sectional 
studies showed that NLR and PLR were elevated in AD patients compared to dementia-free 
controls [17, 18]. In contrast, a longitudinal study assessing the trajectory of NLR found no 
significant difference in its longitudinal evolution between AD patients and dementia-free 
participants [19]. Although they examined differences between AD patients and dementia-
free controls, they did not investigate the risk of developing dementia in dementia-free 
participants in relation to their levels of NLR. In the present study, we did take the time 
until dementia into account by a joint modelling approach and were therefore able to assess 






























Interestingly, recent evidence shows that the NLR and PLR are partly genetically 
determined with 36% estimated heritability for NLR and 64% for PLR in a healthy popula-
tion [42]. Moreover, different single nucleotide polymorphisms (SNPs) identified through 
genome-wide association study (GWAS) were significantly related to the PLR phenotype, 
but not to NLR [43]. Importantly, some but not all of these SNPs were also related to 
platelet, indicating that these SNPs capture the interplay between platelets and lymphocytes. 
Thus far no GWAS for SII has been performed. Exploring the dementia risk by genetically 
predicted blood cell-based ratios may provide more insight in the causal role of immunity 
in dementia. 
Strengths of our study include the population-based setting and the thorough follow-up 
for dementia. Another strength is the prospective design of this study, with the blood cell 
counts being measured at multiple time points. Using an innovative statistical method, we 
combined these repeated measurements with dementia as survival outcome. Moreover, we 
used blood cell counts and their derived ratios, which low-cost and easy to implement in 
the clinic and other research settings. Although these ratios are proven to be associated with 
chronic systemic inflammation, we need to emphasize that it is unknown whether higher 
levels of GLR, PLR, and SII are functional and cause higher levels of pro-inflammatory 
cytokines. To identify the actual involved immune cell populations determination of dif-
ferent cytokines is still needed. Furthermore, the innate and adaptive immune systems are 
overlapping, making it difficult to completely distinguish their separate effects. In addition, 
we used the granulocyte count as proxy for the neutrophil count. Although the relative pro-
portion of neutrophils compared to eosinophils and basophils may be lower in persons with 
several specific diseases such as parasitic infections, asthma, or immune diseases, neutrophils 
are generally the most important subtype of granulocytes. If anything, misclassification of 
the granulocytes would be non-differential and would therefore lead to underestimation of 
the estimates [11]. In addition, we cannot rule out reversed causality, i.e. that dementia is 
subclinical at time of the laboratory assessments and causes higher levels of GLR, PLR, and 
SII. Lastly, we did not have the power to study other neurodegenerative diseases beyond 
dementia such as Parkinson’s disease or amyotrophic lateral sclerosis. It would be interesting 
for future studies to also investigate the relation between inflammation and these diseases.
In conclusion, higher levels of the ratios GLR, PLR, and SII are associated with an 
increased risk of developing dementia in the general population. Higher activation of the 
innate immune system reflected by higher levels of granulocytes and platelets, is associated 
with an increased dementia risk, while the adaptive immune system is suggested to be more 
neuroprotective. These findings support the role of dysregulation of the immune systems in 
the pathogenesis of dementia. Further studies are warranted to assess during which phase 
of the pathogenesis of dementia immunity is involved and to assess causality in order to 
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Supplementary Table 1 Overview of median blood cell counts and blood cell-based ratios measured 














Blood cell types, 109/L, median (IQR)
granulocytes 3.8 (1.6) 4.0 (1.6) 3.6 (1.5)
Platelets 263 (84) 262 (83) 224 (75)
Lymphocytes 2.2 (0.8) 2.2 (0.8) 1.9 (0.9)
Blood cell-based ratios, median (IQR)
granulocyte-to-lymphocyte ratio 1.7 (0.9) 1.8 (0.9) 1.9 (1.1)
Platelet-to-lymphocyte ratio 120 (55) 116 (53) 117 (59.1)
Systemic immune-inflammation index 455 (280) 461 (283) 421 (290)
Abbreviations: IQR, interquartile ratio; N = number of participants; RS = Rotterdam Study.
# The first measurement corresponds with the fourth round of RS-I, second round of RS-II, and first 
round of RS-III.
† The second measurement corresponds with the fifth round of RS-I, third round of RS-II, and second 
round of RS-III.





















Background: Helicobacter pylori infection might increase risk of dementia, but available 
evidence is inconsistent and longitudinal studies are sparse. We investigated the association 
between H. pylori serology and dementia risk in a population-based cohort.
Methods: Between 1997-2002, we measured H. pylori serum IgG titers in 4215 non-
demented participants of the Rotterdam Study with a mean age of 69 years. We determined 
the association between H. pylori at baseline and dementia incidence until 2015, per natural 
log(U/mL) increase in titer, and for seropositive/seronegative, using Cox models adjusting 
for cohort, sex, age, education and cardiovascular risk factors.
Results: During a median follow-up of 13.3 years, 529 participants developed dementia of 
whom 463 had Alzheimer’s disease (AD). H. pylori was not associated with risk of dementia 
(hazard ratio [95% confidence interval] for antibody titer: 1.04 [0.90-1.21]; for seropositiv-
ity 1.03 [0.86-1.22]), nor AD.
















Helicobacter pylori (H. pylori) is a gram-negative bacillus that colonizes the stomach and is 
estimated to infect half of the world’s population [1]. The bacterium is generally acquired 
during childhood by oral ingestion. In adults, the infection is usually chronic and will not 
heal without specific therapy. The clinical course, however, is highly variable. While in some 
individuals infections remain asymptomatic, others may develop serious gastric complica-
tions, such as ulcers or gastric carcinoma [2].
In addition, recent evidence suggests that H. pylori infection might be associated with 
extra-gastric diseases including dementia [3-5]. This may be due to detrimental consequences 
of H. pylori associated anemia, inflammation and hyperhomocysteinemia on vascular and 
neuronal health [6, 7]. A recent systematic review and meta-analysis [8] showed a 71% 
increased risk of dementia with H. pylori infection, but heterogeneity across studies was 
high. This may relate to differences in (geographical) setting and study design, with current 
evidence mainly arising from cross-sectional studies. We aimed to investigate the association 
of H. pylori with dementia in a prospective population-based cohort study.
METHODS
Design and study population
This study was embedded within the Rotterdam Study, a prospective population-based 
cohort study among middle-aged and elderly individuals in the Netherlands [9]. A detailed 
description is provided in the online supplement. Established in 1990, participants were 
invited every 4-5 years to undergo follow-up examinations at the research center. Between 
1997 and 2002, a total of 7444 participants from two subcohorts visited the research center, 
of whom 4215 dementia-free subjects provided blood samples for measurement of H. pylori 
titer (Figure S1).
The Rotterdam Study has been approved by the medical ethics committee according to 
the Population Study Act Rotterdam Study and written informed consent was obtained.
Assessment of anti-H. pylori antibodies
Blood was drawn at baseline. To obtain serum and plasma, tubes were centrifuged according 
to a protocol standardising time and conditions from the drawing of blood to centrifugation. 
All samples were snap frozen at −196°C using liquid nitrogen and stored at −80°C. Anti–H. 
pylori serum IgG antibody titers were measured in 2011 using commercial enzyme immuno-
assays (Pyloriset EIA-G III ELISA; Orion) as described earlier [10]. We used anti-H. pylori 


















defined as an anti–H. pylori IgG titer equal to or greater than 20 U/mL, according to the 
manufacturer’s recommendation.
Ascertainment of incident dementia
Participants were screened for dementia at baseline and subsequent center visits with the 
Mini-Mental State Examination and the Geriatric Mental Schedule organic level. Those 
with a Mini-Mental State Examination score <26 or Geriatric Mental Schedule score >0 
underwent further investigation and informant interview, including the Cambridge Exami-
nation for Mental Disorders of the Elderly. In addition, the entire cohort was continuously 
under surveillance for dementia through electronic linkage of the study center with medical 
records from general practitioners and the regional institute for outpatient mental health 
care. A consensus panel headed by a consultant neurologist established the final diagnosis 
according to standard criteria for dementia (DSM-III-R) and AD (National Institute of 
Neurological and Communicative Disorders and Stroke– Alzheimer’s Disease and Related 
Disorders Association). Follow-up until 1st January 2015, was virtually complete (99.1% 
of potential person-years in the original cohort and for 97.0% of potential person-years in 
the extended cohort). Within this period, participants were censored at date of dementia 
diagnosis, death, loss to follow-up, or administrative censoring date, whichever came first.
Covariates
Potential confounding factors for dementia were chosen on the basis of previous literature 
[8, 11]. In all models, we adjusted for cohort, sex and age at baseline. In multivariate ad-
justed models, we additionally adjusted for education, smoking, systolic and diastolic blood 
pressure, anti-hypertensive drug use, body mass index (BMI), cholesterol, high-density 
lipoprotein (HDL) cholesterol, triglycerides, APOEε carrier status, stroke, diabetes mellitus, 
ethnicity and serum lipid reducing agents at baseline. APOEε carrier status was corrected 
for since a study has shown that H. pylori and ApoE 4 polymorphism may be associated 
with dysphagic symptoms in older adults [12]. Assessment methods of the covariates are 
described in the supplemental materials. Blood samples for determination of levels of hemo-
globin, homocysteine, CRP, interleukin-6, α1-antitrypsin (α1-AT), lipoprotein-associated 
phospholipase A2 activity and fibrinogen were obtained at the research center.
Statistical analysis
Because of a skewed distribution of anti-H. pylori serum IgG antibody titers, we performed 
a natural log transformation. Differences in baseline characteristics between the H. pylori 
positive and negative groups were assessed using Student’s t-test and chi-squared test. We 
determined the association between H. pylori (continuously as well as dichotomized for 














study cohort, education and cardiovascular risk factors. The proportional hazards assump-
tion was met.
We repeated analysis for Alzheimer’s disease only and used higher cut-offs for serop-
revalence (in steps of 5 U/mL from the manufacturer’s recommended cut-off) to explore 
differential effects among individuals with more profound antibody response. We assessed 
interaction by age, sex or medication use by stratification and testing for multiplicative 
interaction. In addition, we tested for multiplicative interaction between H. pylori titer and 
CRP to assess if there is a difference in dementia risk between more severe infected and 
less severely infected groups. Finally, we computed Pearson correlation coefficients for the 
association of H. pylori titer with levels of hemoglobin, homocysteine and CRP, with homo-
cysteine and CRP both natural log transformed. In addition to CRP, which was available 
for all participants, we also determined the correlation between H. pylori and four other 
inflammatory biomarkers that have previously been related to dementia risk [13], and were 
available in a subsample of approximately 500 participants with H. pylori measurement.
All analyses were performed using IBM SPSS Statistics version 21.0 (IBM Corp., Ar-
monk, NY).
RESULTS
Baseline characteristics of the study population are presented in Table 1. During a mean 
follow-up of 10.6 (±4.5) years and median follow-up of 13.3 years (interquartile range of 
5.9) with 47,664 person-years, 529 individuals were diagnosed with dementia of whom 463 
had AD.
Serum antibody titer of H. pylori was not associated with risk of dementia (hazard ratio 
(HR), 95% confidence interval (CI), per log unit increase: 1.04, 0.90-1.21). Similarly, H. 
pylori seroprevalence was not associated with dementia risk (HR 1.03, 0.86-1.22). These 
results were similar for AD (Table 2) and robust for different antibody titer cut-offs defining 
seroprevalence (Online supplement Figure S2). Risk estimates tended to be higher in older 
participants and in men, albeit interaction terms were not statistically significant (p = 0.383 
and p = 0.142, respectively; Figure S3). We observed no significant interaction between 
H. pylori serum IgG titer or use of antibiotics and anti-acids on dementia risk (p = 0.449) 
(Figure S3), nor with CRP (p = 0.974). Antibody titers of H. pylori showed only very weak 
correlation with concurrent levels of hemoglobin, homocysteine and CRP (r = 0.004 and p 
= 0.835, r = 0.086 and p < 0.01 and r = 0.053 and p = 0.001, respectively). Finally, interleu-
kin-6 (IL6), α1-AT, lipoprotein-associated phospholipase A2 activity and fibrinogen showed 
no meaningful correlations with H pylori (r = 0.039 for IL6; r = 0.080 for α1-AT; r = -0.067 


















Table 1. Baseline characteristics of the Rotterdam Study cohort
Study popula-











Age, years 68.4 (8.6) 66.4 (7.5) 65.1 (7.4) <0.001
Female 2288 (54.3) 1093 (52.3) 1195 (56.2) 0.012
Caucasian ethnicity 4140 (98.2) 2056 (98.5) 2081 (97.8) 0.161
Education <0.001




944 (45.2) 928 (43.6)
Intermediate vocational education 1244 (29.5) 602 (28.8) 642 (30.2)
Higher vocational education 561 (13.3) 217 (10.4) 342 (16.1)
Smoking 0.006
Never smoker 1335 (31.7) 615 (29.5) 719 (33.8)
Former, now non-smoker 2130 (50.5) 1077 (51.6) 1051 (49.4)
Current smoker 759 (17.8) 396 (19.0) 357 (16.8)
Systolic blood pressure, mm Hg 143.4 (21.2) 143.8 (21.2) 143.1 (21.2) 0.284
Diastolic blood pressure, mm Hg 76.9 (11.2) 76.6 (11.3) 77.1 (11.1) 0.117
Anti-hypertensive medication 1488 (35.3) 757 (36.3) 728 (34.2) 0.178
Body mass index, kg/m2 27.0 (3.9) 27.0 (3.8) 27.0 (4.0) 0.495
Diabetes mellitus 579 (13.7) 276 (13.2) 304 (14.3) 0.333
Cholesterol, mmol/L 5.8 (1.0) 5.8 (1.0) 5.8 (1.0) 0.939
High-density lipoprotein, mmol/L 1.4 (0.4) 1.3 (0.4) 1.4 (0.4) <0.001
Triglycerides, mmol/L 1.6 (0.8) 1.6 (0.8) 1.6 (0.8) 0.537
Lipid lowering medication 572 (13.6) 291 (13.9) 288 (13.5) 0.742
History of stroke 163 (3.9) 85 (4.1) 78 (3.7) 0.549
Apolipoprotein E genotype 0.701
ε3 homozygote 2478 (58.8) 1218 (58.3) 1264 (59.4)
ε2/ε2 or ε2/ε3 587 (13.9) 299 (14.3) 288 (13.5)
ε4/ε4, ε3/ε4 or ε2/ε4 1149 (27.3) 571 (27.3) 575 (27.0)









H. pylori positive seroprevalence 2088 (49.5)
Abbreviations: N = number of subjects; H. pylori = Helicobacter pylori.
Data presented as mean (standard deviation) for continuous variables and number (percentages) for 
categorical variables. H. pylori serum IgG antibody titers is presented as median (interquartile range).
Differences in baseline characteristics between the H. pylori positive and negative groups were assessed 















In this prospective cohort study, we found no association between H. pylori infection and 
risk of all-cause dementia or AD.
There are only two other longitudinal studies performed on this association, which show 
a hazard ratio of 1.46 (CI 1.01-2.11) [14] and 1.51 (CI 1.25-1.82) [15] for developing 
dementia. These findings are in contrast with our results, but several potential explana-
tions, including methodological differences, may clarify this contrast. For instance, the 
community-based PAQUID cohort study performed in France [14] had an older study 
population (65 years and older) compared with our cohort of 55 years and over. Since 
we show a tendency for an increased risk in older age groups (Figure S3), an older cohort 
may indeed show an effect of H. pylori on dementia. Also, the PAQUID cohort selected 
their study sample on being followed-up for 20 years, thereby selecting the survivors, which 
is more susceptible to selection bias. The other longitudinal study is a Taiwanese registry 
study [15] using medical information from a nationwide population-based dataset. The 
study population was aged ≥40 years and followed during 1998–2010. In this retrospective 
cohort study, dementia diagnosis was therefore based on registries instead of multiple-stage 
designs with in-person screening for dementia diagnosis, making dementia diagnosis less 
reliable. In addition, results are prone to confounding due to the inherent shortcomings 
of the NHRI database. Also, participants with newly diagnosed H. pylori were identified 
with ICD-9 codes, potentially including the symptomatic H. pylori cases which may be 








H. pylori serum Igg, per log(U/mL)* increase 1.07, 0.92-1.23 1.11, 0.94-1.30
H. pylori seroprevalence, positive versus negative 1.03, 0.87-1.23 1.08, 0.89-1.31
Model II
H. pylori serum Igg, per log(U/mL)* increase 1.04, 0.90-1.21 1.06, 0.90-1.25
H. pylori seroprevalence, positive versus negative 1.03, 0.86-1.22 1.06, 0.87-1.29
Abbreviations: n = number of cases; N = number of persons at risk; HR = hazard ratio; CI = confidence 
interval; H. pylori = Helicobacter pylori.
Cox regression model I: Adjusted for age, sex and study cohort.
Cox regression model II: Adjusted for age, sex, study cohort, education, smoking, systolic and diastolic 
blood pressure, anti-hypertensive drug use, body mass index (BMI), cholesterol, high-density lipopro-
tein (HDL) cholesterol, triglycerides, APOEε carrier status, stroke, diabetes mellitus, ethnicity and 
serum lipid reducing agents.


















more virulent and thereby observing a stronger effect of H. pylori on dementia risk in the 
overall population.There are also potential biological explanations for the differences across 
studies, such as geographical differences. Studies have found that the rate of colonization 
with cagA(+) H. pylori strains has become very low in the Netherlands [16, 17]. CagA is a 
highly antigenic protein that is associated with a prominent inflammatory response [18]. 
This finding suggests that the H. pylori infections in the Netherlands may have low virulence 
in general compared with other countries, leading to less complications. For example, in 
studies comparing dyspeptic patients, studies indeed report higher prevalence rates of cagA+ 
strains in France (88%) [19] and Taiwan (99%) [20] compared to 78% in The Netherlands 
in 1996 [21] with a Dutch study from 2013 showing a sharp age specific decline in CagA+ 
from 38% to 14% in randomly selected blood donors [17]. This might be reflected in the 
higher risk estimates in older participants in our study, who would have been exposed more 
to these highly virulent strains in earlier years, suggesting a cohort effect. Thus, infection-
induced cognitive decline can be supported by this finding.
Mechanistically wise, there are several hypotheses regarding the H. pylori and dementia 
association. Prior studies have suggested altered tau phosphorylation [18], vitamin B defi-
ciency (and consequent hyperhomocysteinemia) [7, 22], systemic inflammation [23, 24], 
and anemia [25] as potential mechanisms by which H. pylori could increase risk of dementia. 
Although no studies have directly assessed these factors as potential intermediates, the lack 
of any correlation between H. pylori and homocysteine, inflammatory markers (CRP, IL6, 
α1-AT, lipoprotein-associated phospholipase A2 activity, fibrinogen) and hemoglobin levels 
in our study might also support the notion of a less virulent H. pylori strain that is currently 
prevalent in The Netherlands. This in turn could explain why we did not observe an associa-
tion of H. pylori with risk of dementia.
The role of infectious diseases in the development of dementia has been longer known 
with diseases such as neurosyphilis and acquired immunodeficiency syndrome (AIDS) be-
ing accepted infectious causes [26].However, also more frequently occurring diseases such 
as herpes virus, toxoplasmosis and cryptococcus have been shown to have a relationship 
with dementia [27]. It is postulated that since systemic infection can provoke the enhanced 
synthesis of inflammatory mediators in the brain, infectious diseases may promote the onset 
of dementia [28]. Thus, even more common infections which an individual is unable to 
resolve adequately could lead to chronic inflammation and subsequently neuroinflammation 
[29]. It is therefore important for future studies to identify such sources of inflammation and 
eventually identify individuals with increased susceptibility for infections for treatment and 
prevention purposes.
Several limitations of this study should be taken into account. First, the diagnostic test for 
detecting H. pylori infection has the disadvantage that antibodies are present in blood even 
after eradication of H. pylori. Therefore, current and past infection cannot be distinguished, 














the exposure. However we do not expect that the association with incident dementia would 
be affected, since the timing of infection may only be shifted for several months or years. 
An alternative for future studies would be the stool antigen test, which proves to be more 
accurate and still non-invasive compared to the serology test [30]. Second, considering the 
differences in virulence factors of the bacterium and treatment strategies in different coun-
tries, our findings may not be generalizable to other geographical regions. To take differences 
in virulence factors into account, future studies could assess CagA phenotypes in H. pylori. 
Third, the invasiveness of lumbar puncture prevents cerebrospinal fluid (CSF) sampling in 
participants in the Rotterdam Study and therefore we have not been able to measure H. 
pylori IgG antibodies in CSF. Although CSF measurements are likely more reflective of 
pathology within the CNS, studies show a larger mean concentration of anti-H. pylori IgG 
concentrations both in CSF as well as in serum in AD patients compared to controls [31, 
32]. This finding supports the systemic effect of the infection, which can be thus measured 
in serum. Finally, the length of time with the infection could not be accounted for in this 
present study, which may also contribute to the age-related trend for infection-induced 
cognitive decline that is observed.
In conclusion, we have found no evidence of an association between H. pylori infection 
and risk of all-cause dementia or AD in our Dutch population. This could be due to low 
virulence of H. pylori in the Netherlands. Future studies are warranted to further elucidate 
the role of common infectious diseases in the pathophysiology of Alzheimer’s disease and 
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Of the 10,215 invited inhabitants, 7,984 agreed to participate in the baseline examinations. 
In 2000, the cohort was extended with 4,472 invitees of whom 3,011 agreed to participate. 
From the original cohort, we used the third examination cycle as baseline due to availability 
of H. pylori and homocysteine data. This cohort contained 1892 participants that were 
included in the analyses based on dementia and H. pylori data availability. In the extended 
cohort, 2408 participants were included in the analyses (Figure S1).
Covariates
All covariates were measured at baseline. Since the study population included 2 cohorts from 
the Rotterdam Study, cohort was used as a covariate. Educational level was categorized as low 
(primary education or lower vocational education), intermediate (secondary education or 
intermediate vocational education), and high educational level (higher vocational education 
or university). Smoking habits were categorized as current, former and never smoking. Blood 
pressure was measured twice at the right arm in sitting position at the research center and the 
average of 2 blood pressure readings was used. BMI was calculated as weight in kilograms 
per height in meters squared. Total cholesterol and HDL cholesterol were measured in serum 
in mmol/l. For the anti-hypertensive drugs and serum lipid reducing agents, participants 
presented all the medication they used in the past week during the home interview. Trained 
research assistants registered drug names, dose, and indication on a structured data entry 
form. APOE genotype was determined using polymerase chain reaction on coded DNA 
samples. 
APOEε carrier status was defined as low risk for dementia (2 ε3 alleles), intermediate 
risk for dementia (2 ε2 alleles or 1 ε3 allele and 1 ε2 allele) and high risk for dementia (1 
or 2 ε4 alleles). Diabetes mellitus was defined as a fasting serum glucose level ≥7.0 mmol/L, 
non-fasting serum glucose level ≥11.1 mmol/L, or use of anti-diabetic medication. Ethnicity 
was genetically determined and divided into two different categories: European and other 
ethnicities.
Total plasma homocysteine level was determined with high-performance liquid chroma-
tography. The CRP levels were measured by kinetic nephelometry.
Statistical analysis
Medication use involved anytime use of antacids (H2 receptor antagonists, prostaglandins, 
PPIs, combinations of drugs for eradication of H. pylori and/or other anti-acids). Also, 














amoxicillin and tetracycline. Anytime use involved medication use at baseline or during 
follow-up of the study.
Missing covariate data (maximum 11.2%) were imputed using 5-fold multiple imputa-




Attended first examination cycle 
(n=2725) 
Excluded from analysis (n=3229) 
• Unknown dementia status 
(n=52) 
• No preserved H. pylori serum 
available (n=3092) 




Follow-up for dementia was 
complete for 92.5% of potential 
person-years 
Cohort I (n=7983) 
Original cohort Extended cohort 
Cohort II (n=3011) 
Attended third examination cycle 
(n=4719) 
































Figure S2. Sensitivity analyses for cut-off values for anti-Helicobacter pylori serum IgG antibody titers 
for obtaining seroprevalence states.
Abbreviations: H. pylori, helicobacter pylori; U/mL, units of activity per millilitre; HR, hazard ratio.
Sensitivity analyses for the effect of H. pylori serum IgG (per log increase) on the dementia-free survival 
of persons in a Cox regression model with the following covariates: cohort, sex, age, education, smok-
ing, blood pressure, anti-hypertensive drug use, body mass index, cholesterol, high-density lipoprotein 
cholesterol, triglycerides, APOEε carrier status, stroke, diabetes mellitus, ethnicity and serum lipid 
lowering agents. Error bars indicate 95% confidence intervals of the HR.














   
 
Figure S3. Sensitivity analyses for age, gender and medication use on the association between anti-
Helicobacter pylori serum IgG antibody titers and the risk of dementia.
Abbreviations: n = number of cases; N = total number at risk; H. pylori = helicobacter pylori; PPI = 
proton pump inhibitor; U/mL = units of activity per millilitre; HR = hazard ratio; histamine-2 recep-
tor antagonists = H2 antagonists.
Sensitivity analyses for the effect of H. pylori serum IgG antibody titers per log increase on the de-
mentia-free survival of persons in a fully adjusted Cox regression model stratified for the following: 
age, gender and anytime use of medication (n/N). Medication use includes use of antibiotics (tetracy-
cline, clarithromycin and/or amoxicillin) and antacids (H2 receptor antagonists, prostaglandins, PPIs, 
combinations of drugs for eradication of H. pylori and/or other anti-acids). Error bars indicate 95% 
confidence intervals of the HR.

Chapter 3  
Immunity and stroke




















Background: Atherosclerotic cardiovascular disease (ASCVD) is driven by multifaceted 
contributions of the immune system. However, the dysregulation of immune cells that leads 
to ASCVD is poorly understood. We determined the association of components of innate 
and adaptive immunity longitudinally with ASCVD, and assessed whether arterial calcifica-
tions play a role in this association.
Methods and findings: Granulocyte (innate immunity) and lymphocyte (adaptive immu-
nity) counts were determined 3 times (2002–2008, mean age 65.2 years; 2009–2013, mean 
age 69.0 years; and 2014–2015, mean age 78.5 years) in participants of the population-based 
Rotterdam Study without ASCVD at baseline. Participants were followed-up for ASCVD or 
death until 1 January 2015. A random sample of 2,366 underwent computed tomography 
at baseline to quantify arterial calcification volume in 4 vessel beds. We studied the as-
sociation between immunity components with risk of ASCVD and assessed whether im-
munity components were related to arterial calcifications at baseline. Of 7,730 participants 
(59.4% women), 801 developed ASCVD during a median follow-up of 8.1 years. Having 
an increased granulocyte count increased ASCVD risk (adjusted hazard ratio for doubled 
granulocyte count [95% CI] = 1.78 [1.34–2.37], P < 0.001). Higher granulocyte counts 
were related to larger calcification volumes in all vessels, most prominently in the coronary 
arteries (mean difference in calcium volume [mm3] per SD increase in granulocyte count 
[95% CI] = 32.3 [9.9–54.7], P < 0.001). Respectively, the association between granulocyte 
count and incident coronary heart disease and stroke was partly mediated by coronary artery 
calcification (overall proportion mediated [95% CI] = 19.0% [−10% to 32.3%], P = 0.08) 
and intracranial artery calcification (14.9% [−10.9% to 19.1%], P = 0.05). A limitation of 
our study is that studying the etiology of ASCVD remains difficult within an epidemio-
logical setting due to the limited availability of surrogates for innate and especially adaptive 
immunity.
Conclusions: In this study, we found that an increased granulocyte count was associated 
with a higher risk of ASCVD, whereas an increase in lymphocytes was protective for AS-
CVD in the general population. Moreover, higher levels of granulocytes were associated with 
larger volumes of arterial calcification. Arterial calcifications may explain a proportion of the 































Atherosclerotic cardiovascular disease (ASCVD) arises from various interacting pathophysi-
ological processes [1]. Recent findings point towards a key role of the immune system, which 
can be broadly classified into innate and adaptive immunity [2]. Innate immunity refers to 
immune responses present at birth, whereas adaptive immunity is acquired during life by 
exposure to antigens [3]. The role of innate immunity in the pathophysiology of ASCVD has 
been recognized on the basis of evidence from experimental and observational data [4–8]. To 
date, however, no easy, accessible, low-cost treatment has been identified to effectively target 
the innate immune system for preventing ASCVD [8]. Given the mechanistic diversity of 
inflammatory pathways, considering other pathways could widen avenues for therapeutic 
targets, for example targeting the adaptive immune system. Adaptive immune cells may 
provide protective responses at atherosclerotic sites, as has been shown in neurodegenerative 
disorders [9,10] and also in cardiovascular disease in experimental and clinical studies [11]. 
Moreover, repeatedly measuring inflammation may better capture the biologically dynamic 
processes of these 2 immune systems than a single measurement, because of the assessment 
of changes over time.
Recent work from the field of cancer research suggests that measuring granulocytes 
and platelets provides important markers of innate immunity [12–14], whereas measur-
ing lymphocytes yields information on adaptive immunity [15]. Furthermore, combining 
these measurements into ratios, i.e., the granulocyte-to-lymphocyte ratio (GLR), platelet-
to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), is thought to 
even better reflect the relative balance between innate and adaptive immunity [16–18]. In 
this study, we first determined the longitudinal association of these immunity components 
with risk of ASCVD in the general population by using the framework of joint models 
for longitudinal and survival data, and hypothesized that an increase in innate immunity 
markers and decrease in adaptive immunity lead to increased risk of ASCVD. Second, we 
examined the association between the immunity components and arterial calcifications to 
explore atherosclerosis as a possible mediator.
METHODS
Study population
The present study is embedded within the Rotterdam Study, a prospective population-based 
cohort study in Rotterdam, the Netherlands. The Rotterdam Study started in 1989 with 
7,983 persons (78% response rate) aged ≥55 years and residing in the district Ommoord, 
a suburb of Rotterdam. This first subcohort (RS-I) was extended with a second subcohort 

















third subcohort (RS-III) in 2006, composed of 3,932 persons aged ≥45 years (65% response 
rate). The design of the Rotterdam Study has been described in detail previously [19]. In 
brief, participants were examined at study entry and at follow-up visits every 3 to 5 years. 
They were interviewed at home by a trained research nurse, followed by 2 visits at the re-
search facility for additional interviewing, laboratory assessments, and imaging.
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, 
Welfare and Sport (Population Screening Act [WBO], license number 1071272-159521-
PG). The Rotterdam Study personal registration data collection is filed with the Erasmus 
MC Data Protection Officer under registration number EMC1712001. The Rotterdam 
Study has been entered into the Netherlands Trial Register (https://www.trialregister.nl) 
and into the WHO International Clinical Trials Registry Platform (https://www.who.int/
ictrp/network/primary/en/) under the shared catalogue number NTR6831. All participants 
provided written informed consent to participate in the study and to have their information 
obtained from treating physicians.
For the current study, the analysis plan was drafted in January 2019 (S1 Analysis Plan). 
This study is reported as per the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guideline (S1 STROBE Checklist).
Laboratory tests for granulocytes, platelets, and lymphocytes were introduced from 
2002 onwards, corresponding with the following assessment rounds in the Rotterdam Study 
(baseline in this study): fourth round of RS-I, second round of RS-II, and first round of 
RS-III (n = 9,996 in total).
Assessment of blood cell counts and their derived ratios
Fasting blood samples were drawn during each visit at the research center, with a maximum 
of 3 visits during follow-up. From 7,730 participants, 5,085 participants were available for 
a second blood cell assessment, and 270 participants were available for a third blood cell 
assessment. Full blood count measurements were performed using the Coulter AcT diff2 
Hematology Analyzer (Beckman Coulter, Brea, CA, US) directly after the blood sample was 
drawn. Laboratory measurements included absolute granulocyte, platelet, and lymphocyte 
counts in 109 per liter. GLR and PLR were calculated as the ratio of granulocyte count to 
lymphocyte count and as the ratio of platelet count to lymphocyte count, respectively. SII 
was defined as platelet count times GLR [20].
Assessment of stroke and coronary heart disease
The clinical outcomes of interest included first fatal or nonfatal stroke or coronary heart dis-
ease (CHD) separately as well as combined into ASCVD as previously described. Follow-up 
data were collected through general practitioners and subsequent collection of information 






























included (1) nonfatal myocardial infarction (MI) and (2) CHD mortality (mortality with 
definite MI, definite CHD, or possible CHD as underlying cause of death) [21]. Stroke was 
defined as a syndrome of rapidly developing symptoms of focal or global cerebral dysfunction 
lasting ≥24 hours or leading to death, with apparent vascular cause [22,23]. We categorized 
strokes as ischemic or hemorrhagic, based on neuroimaging reports and clinical symptoms, 
or as unspecified if we were unable to differentiate the stroke type further. Subarachnoid 
hemorrhages due to ruptured aneurysms were not considered as stroke. Follow-up was virtu-
ally complete until 1 January 2015 (96.6% of potential person-years observed). ASCVD 
furthermore included other ASCVD mortality.
Assessment of arterial calcification
Non-contrast computed tomography (CT) images were obtained using a 16-slice or 64-slice 
multidetector CT scanner (Somatom Sensation 16 or 64; Siemens, Forchheim, Germany). 
Using a cardiac scan and an extracardiac scan that reached from the aortic root to the intra-
cranial vasculature (1 centimeter above the sella turcica), we visualized the following vessels: 
coronary arteries, aortic arch, extracranial internal carotid arteries, and intracranial internal 
carotid arteries. Radiation dose and other imaging parameters of both scans are described 
elsewhere [24,25].
The amount of calcification in the coronary arteries, aortic arch, and extracranial carotid 
arteries was quantified using widely used, commercially available dedicated software (Syngo.
via; Siemens). Calcification in the coronary arteries comprised a summation of calcifica-
tion in the left main, left anterior descending, left circumflex, and right coronary artery. 
Calcification in the aortic arch was scored from the origin of the aortic arch (defined as the 
image in which the ascending and descending aorta merge into the inner curvature of the 
aortic arch) to the first 1 cm of the branches originating from the arch. Calcification in the 
extracranial carotid arteries was assessed within 3 cm proximal and distal of the bifurcation 
on both sides and summed.
Intracranial internal carotid artery calcification was assessed from the horizontal segment 
of the petrous internal carotid artery to the top of the internal carotid artery. Scoring was 
done semi-automatically, because automated software is not yet available for this region (the 
close relationship between calcification and the skull base precludes the use of commercial 
software given a high false-positive rate). Regions of interest were manually drawn in the 
course of the intracranial internal carotid artery on both sides, after which the number of 
pixels within these regions above 130 Hounsfield units was summed and multiplied by the 
pixel size and the slice increment in order to obtain a volume in cubic millimeters [26,27].
Covariates
We assessed education, smoking, and use of antihypertensive, lipid-lowering, and antidia-

















sured twice on the right arm with a random-zero sphygmomanometer, of which the mean 
was used. Total cholesterol and high-density lipoprotein (HDL) cholesterol were measured 
with a Coulter AcT diff2 Hematology Analyzer. Body mass index (BMI) was computed 
from measurements of height and weight (kg/m2). Diabetes mellitus was defined as use of 
antidiabetic medication, fasting serum glucose level ≥ 7.1 mmol/l (≥127.9 mg/dl), or ran-
dom non-fasting serum glucose level ≥ 11.1 mmol/l (≥200.0 mg/dl) [28]. High-sensitivity 
C-reactive protein (hs-CRP) was determined in serum that was drawn during the third 
assessment round in the Rotterdam Study, i.e., third round of RS-I (1996–1999), which was 
stored at −20 °C until performance of the hs-CRP measurements in 2003 to 2004. Hs-CRP 
was measured using Rate Near Infrared Particle Immunoassay (Immage Immunochemistry 
System, Beckman Coulter). History of cancer was obtained from general practitioners’ 
medical records (including hospital discharge letters), the Dutch Hospital Data registry, 
and regional histopathology and cytopathology registries. Furthermore, we assessed history 
of immune-modulating medication use—nonsteroidal anti-inflammatory drugs (NSAIDs) 
(ATC code M01), immunosuppressives (ATC code L04), and methotrexate (ATC code 
L01BA01)—by number of prescriptions between 1 January 1995 and blood draw date.
Statistical analysis
Because the blood cell counts and their derived ratios have a skewed distribution and to 
adhere to the linearity assumptions, the analysis was based on the natural logarithmic (Ln) 
transformation of their values. We first determined the association of the granulocyte, 
platelet, and lymphocyte counts and their derived ratios with the risk of stroke and CHD 
separately as well as ASCVD, using the framework of joint models for longitudinal and 
survival data [29]. For the longitudinal data, a linear mixed effects model was used, in which 
we specified the immunity component as the dependent variable and time as the inde-
pendent variable to assess the mean change in immunity components. Random intercepts 
and slopes were used to incorporate individual response trajectories. For modeling survival 
data, we used a Cox regression model in which we included the true underlying profile 
of the blood cell counts as estimated from the longitudinal model. Here the baseline risk 
function assumed a piecewise constant with 6 knots placed at equally spaced percentiles of 
the observed event times. Joint models allow accounting for (1) measurement error during 
follow-up, i.e., biological variation, (2) the effect of factors at an earlier time point on the 
values of blood cell measurements at a later time point [30], and (3) the correlations in 
the repeated measurements of the blood cell counts. Because we are using log-log models 
(logYi = α + βlogXi + ε), we report hazard ratios (HRs) with 95% confidence intervals (CIs) 
obtained by exponentiating Ln(2) times the estimated coefficients from the Cox model. 
These HRs correspond to the increase in risk for a doubling of the blood cell count or ratio. 
We computed 2 nested models: Model I was adjusted for baseline age (continuous, centered 






























status, BMI, diabetes mellitus, systolic and diastolic blood pressure (continuous, centered as 
blood pressure minus mean blood pressure), antihypertensive medication, total cholesterol, 
HDL cholesterol, and lipid-lowering medication. For assessment of the association between 
individual blood cell counts and ASCVD, we performed the analyses with adjustment for 
the baseline blood cell counts of the remaining 2 blood cell types. Follow-up time was used 
as the time scale and started at the date of first laboratory assessment; follow-up continued 
until date of stroke, CHD, death, loss to follow-up, or 1 January 2015, whichever came first. 
We also investigated the association of the blood cell counts and their ratios with ischemic 
and hemorrhagic stroke separately. We assessed the joint model assumptions by examining 
the proportional hazards assumption using Schoenfeld residuals, and goodness of fit using 
Cox–Snell residuals for the survival part and marginal residuals for the longitudinal part.
In sensitivity analyses, we additionally excluded participants with a history of cancer or a 
history of immune-modulating medication at baseline. In addition, we performed additional 
adjustments for NSAID use. We explored effect modification by stratifying by age, sex, hs-
CRP (at a cutoff of 2 mg/l), use of lipid-lowering medication, coronary artery calcification 
volume (at a cutoff of 10 mm3), and smoking, all at baseline. We formally tested interaction 
between these factors and blood cell counts on the multiplicative scale by adding interaction 
terms to model II. Lastly, we repeated the analyses for the granulocytes and lymphocytes and 
risk of ASCVD using age as the time scale instead of follow-up time to account for potential 
residual confounding by age and to minimize potential effects of left truncation.
Next, in order to explore possible mechanisms, we performed a cross-sectional analysis 
assessing the association of the granulocyte, platelet, and lymphocyte counts and their derived 
ratios at baseline, per standard deviation increase, with calcification volume in each vessel 
bed (coronary arteries, aortic arch, extracranial carotid arteries, and intracranial carotid ar-
teries) using linear regression models. To facilitate interpretation of these analyses, we chose 
to first standardize the blood cell counts only, to make results comparable, and keep the rest 
of the variables untransformed. We adjusted these analyses for age and sex (model I), and 
additionally for education, smoking status, BMI, diabetes mellitus, systolic blood pressure, 
diastolic blood pressure, antihypertensive medication, total cholesterol, HDL cholesterol, 
and lipid-lowering medication (model II). To adhere to the homoscedasticity and linearity 
assumptions, we repeated linear regression models after natural log-transforming exposure 
and outcome variables. As a sensitivity analysis, we looked at the association between the 
granulocyte, platelet, and lymphocyte counts and their derived ratios and continuous arte-
rial calcification only in those with non-zero arterial calcification, since the magnitude of 
the increase from 0 to 1 for volume may not be the same as other incremental increases in 
arterial calcification.
Finally, we performed a mediation analysis to assess a possible mediating effect of calci-
fication volume in the coronary arteries and intracranial carotid arteries on the association 

















immunity marker displaying the strongest association with both calcifications and incident 
CHD or stroke for this analysis. We tested the overall proportion mediated by calcifications. 
To test for mediation effects, we used the decomposition analysis techniques as described 
by VanderWeele [31]. Participants with a history of CHD or stroke were excluded from 
the analysis. We analyzed the association of innate immunity with calcifications with linear 
regression models. The association of innate immunity or calcifications with CHD or stroke 
was investigated by Cox regression models.
Multiple imputation by chained equations was used for missing covariates (maximum of 
1.5%), with 5 imputed datasets based on other covariates and the outcome. Rubin’s method 
was used for pooling the 5 analyses to obtain pooled HRs and 95% CIs [32]. Two-sided 
P < 0.05 was considered statistically significant for all analyses. Statistical analyses were 
performed using the R packages mice, survival, nlme, JM, Results
From 8,712 participants, we excluded those with a history of ASCVD (n = 819) at 
baseline, those who had incomplete data regarding their history of ASCVD (n = 95), and 
those who did not provide informed consent to assess medical records during follow-up 
(n = 60). Lastly, we excluded participants with incomplete laboratory assessment (n = 8), 
resulting in 7,730 participants for analysis (flowchart in Fig 1). From the fourth round of 
RS-I and the second round of RS-II, a random sample was invited to undergo non-contrast 







Fig 1. Flowchart of study population.






























Characteristics of the study participants are presented in Table 1. Mean age of included study 
participants was 65.2 years, and 59.4% were women. During a median (interquartile range) 
follow-up of 8.1 (3.4) years (62,095 person-years), 801 participants developed ASCVD, of 
whom 423 participants developed CHD and 378 stroke. ASCVD-free survival probability 
and average change of granulocytes and lymphocytes over time are presented in S1 Fig in the 
total population and in S2 Fig in younger and older individuals separately.
Table 1. Baseline characteristics.




Women 4,594 (59.4%) 1,236 (52.2%)
Age, years 65.2 (10.2) 69.1 (6.7)
Smoking
Ever 5,278 (68.7%) 1,662 (71.2%)
Never 2,401 (31.3%) 670 (28.7%)
Diabetes mellitus 415 (5.4%) 129 (5.5%)
BMI, kg/m2 27.6 (4.4) 27.6 (4.0)
Education 
Primary 830 (10.8%) 179 (7.7%)
Lower 3,124 (40.7%) 979 (42.1%)
Intermediate 2,205 (28.8%) 716 (30.8%)
Higher 1,509 (19.7%) 451 (19.4%)
Systolic blood pressure, mm Hg 142.3 (21.8) 146.7 (20.0)
Diastolic blood pressure, mm Hg 81.3 (11.0) 80.2 (10.7)
Antihypertensive drugs 2,571 (33.6%) 921 (39.5%)
Total cholesterol, mmol/l 5.7 (1.0) 5.6 (1.0)
HDL cholesterol, mmol/l 1.5 (0.4) 1.4 (0.4)
Lipid-lowering medication 1,429 (18.7%) 535 (23.0%)
granulocyte count, ×103/μl 4.0 (1.4) 4.0 (1.3)
Platelet count, ×103/μl 270.9 (66.6) 259.0 (64.0)
Lymphocyte count, ×103/μl 2.3 (1.1) 2.3 (1.0)
gLR 1.9 (0.8) 1.9 (0.9)
PLR 127.9 (46.4) 124.9 (45.8)
SII 509.3 (270.7) 494.3 (272.2)
Data presented as mean (standard deviation) for continuous variables and number (percentage) for categorical variables. Number 
of missing values for the ASCVD-free cohort: 51 (0.7%) for smoking, 22 (0.3%) for diabetes, 25 (0.3%) for BMI, 62 (0.8%) for 
education, 41 for systolic and diastolic blood pressure (0.5%), 69 for blood pressure lowering medication (0.9%), 25 for cholesterol 
(0.3%), 27 for HDL cholesterol (0.3%), and 69 for lipid lowering medication (0.9%). Number of missing values for the sample 
undergoing CT are: 52 (0.6%) for smoking, 22 (0.3%) for diabetes, 26 (0.3%) for BMI, 41 (0.5%) for education, 14 for systolic 
and diastolic blood pressure (0.6%), 35 for blood pressure lowering medication (1.5%), 6 for cholesterol (0.3%), 6 for HDL cho-
lesterol (0.3%) and 35 for lipid lowering medication (1.5%).
BMI, body mass index; CT, computed tomography; GLR, granulocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; 

















An increased granulocyte count, but not platelet count, was associated with an increased risk 
of ASCVD (adjusted HR [95% CI] for doubled granulocyte count = 1.78 [1.34–2.37], P < 
0.001, and for doubled platelet count = 1.17 [0.90–1.51], P = 0.24, Table 2). With respect 
to adaptive immunity, an increased level of lymphocytes was associated with a decreased risk 
of ASCVD, although this result was not statistically significant (adjusted HR for doubled 
lymphocyte count [95% CI] = 0.87 [0.71–1.06], P = 0.17). Both an increased GLR and 
an increased SII were associated with increased ASCVD risk (adjusted HR for doubled 
GLR [95% CI] = 1. 37 [1.14–1.65], P = 0.001, and for doubled SII = 1.19 [1.03–1.36], 
P = 0.02), whereas an increased PLR was not associated with ASCVD risk. We observed 
no major violations of the joint model assumptions. Effect estimates did not materially 
change, and in fact became stronger, when we excluded participants with a history of can-
cer or history of immune-modulating medication at baseline (723 ASCVD cases among 
7,063 remaining participants) (adjusted HR for doubled granulocyte count [95% CI] = 
1.90 [1.41–2.57], P < 0.001, and for doubled lymphocyte count = 0.82 [0.65–1.04], P = 
0.10). Additional adjustment for NSAID use did not change the effect estimates. We found 
that the association between higher levels of granulocytes and risk of ASCVD was more 
pronounced in participants aged younger than the median age of 64 years compared to those 
64 years or older (adjusted HR for doubled granulocyte count [95% CI] = 2.32 [1.20–4.47], 
P < 0.001) (Pinteraction = 0.002). Results of all stratified analyses with interaction terms are 
shown in S1 Table. Lastly, risk estimates were comparable when using age as the time scale 
instead of follow-up time.
Table 2. Joint models for the association between repeated blood-based immunity markers and sub-















2.63 (2.03–3.40) <0.001 2.14 (1.48–3.11) <0.001 3.10 (2.18–4.42) <0.001




1.03 (0.85–1.25) 0.77 0.96 (0.72–1.29) 0.80 1.09 (0.83–1.43) 0.54
Balance between innate and adaptive immunity
GLR 1.52 (1.27–1.82) <0.001 1.47 (1.13–1.91) 0.004 1.56 (1.22–2.01) <0.001
PLR 1.02 (0.87–1.19) 0.84 1.15 (0.91–1.46) 0.24 0.97 (0.78–1.20) 0.76






























When examining CHD and stroke as separate events, an increased granulocyte count was 
associated with an increased risk of both events (adjusted HR for doubled granulocyte 
count [95% CI] = 1.98 [1.34–2.93], P = 0.001, for CHD and 1.50 [1.00–2.27], P = 
0.05, for stroke; Table 2). An increased platelet count was associated with higher risk of 
stroke only (adjusted HR for doubled platelet count [95% CI] = 1.38 [0.95–2.01], P = 
0.09). An increased lymphocyte count showed similar protective effects for both CHD and 
stroke, although these effects were not statistically significant (adjusted HR for doubled 
lymphocyte count [95% CI] = 0.88 [0.66–1.17], P = 0.37, for CHD and 0.85 [0.63–1.15], 
P = 0.29, for stroke). With respect to the ratio measures, an increased GLR was associated 
with both increased CHD and stroke risk (adjusted HR for doubled GLR [95% CI] = 
1.37 [1.07–1.78], P = 0.01, for CHD and 1.31 [1.00–1.70], P = 0.05, for stroke). When 
investigating ischemic and hemorrhagic stroke separately, an increased granulocyte count 
Table 2. Joint models for the association between repeated blood-based immunity markers and subse-















1.78 (1.34–2.37) <0.001 1.50 (1.00–2.27) 0.05 1.98 (1.34–2.93) 0.001




0.87 (0.71–1.06) 0.17 0.85 (0.63–1.15) 0.29 0.88 (0.66–1.17) 0.37
Balance between innate and adaptive immunity
GLR 1.37 (1.14–1.65) 0.001 1.31 (1.00–1.70) 0.05 1.37 (1.07–1.78) 0.01
PLR 1.17 (0.99–1.38) 0.06 1.25 (0.98–1.59) 0.07 1.10 (0.88–1.38) 0.41
SII 1.19 (1.03–1.36) 0.02 1.21 (0.99–1.48) 0.06 1.16 (0.96–1.41) 0.13
HR is per doubled blood cell count. Model I is adjusted for age and sex. Model II is adjusted for age, 
sex, education, smoking status, body mass index, diabetes mellitus, systolic and diastolic blood pres-
sure, antihypertensive medication, high-density lipoprotein cholesterol, total cholesterol, and lipid-
lowering medication=. All markers were logarithmically transformed. 
*Analysis for each blood cell type adjusted for the baseline blood cell counts of the remaining 2 blood 
cell types.
ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; CI, confidence interval; 
GLR, granulocyte-to-lymphocyte ratio; HR, hazard ratio; n, number of incident events; N, number of 
participants for analysis; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index 














































was associated with an increased risk of ischemic stroke (HR for doubled granulocyte count 
[95% CI] = 1.44 [0.90–2.31], P = 0.13) and hemorrhagic stroke (2.48 [0.86–7.14], P = 
0.09), whereas platelets only increased risk of ischemic stroke (HR for doubled platelet 
count [95% CI] = 1.44 [0.93–2.22], P = 0.10).
Regarding the association of immunity with arterial calcification, we found that higher 
levels of granulocytes at baseline related to larger calcification volumes in all arteries, but 
most prominently in the coronary arteries (mean difference in calcium volume [mm3] per 
SD increase in granulocyte count [95% CI] = 32.3 [9.1 to 54.7], P < 0.001). Regarding 
adaptive immunity, higher levels of lymphocytes were not related to calcification volumes. 
Higher levels of GLR and SII were related to larger calcification volumes in the aortic arch 
only (mean difference in calcium volume [mm3] per SD increase [95% CI] = 48.6 [2.5 to 
94.8], P = 0.04, and 58.8 [13.8 to103.8], P = 0.03, respectively). In Table 3, the linear 
regression models after transforming the exposure and outcome variables are presented. 
Our sensitivity analyses with non-zero calcifications similarly showed associations between 
higher levels of granulocytes and larger calcification volumes in all arteries, but the analysis 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































The association between granulocytes and incident CHD was partly mediated by coronary 
artery calcifications (overall proportion mediated [95% CI] = 19.0% [−10% to 32.3%], P = 
0.08), while the association between granulocytes and incident stroke was partly mediated 
by intracranial artery calcifications (14.9% [−10.9% to 19.1%], P = 0.05), albeit this finding 
was not statistically significant.
DISCUSSION
In this study, we found that an increase of innate immunity markers over time, as reflected 
by a doubling of the granulocyte count and the ratios GLR and SII, was robustly associated 
with a higher risk of ASCVD. Furthermore, higher levels of granulocytes at baseline were 
related to larger burden of subclinical atherosclerosis, as measured by arterial calcifications. 
Coronary artery calcifications mediated 19.0% of the association between granulocytes and 
CHD, while intracranial artery calcifications mediated 14.9% of the association between 
granulocytes and stroke.
To date, few population-based studies have investigated the association between innate 
immunity markers and cardiovascular outcomes. Elevated GLR has been linked to ischemic 
stroke incidence and cardiovascular disease [35,36]. A meta-analysis of 38 studies showed 
that elevated GLR was associated with coronary artery disease, acute coronary syndrome, 
stroke, and composite cardiovascular events [37]. However, most of these studies were cross-
sectional or were performed in selected clinical populations of patients with cardiovascular 
disease. Besides observational studies, various clinical trials have targeted the immune system 
to reduce the risk of ASCVD. One of the largest is the CANTOS (Canakinumab Anti-in-
flammatory Thrombosis Outcome Study) randomized trial, in which patients with elevated 
hs-CRP and previous MI were assigned to receive canakinumab or placebo. Canakinumab 
selectively inhibits interleukin-1β, resulting in an inhibition of the innate immunity. The 
150-mg dose resulted in a lower incidence of recurrent cardiovascular events, compared to 
placebo [38]. In addition to interleukin-1β, also hs-CRP, fibrinogen, and interleukin-6, all 
markers in the same cascade, have been shown to have an association with CHD [39–41]. 
Our findings also show an important role of innate immunity in first-ever stroke and CHD 
risk in the general population, independent of hs-CRP level or lipid-lowering medication 
use.
Interestingly, a more recent trial assessing low-dose methotrexate to reduce inflamma-
tion in order to prevent recurrent cardiovascular disease showed that methotrexate did not 
lower levels of interleukin-1β, interleukin-6, or hs-CRP, and that it did not result in a lower 
number of cardiovascular events compared to placebo [8]. Together with the results from 
the CANTOS trial, these studies indicate that reducing the risk of cardiovascular events 






























pathways, our results indicate that the pathway of adaptive immunity may also affect the risk 
of cardiovascular disease. More specifically, lymphocyte count, an important player in adap-
tive immunity, showed protective effects on the risk of ASCVD, although this finding was 
not statistically significant. Indeed, mobilizing anti-inflammatory T cells to atherosclerotic 
sites may provide protective responses as has been shown in neurodegenerative disorders [9] 
and also in cardiovascular disease in experimental and clinical studies [11]. These cells thus 
additionally serve as a promising therapeutic target to control the proinflammatory processes 
of atherosclerosis. The significant association we found between GLR and SII and incident 
ASCVD, although weaker than with granulocytes, supports the hypothesis that ASCVD 
results from an imbalance between innate and adaptive immunity. Future studies may focus 
more specifically on targeting both innate and adaptive immunity, rather than only innate 
immunity, and refine insights into these pathways.
Although previous studies have established the inflammatory hypothesis of atherothrom-
bosis in coronary artery disease, fewer studies have specifically investigated stroke. However, 
increasing evidence from experimental studies suggests an equally important role for the im-
mune response in stroke [42]. Similarly, we demonstrated that higher levels of granulocytes 
were associated with stroke of any type, as well as with ischemic and hemorrhagic stroke 
separately. Especially the latter finding warrants further research since most studies so far 
have mainly focused on inflammatory responses after the occurrence of an intracerebral 
hemorrhage, and not before [43].
An interesting finding of our study is that the association between higher levels of 
granulocytes and risk of ASCVD was more pronounced in younger individuals than older 
individuals (age below the median [64 years]: adjusted HR [95% CI] for doubled granulo-
cyte count = 2.32 [1.20–4.47], P < 0.001; age at or above the median: 1.67 [1.21–2.29], P 
=  0.002). Recently, an English and Dutch study found that while there has been a decline 
in mortality from acute stroke within 30 days, stroke event rates have increased and 15-year 
mortality risk in young stroke-survivors remained elevated [44,45]. This suggests that stroke 
awareness and stroke prevention need to start at much lower age to reduce the occurrence of 
stroke in younger people. Our results show that inflammation reduction could be a potential 
important strategy to achieve this.
Moreover, our study showed that coronary and intracranial carotid artery calcifications 
substantially mediate the association of granulocytes with CHD and stroke, respectively. 
The observed proportion of mediation for CHD was 19.0%, while for stroke the proportion 
mediated was 14.9%. This is meaningful given the multiple mechanisms through which 
innate immunity affects cardiovascular health, including atrial fibrillation (AF) and coagula-
tion [46]. Indeed, the infiltration of immune cells and proteins that cause an inflammatory 
response in cardiac tissue and circulatory processes is associated with AF [47], and AF is 
in turn an important risk factor for CHD and stroke. Another possible mediator is blood 

















mediated thrombin generation, downregulation of physiological anticoagulant mechanisms, 
and inhibition of fibrinolysis, increasing the risk of CHD and stroke [48]. Furthermore, 
besides calcifications, plaques may consist of intraplaque hemorrhage and a lipid core. 
Although calcifications are an adequate quantitative measure for atherosclerosis, vulnerable 
plaques without calcification, which are more strongly associated with ASCVD [49], are not 
quantified by this method. Therefore, it is plausible that the true proportion of inflamma-
tion mediated through atherosclerosis of all plaque components is actually higher than the 
measured proportion mediated through the calcification component.
Blood cell count measurements display short-term variability or measurement error, but 
we do not expect that this variability affected our results for several reasons. First, we expect 
to have captured a more chronic or stable effect of immune status because we used blood 
cell counts measured at multiple time points per participant. Although this longitudinal 
information was collected intermittently and with error, we could successfully reconstruct 
the complete longitudinal history by postulating a suitable mixed effects model to describe 
participant-specific time evolutions. The mixed model accounted for the measurement er-
ror problem by postulating that the observed level of the blood cell count measurements 
equaled the true level of the blood cell count measurements plus a random error term. Thus, 
the joint models we used accounted for measurement error or variability of the blood cell 
count measurements. Second, as a sensitivity analysis, we additionally excluded participants 
with a history of cancer or a history of immune-modulating medication at baseline, and we 
performed additional adjustments for NSAID use. We performed these sensitivity analyses 
specifically to address the issue of participants having significantly altered blood cell counts 
due to underlying disease processes. The results of these analyses did not show significant 
changes in our effect estimates. Lastly, by extensively correcting for potential confounders 
such as BMI, we attempted to rule out effects of determinants of blood cell counts as much 
as possible.
Our study has some limitations. First, studying the etiology of ASCVD, which is the 
focus of this study, remains difficult within an epidemiological setting due to the limited 
availability of surrogates for innate and especially adaptive immunity. Second, we could not 
directly relate the effect of hs-CRP with the different blood cell measurements and ASCVD 
risk since we did not have hs-CRP measurements available at study baseline, but only 1 
round before. Third, the vast majority of our population is of European ancestry (97.6%), 
potentially limiting generalizability to other ethnicities. Fourth, it is important to note the 
possible influence of unmeasured confounders on our results. Fifth, due to the cross-sectional 
nature of the analyses regarding the association between immunity markers and calcifica-
tions, there is potential for reverse causality. However, according to the present evidence, it 
is very plausible that inflammation comes first since activation of endothelial cells results in 
increased expression of leukocyte adhesion molecules and the release of chemokines, which 






























Finally, the measurement error for both subclinical ASCVD and immune cell subsets limits 
the mediation analysis in its reliability. However, since this measurement error introduces 
random error into the direct effect, it is expected to lead to underestimation of the media-
tion. Of course, we cannot rule out that it could bias the results in the opposite direction 
and inflate mediation estimates.
In conclusion, our study shows that increased granulocyte count, GLR, and SII are 
associated with a higher risk of ASCVD, whereas increased lymphocyte count is protective 
for ASCVD in the general population. Moreover, higher levels of granulocytes are associated 
with subclinical atherosclerosis, as measured by arterial calcifications. These calcifications 
explain a substantial proportion of the link between granulocytes and ASCVD. Our findings 
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S1 Fig. ASCVD-free survival and mean change of blood cell count over time in the total population. 
The left axis in each panel denotes the blood cell count (dotted line), the right axis the ASCVD-free 




S2 Fig. ASCVD-free survival and mean change of granulocyte count over time stratified by younger 
and older participants. 
Younger participants are those below the median age of 64 years. Of these participants, 142 developed 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 4  
Brain pathology

4.2 Immunity and amyloid-beta, 


















We investigated how components of immunity relate to biomarkers of Alzheimer’s disease 
(AD) in plasma and explored the influence of AD genetic risk factors in the population-
based Rotterdam Study. 
Methods
In 7,397 persons, we calculated the granulocyte-to-lymphocyte ratio[GLR], platelet-to-
lymphocyte ratio[PLR], and systemic immune-inflammation index[SII]. In 3,615 of these 
persons, plasma amyloid-beta (Aβ)-42 and Aβ-40 were measured. Next, we constructed an 
overall genetic risk score[GRS] based on genome-wide significant variants, both including 
and excluding APOE-ε4.
Results
All innate immunity phenotypes were related to higher Aβ, most strongly with a doubling 
in GLR leading to a 1.9% higher Aβ-42 (95% confidence interval [95%CI] 0.4;3.3%) and 
3.2% higher Aβ-40 [95%CI 2.0;4.3%]. Higher AD GRS including APOE-ε4 was associ-
ated with higher immunity markers.
Discussion
Higher levels of immunity markers were associated with higher Aβ in plasma. Participants 
with a higher genetic predisposition to AD had higher immunity markers, where these ef-





































Alzheimer’s disease (AD) is characterized pathologically by accumulation of amyloid-beta 
(Aβ) as amyloid plaques and phosphorylated tau as neurofibrillary tangles [1]. This accumu-
lation gave rise to the amyloid hypothesis, posing that Aβ activates a cascade of pathologic 
changes [2]. As an extension to the amyloid hypothesis, the antimicrobial protection model 
was recently proposed suggesting that Aβ oligomerization is not intrinsically pathological, 
but emerges as an innate immune response [3]. Genetic variants identified through genome-
wide association studies (GWAS) support this role for immunity [4]. It has also been found 
that higher activation of the innate immune system and lower activation of the adaptive 
immune system leads to higher dementia risk [5]. Yet, the link between immunity and 
AD-related brain pathology is largely unknown.
In the early 1990s, Apolipoprotein E (ApoE) was found to be a component of amyloid 
plaques [6, 7]. However, how ApoE’s function as a lipid-carrier is in itself related to AD, 
either in relation to amyloid-β or other factors, is not entirely clear. Lipids serve more than 
pure nutritional purposes; they also play essential roles in immune regulation [8]. Innate 
immunity in turn affects amyloid-β and tau pathology buildup. Insoluble tau isolated from 
postmortem AD brain is shown to be taken up by microglia in vitro and in vivo [9]. This 
taking in of tau may participate in tau spreading by microglia subsequently releasing some 
form of tau [10].
To study further how AD relates to the immune response, we may use serum levels of 
various blood cells which reflect a systemic immune response [11] and relate them with 
biomarkers of AD pathology and progression. Serum levels of  granulocytes and platelets are 
known biomarkers of the innate immunity, whereas lymphocyte levels may yield information 
on the adaptive immunity [12]. Combining these measurements into ratios is thought to 
even better reflect the relative balance between innate and adaptive immunity, obtaining the 
granulocyte-to-lymphocyte ratio (GLR), platelet-to-lymphocyte ratio (PLR) and systemic 
immune-inflammation index (SII) as phenotypical markers of immunity [13]. Whereas for 
the diagnosis of AD, biomarkers are grouped into those of β amyloid deposition, pathologic 
tau, and neurodegeneration [ATN] according to the recent classification by Jack et al [14], 
yielding plasma Aβ, total-tau and neurofilament light chain (NfL) as biomarkers of AD-
related brain pathology, respectively.
In an earlier study investigating the role of various biological pathways based on a ge-
netic risk score, we found an important role for the immune response pathway in early AD 
pathology [15]. Relating phenotypical immunity and AD-related markers to each other and 
additionally to genetic predisposition to AD may help to understand the role of immunity 
biomarkers in AD pathology and their relation with AD genetic risk, and ultimately identify 
therapeutic strategies targeting upstream events of altered immune response in amyloidosis 
















over time reflecting higher innate immunity increase dementia risk [5]. Since we also previ-
ously found that low Aβ-42 and high NfL plasma levels were associated with risk of AD 
[16], we hypothesized that higher innate immunity affects the serum levels of Aβ-42 to be 
lower and NfL to be higher. We tested this hypothesis by investigating whether serum GLR, 
PLR and SII were associated with Aβ, total-tau and NfL and how genetic predisposition to 
AD affected these markers.
METHODS
Study population
The present study is embedded within the Rotterdam Study, a prospective population-based 
cohort study in Rotterdam, the Netherlands. The Rotterdam Study started in 1989 with 
7,983 persons (response of 78%) aged ≥55 years and residing in the district Ommoord, a 
suburb of Rotterdam. This first subcohort (RS-I) was extended with a second subcohort 
(RS-II) in 2000, consisting of 3,011 persons (response of 67%) and with a third subcohort 
(RS-III) in 2006, composed of 3,932 persons aged ≥45 years (response of 65%). The design 
of the Rotterdam Study has been described in detail previously [17]. In brief, participants 
were examined at study entry and follow-up visits every three to five years. They were in-
terviewed at home by a trained research nurse, followed by two visits at the research facility 
for additional interviewing and laboratory assessments. The Rotterdam Study has been ap-
proved by the Medical Ethics Committee of the Erasmus Medical Center and by the board 
of the Netherlands Ministry of Health, Welfare, and Sports. Written informed consent was 
obtained from all participants.
Laboratory tests for granulocytes, platelets, and lymphocytes were introduced from 
2002 onwards, corresponding with the following assessment rounds in the Rotterdam Study 
(baseline for this study): fourth round of RS-I (RS-I-4), second round of RS-II (RS-II-2), 
and first round of RS-III (RS-III-1). Plasma biomarkers of AD-related brain pathology were 
only assessed in RS-I-4 and RS-II-2. Blood was drawn from 11,496 participants for geno-
typing. Of these participants, 7,413 underwent granulocytes, platelets, and lymphocytes 
assessments, while 3,627 participants underwent plasma Aβ, total-tau and NfL assessment. 
We excluded participants with missing APOE genotype and participants with incomplete 
assessments of serum markers, leaving (n=7,397) participants for analysis with complete 
blood assessment for immunity markers and 3,615 participants with complete plasma Aβ, 
total-tau and NfL assessment (Figure 1).
genotyping
DNA genotyping was performed at the internal genotyping facility of the Erasmus Medical 




































arrays. Genotyping quality control criteria include call rate <95%, Hardy-Weinberg equilib-
rium of P <1.0 × 10-6, and minor allele frequency <1%. Moreover, study samples with excess 
autosomal heterozygosity, call rate <97.5%, ethnic outliers, and duplicate or family relation-
ships were excluded during quality control analysis. Genetic variants were imputed from the 
Haplotype Reference Consortium reference panel (version 1.0) [18], using the Michigan 
imputation server [19]. The server uses SHAPEIT2 (v2.r790) [20] to phase the genotype 
data and performs imputation with Minimac 3 software [21]. For this study, we used genetic 
variants that had imputation quality (R2) > 0.5. APOE genotype was determined separately 
by PCR on coded DNA samples in the baseline cohort and with a bi-allelic Tacqman assay 
in the extensions of the Rotterdam Study [22].
Assessment of blood cell counts and their derived ratios
Full blood count measurements were performed using the COULTER® Ac·T diff2™ Hema-
tology Analyzer (Beckman Coulter, San Diego, California, USA) directly after blood sample 
drawn. Laboratory measurements included absolute granulocyte, platelet, and lymphocyte 
counts in 109 per litre. The GLR and PLR were calculated as the ratio of granulocyte count to 
lymphocyte count, and as the ratio of platelet count to lymphocyte count, respectively. The 




















the commonly used neutrophil-to-lymphocyte ratio, as granulocytes are the most abundant 
subtype of neutrophils.
Assessment of plasma Aβ, total-tau and NfL
Blood was sampled in EDTA treated containers and centrifuged. Subsequently plasma was 
aliquoted and frozen at -80⁰C according to standard procedures. Measurements were done 
in two separate batches. The first batch included in total 2,000 samples, obtained from a 
random selection of 1,000 participants from sub-cohort RS-I-4 and 1,000 from RS-II-2. 
The second batch included in total 3,094 samples from the remaining participants.
All measurements were performed at Quanterix (Lexington, MA, USA) on a single 
molecule array (Simoa) HD-1 analyzer platform [23]. Samples were tested in duplicate. Two 
quality control (QC) samples were run on each plate for each analyte. NfL was measured 
with the NF-light advantage kit [24]. The Simoa Human Neurology 3-Plex A assay (N3PA) 
was used for measuring the concentration of total-tau, Aβ-42 and Aβ-40. When duplicates 
or single measurements were missing (the majority of missing samples were due to system 
failures (n=279), and few because of insufficient volume (n=47)) or in the case the concen-
tration coefficient of variation (CV) exceeded 20% (14 to 87 samples) or control samples 
were out of range (none), participant’s data were excluded from the analyses [16].
genetic risk scores
We computed genetic risk scores, by selecting late-onset AD-associated single-nucleotide 
polymorphisms (SNPs) reaching genome-wide significance (P < 5.0 × 10-8). Among com-
mon variants, we considered only variants identified by the International Genomics of 
Alzheimer’s Project (IGAP) meta-analyses [4]. In addition, we included four rare variants 
which can be classified under immune response based on their functional role [25, 26], 
leading to a total of 28 independent genome-wide significant AD-associated variants. A 
weighted genetic risk score was constructed using the effect sizes (log of odds ratio) of the 
genome-wide significant variants from the IGAP meta-analysis as weights and their respec-
tive allele dosages from imputed genotype data of our study cohorts. A genetic risk score was 
constructed as the sum of the products of SNP dosages and their corresponding weights. 
We constructed genetic risk scores in three ways: (1) combining all 28 selected variants, (2) 
excluding the APOE-ε4 variant to identify the joint independent effect of all other genome-
wide significant SNPs and (3) clustering the variants into the immune response pathway. 
We classified AD associated SNPs into immune system pathway based on information on 
current investigations and reviews [4, 27-29]. Of the 28 SNPs, 9 could be clustered into the 
immune response pathway-based genetic risk score; Table S1. All genetic risk scores were 





































Potential confounding factors were chosen on the basis of previous literature [13, 30]. All 
covariates were measured at the same rounds as the assessments of AD-related brain pathol-
ogy and immunity markers. Smoking habits were categorized as current vs former and never 
smoking. Body mass index (BMI) was calculated as weight in kilograms per height in meters 
squared. Blood pressure was measured twice at the right brachial artery with the participant 
in sitting position, out of which the mean was used. Diabetes mellitus was defined as use 
of antidiabetic medication, fasting serum glucose level ≥7.1 mmol/L (≥127.9 mg/dL), or 
random non-fasting serum glucose level ≥11.1 mmol/L (≥200.0 mg/dL) [31]. Additional 
information from the serum samples was collected on high sensitivity C-reactive protein 
(hs-CRP) and creatinine in a subsample (N=1,342).
Statistical analysis
As the GLR, PLR and SII had a skewed distribution, analysis was based on the natural 
logarithmic (Ln) transformation of their values. For the same reason, all plasma biomark-
ers of AD-related brain pathology, except Aβ-40 which had a normal distribution, were 
Ln transformed. We first determined the association between the GLR, PLR and SII with 
plasma biomarkers of AD-related brain pathology  using linear regression. For this analysis, 
we conducted two different transformations: 1) Because we transformed both exposure and 
outcome: logYi = α + βlogXi + ε, we reported mean differences in percentages with 95% 
confidence intervals (CIs) obtained by exponentiating Ln(2) times the estimated coefficients 
from the linear regression model to facilitate interpretation of results: These mean differences 
correspond to the percentage change in plasma Aβ, total-tau or NfL for a doubling of the 
GLR, PLR and SII. For this analysis, Aβ-40 was also Ln transformed. 2) We standardized 
all blood markers to allow direct comparison of the results. We adjusted all models for age, 
sex and study cohort (model I). In addition, the following covariates were added to a second 
model (model II):, smoking, diabetes, BMI and systolic blood pressure and APOE-ε4 car-
riership. Since plasma Aβ, total-tau and NfL were measured in two batches, we addition-
ally corrected for batch effects in models. We performed additional adjustment for platelet 
count when analysing GLR in model II. We assessed effect measure modification by APOE 
genotype by stratifying for participants having the ε2/ε2 or ε2/ε3, ε3/ε3 and ε3/ε4 or ε4/ε4 
genotype. We formally tested interaction between APOE genotype and ratios of blood cell 
counts on the multiplicative scale by adding interaction terms to model II. In addition, we 
assessed effect measure modification by activity of the innate immune system by stratifying 
for median granulocyte count (as pure innate immunity marker rather than studying the 
effect of the balance between innate and adaptive immunity) when assessing the associa-
tions between genetic risk scores and plasma biomarkers of AD-related brain pathology as 
outcome. We formally tested interaction between genetic risk scores and granulocyte counts 
















we also adjusted for creatinine and hs-CRP in a subsample of participants in which these 
markers were measured. Because hs-CRP is also an important inflammatory biomarker, we 
also assessed the association between Ln(hs-CRP) as exposure and the standardized plasma 
biomarkers of AD-related brain pathology as outcome using linear regression. We adjusted 
all models for age, sex, cohort, smoking, diabetes, BMI, systolic blood pressure, APOE-ε4 
carriership, batch effects, platelet count and creatinine.
We then determined associations between all three genetic risk scores per standard deviation 
(SD) increase as exposure with the standardized immunity markers (Ln(GLR), Ln(PLR) 
and Ln(SII)) and with the standardized plasma biomarkers of AD-related brain pathology 
(Ln(Aβ-42, Aβ-40, Ln(Aβ-42/40 ratio), Ln(total-tau) and Ln(NfL)) as separate outcomes, 
using linear regression. These analyses were all adjusted for age, sex and study cohort.
Furthermore, we investigated the association between APOE-allele carriership as exposure 
with serum markers of immunity and plasma biomarkers of AD-related brain pathology as 
outcomes. For this analysis, we defined APOE-allele carriership as either carrying ε2 (ε2/ε2 or 
ε2/ε3 genotype), being homozygous for ε3 (ε3/ε3 genotype) or carrying ε4 (ε3/ε4 or ε4/ε4 
genotype). People with the ε2/ε4 genotype were excluded from the analyses and ε3 homozygos-
ity was considered the reference group. Analyses were adjusted for age, sex and study cohort. We 
calculated mean levels of hs-CRP and creatinine levels within the different APOE genotypes.
Missing covariate data (maximum 0.7%) were imputed using 5-fold Multiple Imputa-
tion by Chained Equations based on determinant, outcome, and included covariates. All 
analyses were performed using RStudio version 1.0.153 (R version 3.6.1, RStudio, Inc., 
Boston, MA). We corrected for multiple testing using Bonferroni adjustment for all analyses 
using the total population (i.e. not stratified or no subgroup analyses): For the associations 
between serum markers of immunity and plasma biomarkers of AD-related brain pathology, 
results are considered statistically significant if P below 0.05/(6×5)=0.002; for the associa-
tions of genetic risk scores reflecting AD including and excluding APOE-ε4 and immune 
response with plasma biomarkers of AD-related brain pathology and serum markers of im-
munity, results were considered statistically significant if P below 0.05/(9×5)=0.001 and for 
the associations of APOE genotypes with plasma biomarkers of AD-related brain pathology 
and serum markers of immunity, results are considered statistically significant if P below 
0.05/16=0.003. For these analyses, a suggestive association was considered at the level al-
pha=0.05. All other analyses were considered statistically significant at the level alpha=0.05.
RESULTS
Characteristics of study participants are displayed in Table 1. The mean age of participants 




































Table 1. Characteristics of study population.
 Characteristic
Sample with serum 
markers of immunity 
(N = 7,397)
Sample with plasma 
biomarkers of AD-related 
brain pathology
(N = 3,615)
Women 4,208 (56.9%) 2,059 (56.8%)
Age, years 66.1 ±10.4 71.9 ±7.3
Study cohort
Cohort 1 2,656 (35.9%) 2,159 (59.7%)
Cohort 2 1,704 (23.0%) 1,456 (40.3%)
Cohort 3 3,037 (41.1%) -
Current smokers 1,427 (19.4%) 536 (14.9%)
Diabetes mellitus type 2 433 (5.9%) 214 (5.9%)
Body mass index, kg/m2 27.6 ±4.3 27.6 ±4.1
Systolic blood pressure, mmHg 142.8 ±21.9 149.2 ±21.0
APOE genotype
ε2/ε2 46 (0.6%) 31 (0.9%)
ε2/ε3 952 (12.9%) 490 (13.6%)
ε2/ε4 202 (2.7%) 103 (2.8%)
ε3/ε3 4293 (58.0%)  2119 (58.6%)
ε3/ε4 1741 (23.5%) 810 (22.4%)
ε4/ε4 163 (2.2%) 62 (1.7%)
granulocyte count, × 103/microL 4.0 ±1.4 4.0 ±1.3
Platelet count, × 103/microL 268.2 ±67.2 256.4 ±64.4
Lymphocyte count, × 103/microL 2.3 ±1.2 2.2 ±1.3
granulocyte-to-lymphocyte ratio 1.9 ±0.9 2.0 ±0.9
Platelet-to-lymphocyte ratio 128.2 ±47.3 130.0 ±49.8
Systemic immune-inflammation 
index
517.3 ±280.1 522.0 ±290.9
Amyloid-beta 42, pg/mL - 10.6 ±3.0
Amyloid-beta 40, pg/mL - 265.6 ±54.6
Amyloid-beta 42/40 ratio - 0.04 ±0.009
Total-tau, pg/mL - 2.6 ±2.5
Neurofilament light chain, pg/mL - 15.7 ±11.6
Abbreviations: N = number of participants included in study. Data presented as mean (standard devia-
tion) for continuous variables and number (percentages) for categorical variables. Data here are un-
imputed. Number of missing values for the immunity cohort: 39 (0.5%) for smoking, 19 (0.3%) for 
diabetes, 20 (0.3%) for BMI, 37 (0.5%) for systolic blood pressure, 0 for APOE carriership. Number 
of missing values for the sample undergoing serum AD measurements are: 25 (0.7%) for smoking, 8 
















women and the mean age of the sample undergoing serum AD marker measurements was 
71.9 (±7.3) years of which 2,059 (57%) were women.
We found that a doubling of SII was associated with a 1.2% higher serum Aβ-42, albeit 
not statistically significant (95% confidence interval (95% CI) -0.005% to 2.3%, P=0.051) 
and a 1.8% higher serum Aβ-40 (95% CI 0.9 to 2.7%, P=<0.001). Estimates were even 
higher for a doubling of GLR, leading to a 1.9% higher serum Aβ-42 (95% CI 0.4 to 3.3%, 
P=0.010) and 3.2% higher serum Aβ-40 (95% CI 2.0 to 4.3%, P=<0.001). The Aβ-42/40 
ratio was lower with a doubling in GLR only (-1.2% [-2.3 to -0.1%], P=0.028). Only a 
doubling in PLR was significantly associated with lower total-tau (-3.6% [-5.5% to -1.7%], 
P=<0.001). NfL was higher with all innate immunity phenotypes, most strongly with a dou-
bling in GLR (4.7% [2.5 to 7.1%], P=<0.001); Table 2 and Table S2. Stratification did not 
reveal statistically significant differences across strata of APOE carriership, with the effects 
in the APOE ε3/ε4 or ε4/ε4 stratum being only non-significantly stronger than in the other 
strata, especially for NfL; Figure 2 and Table S2. In addition, the associations between all 
genetic risk scores with lower Aβ-42/40 ratio became lower in participants with granulocyte 
counts higher than the median (mean difference = -0.18, 95% = CI -0.23; -0.13, P=<0.001 
for the overall AD genetic risk score, mean difference = -0.06, 95% CI = -0.11; -0.02, 
P=0.007 for the overall AD genetic risk score excluding APOE and mean difference = -0.05, 
95% CI = -0.10; -0.004, P=0.035 for the immune response pathway-based genetic risk 
score, yet the interaction remained non-significant; Table S3). When additionally adjusting 
for hs-CRP and creatinine (in a subsample: N=1,341), the associations between GLR and 
SII with higher Aβ-42 and NfL disappeared, the associations between immunity markers 
with higher Aβ-40 were borderline significant and the associations with lower Aβ-42/40 
ratio and lower total-tau persisted; Table S4. Higher hs-CRP was significantly associated 
with a higher Aβ-40 and higher total-tau; Table S5.
Furthermore, we found that a standard deviation (SD) increase in the overall AD ge-
netic risk score including APOE-ε4 was associated with higher GLR (mean difference in 
Ln(GLR) [SD] = 0.024, 95% CI = 0.002; 0.046, P=0.032) and significantly with lower 
Aβ-42 and Aβ-42/40 ratio (mean difference in Aβ-42 [SD] = -0.129, 95% CI = -0.162; 
-0.095, P=<0.001 and Ln(Aβ-42/40) [SD] = -0.157, 95% CI = -0.190; -0.124, P=<0.001, 
respectively). These associations were mainly driven by the APOE-ε4 variant; Figure 3. 
The genetic risk score reflecting the immune response showed a suggestive association with 
lower Aβ-42/40 ratio (mean difference = -0.038, 95% CI = -0.070; -0.006, P=0.020), but 
not with the serum markers of innate immunity; Figure 3 and Table S6. We found that 
APOE-ε2 carriers displayed lower serum markers of innate immunity levels compared to ε3/
ε3, while these markers were elevated in APOE-ε4; Figure 4 and Table S7. Mean levels of 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Associations between serum markers of immunity and plasma biomarkers of AD-related 
brain pathology. 
Abbreviations: CI = confidence interval, SD = standard deviation, Ln = natural logarithmic transfor-
mation, GLR = granulocyte-to-lymphocyte ratio, PLR = platelet-to-lymphocyte ratio, SII = systemic 
immune-inflammation index, Aβ-42 = amyloid-beta 42, Aβ-40 = amyloid-beta 40, Aβ-42/40 ratio = 
amyloid-beta 42-to-40 ratio, NFL = neurofilament light chain, e2/e2 or e2/e3 = apolipoprotein Eε2/
ε2 genotype, e3/e3 = apolipoprotein Eε3/ε3 genotype, e3/e4 or e4/e4 = apolipoprotein Eε3/ε4 or ε4/
ε4 genotype. Model adjusted for age, sex, study cohort, smoking, diabetes, BMI, platelets, systolic 
blood pressure, APOE-ε4 and batch effects. Additional adjustment for platelet count when analysing 
Ln(GLR). All phenotypical markers were Ln(transformed) except for Aβ-40. The GLR, PLR and SII 
reflect the balance between innate and adaptive immunity, with higher markers indicating a dysbalance 




Figure 3. Associations of genetic risk scores reflecting AD including and excluding APOE-ε4 and 
immune response with plasma biomarkers of AD-related brain pathology and serum markers of im-
munity. 
Abbreviations: Ln = natural logarithmic transformation, AD = Alzheimer’s disease, GRS = genetic 
risk score, GLR = granulocyte-to-lymphocyte ratio, PLR = platelet-to-lymphocyte ratio, SII = sys-
temic immune-inflammation index, Aβ-42 = Amyloid-beta 42, Aβ-40 = Amyloid-beta 40, Aβ-42/40 





































In this study, we found associations between higher levels of GLR, PLR and SII reflecting 
higher innate immunity, with higher Aβ42 and 40, lower Aβ-42/40 ratio, lower total-tau 
and higher NfL in plasma. In APOE-ε4 carriers, these associations were even stronger. 
The overall genetic risk score including APOE-ε4 was associated with higher GLR and 
SII and with lower Aβ-42 and Aβ-42/40 ratio. These effects were mainly driven by the 
APOE-ε4 variant. The genetic risk score reflecting the immune response was associated with 
lower Aβ-42/40 ratio, but not with the serum immunity markers. Furthermore, we found 
that APOE-ε2 carriers displayed lower serum markers of innate immunity compared to 
APOE-ε3/ε3, while these markers were elevated in APOE-ε4 carriers.
study cohort. GRS are per SD increase. All phenotypical markers were Ln(transformed) except for 
Aβ-40. Gray dotted circle indicates the null with associations becoming increasingly negative towards 
the centre of the circle. Orange indicates the plasma biomarkers of AD-related brain pathology while 
blue indicates the immunity phenotypes. The GLR, PLR and SII reflect the balance between innate 





Figure 4. Associations of APOE genotypes with plasma biomarkers of AD-related brain pathology and 
serum markers of immunity. 
Abbreviations: CI = confidence interval, SD = standard deviation, GRS = genetic risk score, AD = 
Alzheimer’s disease, Ln = natural log transformation, GLR = granulocyte-to-lymphocyte ratio, SII 
= systemic immune inflammation index, Aβ-42 = Amyloid-beta 42, Aβ-40 = Amyloid-beta 40, Aβ-
42/40 = Amyloid-beta 42-to-40 ratio, NFL = neurofilament light chain, APOE = Apolipoprotein E, 
e2/e2 or e2/e3 = apolipoprotein Eε2/ε2 genotype, e3/e3 = apolipoprotein Eε3/ε3 genotype, e3/e4 or 
e4/e4 = apolipoprotein Eε3/ε4 or ε4/ε4 genotype. Adjusted for age, sex and study cohort. All pheno-
typical markers were Ln(transformed) except for Aβ-40. The GLR, PLR and SII reflect the balance 

















Interestingly, we found that higher innate immunity was associated with higher serum 
Aβ-42, but with even higher Aβ-40. The 40-residue peptide represents the most abundant 
Aβ isoform in the brain [32], while the 42-residue shows a significant increase with certain 
forms of AD. Our findings are concordant with the notion that Aβ functions as an anti-
microbial peptide (AMP), because the physiochemical and biological properties previously 
reported for Aβ are similar to those of AMPs. In addition, experiments have shown that Aβ 
is active against at least eight common and clinically relevant microorganisms [33]. Activity 
was isoform-specific for six organisms with Aβ-42 showing greater potency compared to 
Aβ40 [33]. Taken all evidence together, we propose that APOE-ε4 carriers display stronger 
innate immune responses, and thus produce more/excess Aβ in response to pathogens. Of 
the two isoforms, Aβ42 will aggregate in the brain (possibly due to its larger size) while 
Aβ40 will not aggregate (or to a lesser extent) and as a consequence will be higher in serum. 
Further study is needed to confirm this hypothesis.
Furthermore, we found that both higher serum markers of innate immunity and the 
genetic risk score reflecting the immune response associate with the lower serum Aβ-42/40 
ratio. APOE-ε4 carriership, which is the major genetic risk factor for AD, also displays lower 
serum Aβ-42/40 ratio as well as lower Aβ-42. In line with this, a meta-analysis of prospective 
cohort studies has shown that lower serum Aβ-40, even lower Aβ-42 and consequently 
lower Aβ-42/40 ratio lead to higher AD risk.[34] Previous reports of associations of low 
plasma Aβ-42/40 ratio with increased amyloid brain uptake, as measured by Pittsburgh 
compound B (PiB) positron emission tomography (PET) scan, support the notion that 
lower plasma Aβ reflect the aggregation of Aβ in the brain.[35-38] In this context, our 
finding that APOE-ε4 carriers have higher activity of innate immunity compared to ε3/
ε3, while we see the opposite in APOE-ε2 carriers suggests that APOE-ε4 might have an 
overactive innate immune response. Our results support experimental studies showing the 
capacity of APOE to modulate inflammation. Indeed, in healthy humans challenged with 
intravenous lipopolysacharide (LPS) infusion, ε4 carriers demonstrated significantly higher 
elevation of body temperature and plasma tumor necrosis factor levels than ε4 non-carriers.
[39] In this same study, when whole blood isolates from human subjects were stimulated 
ex-vivo with Toll-like receptor ligands, increased production of a wide panel of cytokines and 
chemokines was observed in blood from ε4+ donors compared with ε4− donors. A higher 
immune response associated with the ε4 allele is also observed in human APOE-targeted 
replacement mice and in cultured microglia and/or macrophages upon LPS stimulation.[39-
41] How APOE achieves this is not yet well-understood.[8] Evidence shows that lipid rafts 
play an essential role in immune activation by serving as platforms for signaling complexes.
[42] APOE-ε4 is reported to be less effective than APOE-ε3 in inducing cholesterol efflux 
from macrophages[43], which leads to cholesterol accumulation on cell membranes.[39, 43] 




































APOE-ε4[8], but further studies are needed to explore this or potential other mechanisms 
further.
In addition to the role of immune response pathways in Aβ, our data show that higher 
innate immunity related to lower plasma total-tau. Others assessed the effect of microglial 
activation on tau pathogenesis, where they found that microglial activation is shown to 
precede tau pathology in a tauopathy mouse model (Yoshiyama et al. 2007) and administer-
ing an immunosuppressant drug FK506 from an early age drastically reduces tau pathology 
[44]. According to previous studies, higher plasma tau is associated with AD dementia [16, 
45], although correlations were weak [45] and non-linear (J-shape) [16], making the role of 
immunity in tau elusive. Future studies are implicated relating the same crude markers of the 
immune system in relation to phospho tau.
The associations between immunity markers with higher Aβ-42 and NfL disappeared 
when additionally adjusting for hs-CRP and creatinine. There could be two explanations: 
1) This analysis was performed within a subsample of the total population, impeding com-
parison of the results in the total population and decreasing the power of the analysis. 2) 
We found that higher hs-CRP was also associated with higher NfL, albeit not statistically 
significant, suggesting that hs-CRP could be acting as a mediator.
Our result that the immune GRS was not related to the immunity biomarker levels 
is surprising, especially since several immune genes are key players for innate immunity, 
including TREM2 [46]. TREM2 overexpression is thought to enhance microglial phago-
cytotic capacity, but transcription analyses show mixed microglial activation patterns with 
suppression of certain disease-associated microglia (DAM) genes, but further activation pat-
terns of other DAM genes [47], making the role of TREM2 in AD unclear. Further studies 
are needed to identify the precise gene signatures of microglia that mediate pathology-and 
neurodegeneration-associated sterile inflammation.
Our study has several limitations. First, ours is a cross-sectional study, limiting our ability 
to draw causal inferences. Longitudinal cohort studies are required to confirm our findings. 
Second, we were limited to studying crude markers of the immune system in this popula-
tion-based setting. These types of measures have been associated with other outcomes like 
cancer-related, pancreatitis, and many other responses [48]. These ratios could be proxies for 
different systemic inflammatory responses that affect mobilization of bone marrow-derived 
cells and egress of leukocytes into tissue [49]. It could also be related to immunosenescence 
and this might explain the association with NfL because it too, increases with age [50]. 
Third, we were similarly limited to crude markers of AD-related brain pathology which 
are not diagnostic of AD, especially since the ATN-classification includes AD biomarkers 
as measured by PET, structural MRI or CSF and we do not have phospho tau measured. 
However, plasma and CSF levels of these biomarkers are strongly correlated [51-53]. Also 
NfL is a global biomarker and not specific for AD. Fourth, we were unable to categorise 
















onset AD patients within our population-based cohort. It would be helpful to categorise the 
biomarkers according to early and late onset AD in future studies, because Aβ has a better 
correlation in early onset AD. Early onset AD differs from late onset AD not only with 
respect to genetic predisposition and pathology but also in relation to the clinical outcome 
and the natural course. Only 11% of early AD patients has familial mutations with APP, 
PSEN1 and PSEN2. For example, patients with early AD have a greater burden in precuneus 
and parietal lobes and to a lesser extent in the frontal lobes [54]. Fifth, we did not offer 
replication data. We hope that our study provides a stimulus for other cohort studies to 
replicate our findings. Lastly, our study contains predominantly Caucasians, which limits 
its external generalizability. Further study in other ethnicities is needed to identify potential 
ethnic differences.
In summary, in this population-based study we showed that higher innate immunity, as 
reflected by higher levels of serum GLR, PLR and SII, were associated with higher plasma 
Aβ42, 40, and NfL, and with lower Aβ-42/40 and total-tau. Furthermore, APOE-ε2 car-
riers displayed lower serum markers of innate immunity levels compared to ε3/ε3, while 
these markers were elevated in APOE-ε4. Knowledge on the potential pro-inflammatory 
role of APOE-ε4 should encourage future studies to find ways to scale down innate immune 
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Table S1. Clustering of genome-wide significant variants into the immune response pathway. 
Pathway














CLU Common rs9331896 Yes Yes Yes Yes
CR1 Common rs4844610 Yes Yes Yes Yes
INPP5D Common rs10933431 Yes Yes Yes Yes
EPHA1 Common rs10808026 - - - Yes
MS4A2 Common rs7933202 - Yes - Yes
MEF2C Common rs190982 Yes - - Yes
ABI3 Rare rs616338 - Yes - -
PLCG2 Rare rs72824905 Yes Yes Yes -
TREM2 Rare rs75932628 - Yes - Yes

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S8. Descriptive statistics of high-sensitive CRP and creatinine levels within APOE genotypes.
APOE genotype Mean hs-CRP level Mean creatinine level
ε2/ε2 or ε2/ε3 (N=203) 3.5 82.1
ε3/ε3 (N=799) 3.4 84.3
ε3/ε4 or ε4/ε4 (N=304) 2.3 84.3
Abbreviations: hs-CRP = high-sensitive CRP, APOE = Apolipoprotein E, e2/e2 or e2/e3 = apolipopro-
tein Eε2/ε2 genotype, e3/e3 = apolipoprotein Eε3/ε3 genotype, e3/e4 or e4/e4 = apolipoprotein Eε3/
ε4 or ε4/ε4 genotype.



















There is a wide interest in biomarkers that capture the burden of detrimental factors as these 
accumulate with the passage of time, i.e., increasing age. Telomere length has received consid-
erable attention as such a marker, because it is easily quantified and it may aid in disentangling 
the aetiology of dementia or serve as predictive marker. We determined the association of 
telomere length with risk of Alzheimer disease and all-cause dementia in a population-based 
setting. Within the Rotterdam Study, we performed quantitative PCR to measure mean leu-
kocyte telomere length in blood. We determined the association of telomere length with risk 
of Alzheimer’s disease until 2016, using Cox regression models. Of 1,961 participants (mean 
age 71.4±9.3 years, 57.1% women) with a median follow-up of 8.3 years, 237 individuals 
were diagnosed with Alzheimer’s. We found a U-shaped association between telomere length 
and risk of Alzheimer’s: compared to the middle tertile the adjusted hazard ratio was 1.59 
(95% confidence interval (CI), 1.13-2.23) for the lowest tertile and 1.47 (1.03-2.10) for the 
highest tertile. Results were similarly U-shaped but slightly attenuated for all-cause dementia. 
In conclusion, shorter and longer telomere length are both associated with an increased risk 
of Alzheimer’s disease in the general population.

























Dementia is a devastating disease affecting millions of people worldwide. While advances 
over the past decades have unravelled several pathological mechanisms underlying dementia, 
chronological age remains the most important predictor for dementia onset (Collaborators, 
2018). There is, therefore, a wide interest in biomarkers that capture the burden of detrimen-
tal factors as these accumulate with the passage of time, i.e., increasing age. Such markers, 
that are preferably easily quantified, may aid in disentangling the aetiology of dementia or 
ultimately serve as predictive markers. Against this background, telomere length has received 
considerable attention (Blackburn et al., 2015).
Telomeres are repetitive base pair sequences at the end of chromosomes and facilitate 
complete chromosome replication (Martinez and Blasco, 2015). Since the replication 
machinery is unable to copy the ends of DNA, telomeres will shorten with each cell divi-
sion. A change in telomere length resulting in shortened telomeres induces a DNA damage 
response that leads to a growth arrest during which cells attempt to repair the damage and 
if DNA damage is irreparable, replicative senescence or cell death is triggered (Martinez and 
Blasco, 2018). Very short telomeres have relatively low cancer risk (due to cell senescence 
blocking cell division), but could be associated with increased DNA damage (Min et al., 
2017). Given the tight link with cell death, short telomere length has been linked to poorer 
survival (Fasching, 2018; Wang et al., 2018) and other age-related diseases, including de-
mentia as has been shown in a recent meta-analysis (Forero et al., 2016). Conversely, there 
is evidence that over-elongated telomeres represent pathological cell function with decreased 
DNA repair and increased cancer risk (Zhang et al., 2017), which has also been shown 
in human embryonic stem cells (Rivera et al., 2017), while “normally” long telomeres are 
protective, including against DNA damage. With respect to Alzheimer’s disease, there is also 
evidence suggesting an increased risk of mild cognitive impairment related to both short 
and long telomeres (Roberts et al., 2014). Additionally, hippocampal cells of Alzheimer’s 
disease brains are shown to have longer telomeres compared to control samples (Thomas et 
al., 2008). It is, thus, conceivable that not only shorter but also longer telomere length may 
be detrimental for dementia risk. However, the temporal relation between longer telomere 
length and dementia has so far not been investigated. Therefore, the aim of this study is to 
investigate the association between blood cell telomere length and risk of Alzheimer’s disease 

















Design and study population
This study was embedded within the Rotterdam Study, a prospective population-based 
cohort study among middle-aged and elderly individuals in the Netherlands. Three cohorts 
were established in 1990, 2000 and 2006, respectively. From each cohort, participants were 
invited every 4-5 years to undergo follow-up examinations. We refer the reader to the Rotter-
dam Study methods paper for further information (Ikram et al., 2017). For this study, a total 
of 2,140 participants were randomly selected from the first (1990-2004, N=7983) and third 
cohorts (2006-2008, N=3932) for telomere length measurement. From these participants, 
1,961 were dementia-free at baseline visit and had complete telomere length data available 






















Cohort I (n=7983) 
Original cohort Extended cohort 
Cohort III (n=3932) 
Random subset of subjects were 





Follow-up for dementia was complete for 
95.0% of potential person-years 
Excluded from analysis: 
• No telomere length available 
for analysis (n=74) 












Excluded from analysis: 
• Participants with prevalent dementia (n=85) 
• Insufficient baseline screening (n= 7) 



































The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, imple-
menting the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). 
All participants provided written informed consent to participate in the study and to obtain 
information from their treating physicians.
Assessment of telomere length
Blood for all samples was collected in EDTA tubes and stored at -20°C until DNA isolation. 
DNA isolation was done with a method based on salting out, with different lysis buffers for 
the different cohorts. The OD260/280 and OD260/230 for both isolation methods did not 
differ significantly between the two cohorts. The average OD260/280 ratio was 1.90 with a 
standard deviation of 0.10 and the average OD260/230 ratio was 1.61 with a standard devia-
tion of 0.46 in a random sample of 168.Telomere length was measured using a qPCR assay 
based on the method described by Cawthon (Cawthon, 2002) with minor modifications. The 
SDS software of the 7900HT qPCR machine is not able to analyse the qPCR data produced 
at two different temperature points. Therefore we chose the singleplex assay for this study. 
For each sample the telomere and 36B4 assay were run in separate wells but in the same 384 
wells PCR plate. Each reaction contained 5 ng DNA, 1 uM  of each of the telomere prim-
ers (tel1b-forward: GGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT, 
tel2b-reverse: GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT) or 
250 nM of the 34B4 primers (36B4u-forward: CAGCAAGTGGGAAGGTGTAATCC, 
36B4d-reverse: CCCATTCTATCATCAACGGGTACAA) and 1x Quantifast SYBR green 
PCR Mastermix (Qiagen). The reactions for both assays were performed in duplicate for 
each sample in a 7900HT machine (Applied Biosystems). Ct values and PCR efficiencies 
were calculated per plate using the MINER algorithm (Codd et al., 2010). Duplicate Ct 
values that had a Coefficient of Variance (CV) of more than 1% were excluded from further 
analysis. Using the average Ct value per sample and the average PCR efficiency per plate 
the samples were quantified using the formula Q=1/(1+PCR eff)^Ct. The relative telomere 
length was calculated by dividing the Q of the telomere assay by the Q of the 34B4 assay. 
To validate the assay 96 random samples were run twice and the CV of that experiment was 
4.5%.Telomere length was measured in 37 batches.
Ascertainment of incident dementia
Baseline and follow-up ascertainment methods for dementia have previously been described 
in detail (de Bruijn et al., 2015). In brief, participants were screened for dementia at baseline 
and subsequent center visits. In addition, the entire cohort was continuously under surveil-
lance for dementia through electronic linkage of the study database with medical records. A 
consensus panel led by a consultant neurologist established the final diagnosis according to 
















Within this period, participants were censored at date of dementia diagnosis, death, loss to 
follow-up, or 1st of January 2016, whichever came first. 
APOE genotyping
APOE genotype was determined using polymerase chain reaction on coded DNA samples 
in the baseline cohort (Slooter et al., 1998) and with a bi-allelic Tacqman assay (rs7412 and 
rs429358) in the extensions of the Rotterdam Study (Ikram et al., 2017). APOE-ε4 carrier 
status was defined carriers versus non-carriers of the ε4 allele.
Other covariates 
Potential confounding factors were chosen on the basis of previous literature (de Bruijn 
et al., 2015; Nilsonne et al., 2015). All covariates were measured at baseline. Educational 
attainment was categorized as low (primary education or lower vocational education), inter-
mediate (secondary education or intermediate vocational education), and high educational 
level (higher vocational education or university). Smoking habits were categorized as current, 
former and never smoking. BMI was calculated as weight in kilograms per height in meters 
squared. Blood pressure was measured twice at the right brachial artery with the participant 
in sitting position, out of which the mean was used. Hypertension was defined as a resting 
blood pressure exceeding 140/90 mmHg or the use of blood pressure lowering medication. 
Hypercholesterolemia was defined as a total cholesterol of ≥6.2 mmol/L or the use of serum 
lipid-reducing agents. White blood cell counts were assessed with a Coulter AcT diff2 He-
matology Analyzer at the research centre in Ommoord. At 14 February 2005 a new device 
of the same brand and type was installed. Prevalent stroke was assessed at baseline during 
interview and we verified these data with medical records. After study entry, we continuously 
monitored participants after enrollment for incident stroke through linkage of the study 
database with files from general practitioners. Files of nursing home physician’s and files 
from general practitioners of participants who moved out of the district were also checked. 
We obtained additional information from hospital records. When potential strokes were 
found, they were reviewed by research physicians and verified by an experienced neurologist.
Statistical analysis
Missing covariate data (maximum 2.2%) were imputed using 5-fold multiple imputation 
based on determinant, outcome, and included covariates. In all models, we adjusted for 
age continuously, sex and center visit since data was randomly selected from 4 center visits 
from 2 subcohorts. We additionally adjusted for educational attainment, APOE-ε4 carrier 
status, smoking, body mass index (BMI), hypertension, hypercholesterolemia and white 
blood cell count in a second model, all at time of blood draw. We first explored linearity of 
telomere length with Alzheimer’s disease and dementia risk by entering T/S ratio as restricted 























non-linearity, T/S ratio was subsequently divided into tertiles, defined as T/S ratio of 0.31-
0.87, 0.87-1.02 and 1.02-1.79, respectively. To provide a parsimonious description of the 
telomere-dementia relationship and facilitate communication of the results, we assessed the 
association between telomere length in tertiles, comparing lowest and highest tertiles that 
represent the shortest and longest telomere lengths, respectively, to the middle tertile, with 
risk of Alzheimer’s disease and dementia. We repeated the analysis for Alzheimer’s disease, by 
adjusting not only for age at blood draw, but also for age at dementia diagnosis or date of last 
follow-up as an attempt to assess survival bias. We further verified that age was robustly con-
trolled for by comparing results across models using five different ways of age-adjustment. 
These included no adjustment for age, entering age and age2 in the model, entering age as 
cubic splines, repeating the analyses with age rather than follow-up time as the time scale 
and finally regressing the effect of age out of T/S ratio before creating T/S ratio tertiles. 
We performed an additional adjustment for plate number to rule out batch effects. The 
proportional hazards assumption was assessed using Schoenfeld residuals. We next repeated 
the analyses for AD, but excluding all participants with prior clinical stroke at baseline and 
censoring for incident clinical stroke during follow-up using Cox models.
We also assessed interaction by age, sex, education or APOE-ε4 carrier status by stratification 
and testing for multiplicative interaction by including the product of the interacting factor 
and T/S ratio continuously as a restricted cubic spline (4 knots) to take into account the 
non-linear relationship between T/S ratio and Alzheimer’s disease. We stratified for age by 3 
groups, namely 45-65 years, 65-85 years and 85-105 years. 
All analyses were performed using RStudio version 0.99.903 (R version 3.4.3(Team, 
2017), RStudio, Inc., Boston, MA). We used the following R packages for our analyses: 

















Baseline characteristics of the study population are presented in Table 1. The mean age of 
the participants was 71.4±9.3 years with 57.1% women. During a median follow-up of 7.3 
(interquartile range 4.9-11.7) years (26,025 person-years), 305 individuals were diagnosed 
with dementia of whom 237 were Alzheimer’s disease.










Primary education 366 (18.9%)
Lower/intermediate general education 806 (41.5%)
Intermediate vocational education 535 (27.6%)
Higher vocational education 233 (12.0%)
Apolipoprotein E4ε carriership
Non-carrier (ε2/ε2 , ε2/ε3 or ε3/ε3) 1411 (72.0%)












White blood cell count 6.9 ±2.3
Telomere length, T/S ratio 0.95 ±0.18
Abbreviations: N = number of participants included in study. Data presented as mean (standard devia-
tion) for continuous variables and number (percentages) for categorical variables. T/S ratio is relative 
telomere to single copy gene ratio. Data represent original data without imputed values. Number of 
missing values are 43 (2.2%) for smoking, 21 (1.1%) for education, 27 (1.4%) for hypertension, 17 
(0.9%) for hypercholesterolemia, 29 (1.5%) for body mass index and 157 (8.0%) for white blood cell 























There was evidence of non-linearity in the association between telomere length and 
Alzheimer’s disease; Figure S1. Compared to the middle tertile of telomere length, we found 
an adjusted hazard ratio (aHR) of 1.59; 95% confidence interval (CI), 1.13-2.23 for lowest 
tertile of telomere length and 1.47; 95%CI, 1.03-2.10 for highest tertile of telomere length 
for Alzheimer’s disease, with similar but lower estimates for dementia (Table 2). When addi-
tionally adjusting for age at dementia diagnosis or date of last follow-up,  we found an aHR 
of 1.52; 95%CI, 1.07-2.18 for lowest tertile of telomere length and 1.75; 95%CI, 1.21-2.54 
for highest tertile of telomere length for Alzheimer’s disease, compared to the middle tertile. 
Other approaches of age-adjustment yielded similar results (Table 3). There were no batch 
effects. The proportional hazards assumption was met for all models. Results were slightly 
attenuated but remained U-shaped after excluding participants with prior clinical stroke at 
baseline and censoring for incident clinical stroke: compared to middle tertile aHR: 1.44, 
1.02-2.05 for lowest tertile of telomere length and aHR 1.30, 95% CI 0.90-1.89 for highest 
tertile of telomere length.
In the stratified analyses, the association between shorter and longer telomeres and 
Alzheimer’s disease was stronger in APOE-ε4 carriers compared to non-carriers (Figure 2) 
with the multiplicative interaction term yielding p=0.087. Stratification for age, sex and 
education did not provide different risk estimates (P-values for interaction: p = 0.554, p = 
0.600 and p = 0.123, respectively).
Table 2. Telomere length and the risk of Alzheimer’s disease and all-cause dementia.
n/N Alzheimer’s disease n/N All-Cause dementia
Model I HR, 
95% CI
Model II HR, 
95% CI




























Abbreviations: n = number of cases; N = number of persons at risk; HR = hazard ratio; CI = confidence 
interval; T/S ratio = relative telomere to single copy gene ratio. Cox regression model I: Adjusted for 
age, sex and visit. Cox regression model II: Adjusted for age, sex, visit, education, APOE-ε4 carrier 


































































































































































































































































































































































































































































































































































































































































































































In this study, shorter as well as longer telomere length were significantly associated with 
increased risk of dementia, specifically Alzheimer’s disease.
Thus far, focus in the dementia field has been on shorter telomere length with studies 
finding observationally as well as genetically associations between shorter telomere length 
and increased risk of AD (Honig et al., 2012; Zhan et al., 2015; Guo and Yu, 2019; Scheller 
Madrid et al., 2019). Moreover, a recent meta-analysis which included 13 primary studies 
demonstrated significantly shorter telomere length in 860 AD patients compared to 2,022 
controls (Forero et al., 2016). Interestingly, we found that in addition to shorter telomere 





Figure 2. The association between telomere length and the risk of Alzheimer’s disease stratified for 
APOE4 allele carriers and non-carriers.
A visual representation of telomere length and the risk of Alzheimer’s disease (AD) stratified by 
APOEε4 carriership with restricted cubic splines in Cox model II, adjusted for age, sex, study visit, ed-
ucation, APOEε4 carrier status, smoking, BMI, hypertension, hypercholesterolemia and white blood 
cell count. Number of AD cases in APOEε4 carrier group: 102 with 550 persons at risk; number of 
















finding is in line with previous studies (Wikgren et al., 2012a; Wikgren et al., 2012b), 
particularly the study by Roberts and others (Roberts et al., 2014) showing that short and 
long telomeres increase risk of amnestic mild cognitive impairment. Yet, we emphasize that 
further replication is necessary to confirm the robustness of our findings with dementia.
An explanation for our observations with longer telomere length might be survival 
bias, where presumably participants with the longest telomere length live long enough to 
develop dementia. This is however less likely since associations remained after additional 
adjustment for age at dementia diagnosis or end of follow-up. Alternatively, it is plausible 
that a disturbed equilibrium of telomere length towards either direction is harmful. Indeed, 
over-elongated telomeres become fragile and accumulate DNA damage, as has been shown 
by an experimental study in human embryonic stem cells, and very tight control of telomere 
length homeostasis is regulated by not only telomerase-dependent elongation, but also by 
telomere trimming events (Rivera et al., 2017). Another study has shown that telomerase 
RNA component (TERC) knockout mice with AD, which present with telomere shorten-
ing, slows down the progression of Aβ pathology, showing a more protective effect of short 
telomere length (Rolyan et al., 2011), thereby supporting  a detrimental effect of longer 
telomere length. The potential biological link between over-elongated telomeres and higher 
AD risk remains to be further elucidated. In contrast with longer telomere length, more 
is known about the potential biological link between shorter telomeres and increased AD 
risk. Neurons lacking telomerase reverse transcriptase (TERT) in knockout mice and thus 
have shorter telomeres, display an increased production of oxidative species and an increase 
in cellular oxidative damage in response to tau, demonstrating a harmful effect of shorter 
telomeres (Spilsbury et al., 2015). Therefore, telomerase may play different roles in the tau 
and amyloid pathology via multiple mechanisms (Liu et al., 2018). In addition, microglial 
cellular senescence may also be an important mechanism in the development of AD, which 
is suggested to be exacerbated by the presence of amyloid (Flanary, 2005; Flanary et al., 
2007). Further studies are warranted to differentiate between a true biological association 
and survival bias. If a true biological association exists between longer telomere length and 
risk of dementia, telomerase therapies, which have been successful in mice (Jaskelioff et 
al., 2011; Bernardes de Jesus et al., 2012), would need further fine-tuning to prevent over-
elongation of telomere length.
Interestingly, we found stronger effects for Alzheimer’s disease compared to all-cause de-
mentia. This might be reflective of the fact that Alzheimer’s disease is a more homogeneous 
entity than all-cause dementia, which includes a plethora of etiologies.
Certain limitations must be taken into account. First, we measured telomere length 
in leukocytes in blood. This may not be representative of telomere length in the brain, 
in particular glial cells. However, a previous study has shown a direct correlation between 
telomeres measured from peripheral blood and cerebellum (Lukens et al., 2009), suggesting 























mere length in leukocytes is that lymphocytes are the only peripheral blood cells expressing 
telomerase activity and therefore are able to maintain telomere length despite proliferation, 
while granulocytes lack the ability for further cell division (Akbar and Vukmanovic-Stejic, 
2007). Therefore, it is possible that the older individuals without dementia have a greater 
proportion of lymphocytes (fewer granulocytes) (van der Willik et al., 2019), and thus longer 
telomere length. Unfortunately, we were not able to adjust for the percentage of lymphocytes 
to overcome this issue, since this data was not available for all center visits. Another issue 
is that leukocytes divide peripherally in response to various stresses (e.g., infection) and 
the telomere length may therefore change unexpectedly. Also, research centers may vary 
in reliability in measuring leukocyte telomere length. Second, we measure mean telomere 
length, while cell senescence is suggested to be related to and modulated by the shortest 
telomere length per cell (Hemann et al., 2001). Third, the external validity of the results 
may be limited due to the single centre nature of this study. Finally, despite using different 
approaches yielding similar results, the effect of age may not have been taken into account 
entirely. Nevertheless, given the link of older age with shorter telomere length and older age 
with Alzheimer’s disease, controlling for age would if anything strengthen the association 
between longer telomere length and risk of Alzheimer’s disease.
In conclusion, shorter and longer telomere length are associated with an increased risk of 
Alzheimer’s disease in a sample of elders in The Netherlands. Further studies are warranted 
to confirm our findings, in particular studies with imaging or fluid biomarkers available 
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Figure S1. The association between telomere length and the risk of Alzheimer’s disease.
A visual representation of telomere length and the risk of Alzheimer’s disease (AD) with restricted cubic 
splines in Cox model II, adjusted for age, sex, study visit, education, APOEε4 carrier status, smok-
ing, BMI, hypertension, hypercholesterolemia and white blood cell count. The U-shaped association 
between telomere length and Alzheimer’s disease risk is clearly visible, showing elevated risk for both 
shorter and longer telomere length. The black line indicates the hazard ratio and gray area indicates 
the 95% confidence interval.


Chapter 5  
Brain hemodynamics

5.1 global brain perfusion and the risk of 


















Background – The role of subtle disturbances of brain perfusion in the risk of TIA or isch-
emic stroke remains unknown. We examined the association between global brain perfusion 
and risk of TIA and ischemic stroke in the general population.
Methods and Results - Between 2005-2015, 5289 stroke-free participants (mean age 
64.3 years, 55.6% women) from the Rotterdam Study underwent phase-contrast brain 
magnetic resonance imaging at baseline to assess global brain perfusion. These participants 
were followed for incident TIA or ischemic stroke until January 1st, 2016. We investigated 
associations between global brain perfusion (mL blood flow/100mL brain/minute) and risk 
of TIA and ischemic stroke using Cox regression models with adjustment for age, sex, and 
cardiovascular risk factors. Additionally, we investigated whether associations were modi-
fied by retinal vessel calibers, small and large vessel disease, blood pressure and heart rate. 
During a median follow-up of 7.2 years (36,103 person-years), 137 participants suffered 
a TIA and another 108 an ischemic stroke. We found that lower global brain perfusion 
was associated with a higher risk of TIA but not with the risk of ischemic stroke (adjusted 
hazard ratio (aHR), 95% confidence interval (CI), per standard deviation decrease of global 
brain perfusion: 1.29, 1.07–1.55 for TIA and aHR of 1.06, 0.87–1.30 for ischemic stroke). 
Across strata of wider arteriolar retinal calibers, lower brain perfusion was more prominently 
associated with TIA, but not with ischemic stroke.
Conclusions - In a community-dwelling population, impaired global brain perfusion 











































Stroke is caused by insufficient perfusion to specific regions of the brain, leading to neuronal 
dysfunction and ultimately cell death1. If the disruption is of short duration, it may instead 
lead to a transient ischemic attack  (TIA) 2. Maintenance of sufficient perfusion of the 
brain is achieved primarily by arterioles, which either dilate or contract3.  In the presence of 
cardiovascular risk factors and arteriolosclerosis this regulating ability of arterioles is affected 
and can lead to disruptions in brain perfusion. In this light, cerebral hypoperfusion has been 
suggested as a potential link between vascular damage and TIA and stroke and is a potential 
target for preventive interventions 4, 5. However, the temporal relationship between cerebral 
hypoperfusion and the risk of TIA or stroke remains undefined. Global brain perfusion is 
a hemodynamic factor, which reflects more subtle and chronic changes in brain perfusion6. 
Until recently, studies assessing global brain perfusion have only been performed in people 
with previous stroke or in patients with asymptomatic or symptomatic high-grade carotid 
stenosis, in which lower global brain perfusion increased the risk of stroke7. Yet, it is un-
known whether in the absence of high-grade carotid stenosis global brain perfusion is related 
to the occurrence of TIA and stroke. Moreover, it is unclear whether any impact of poor 
global brain perfusion on stroke risk is augmented by additional pathology along the brain 
vasculature, either as large vessel or small vessel disease. Identifying individuals who are at 
increased hemodynamic risk of stroke can be of major importance for preventive purposes.
Against this background, we investigated the association of global brain perfusion at baseline 
with the risk of TIA and ischemic stroke in a large sample of community-dwelling elderly 
with an average follow-up of 7 years. We hypothesized that lower global brain perfusion is 
a risk factor for incident TIA and ischemic stroke and that this association is modified by 
markers of small and large vessel disease.
METHODS
Study population
This study is embedded within the Rotterdam Study, a large population-based cohort study 
in the Netherlands that started in 1990. The study is aimed at investigating determinants 
of various chronic diseases among elderly people8. The original study population consisted 
of all residents of Ommoord, a district in Rotterdam, aged 55 years and older. In 2000, the 
cohort was expanded with another 3,011 participants with the same inclusion criteria and 
in 2006, a further expansion of the cohort was initiated in which 3,932 participants were 
included, aged 45-54 years. Follow-up examinations at the research center are performed 
every 3 to 5 years. From 2005 onwards, brain MRI was implemented in the core study 

















Th e Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare 
and Sport (Population Screening Act WBO, license number 1071272-159521-PG). Th e 
Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; www.
trialregister.nl) and into the WHO International Clinical Trials Registry Platform (ICTRP; 
www.who.int/ictrp/network/primary/en/) under shared catalogue number NTR6831. All 
participants provided written informed consent to participate in the study and to have their 
information obtained from treating physicians. Requests to access the dataset from quali-
fi ed researchers trained in human subject confi dentiality protocols may be sent to Dept. of 
Epidemiology, Erasmus MC University Medical Center at f.vanrooij@erasmusmc.nl.
Population for analysis
Of 5,644 persons undergoing a fi rst MRI scan, no reliable measure of cerebral blood fl ow 
could be obtained in 5 (0.09%) persons. After excluding participants with prevalent TIA or 
stroke (n = 320) and 30 participants with missing follow-up (n = 30) data, 5,289 partici-
pants were included for analysis. Follow-up for TIA and stroke was complete for 93.7% of 




Follow-up for TIA or stroke was complete for 
93.7% of potential person-years 
Participants with prevalent TIA or stroke (n=320) 
Subjects with perfusion measurements (n=5639) 
Eligible and scheduled for first MRI scan 
(n=5644) 
Excluded from study (n=5): 
No perfusion measurement 
TIA or stroke-free participants (n=5319) 
Cohort I (n=3558) Cohort II (n=2506) Cohort III (n=3932) 
Participants with missing follow-up time (n=30) 
Study population (n=5289) 










































Assessment of global brain perfusion
All participants were scanned at baseline on a 1.5-Tesla MRI scanner (General Electric 
Healthcare, Milwaukee, WI, USA) with a dedicated eight-channel head coil. The full MRI 
protocol has been described in detail before9. Specifically, for the flow measurements, we 
performed a 2D phase-contrast sequence10, 11. A 2D thick slab projection phase contrast 
angiographic localizer (60 mm thick, velocity encoding (VENC) = 60 cm/sec) is positioned 
sagittally in order to determine the location of the carotid and basilar arteries. Next, a thin 
slice perpendicular to all three vessels at the level of the precavernous internal carotid artery is 
positioned (VENC = 120 cm/s, slice thickness 5 mm, NEX = 8). From the resulting images, 
we calculated cerebral blood flow using interactive data language-based custom software 
(Cinetool version 4, General Electric Healthcare, Milwaukee, WI, USA). Two independent, 
experienced technicians drew circular to elliptical regions of interest (ROIs) manually around 
both carotids and the basilar artery at the level of the clinoid segment on the phase-contrast 
images, encompassing the entire lumen of the vessel (inter-rater correlations > 0.94 for all 
vessels)12. For improved visualization of vessel boundaries, the contrast between the arteries 
of interest and the background were inverted. In each ROI, the value of mean signal inten-
sity reflected the flow velocity in the vessel (cm/sec). By multiplying the average velocity 
with the cross-sectional area of the vessel, flow (in mL/sec) was calculated. To obtain global 
cerebral blood flow (tCBF) in mL/min, flow rates for the carotid arteries and the basilar 
artery were summed and multiplied by 60 secs/min. We calculated global brain perfusion 
(in mL/min blood per 100 mL brain) by dividing tCBF (mL/min) by each individual’s brain 
volume (mL) and multiplying the obtained result by 100 mL brain volume. Brain volume 
was calculated by adding up gray and white matter volumes, converted to millilitres.
Assessment of retinal vessel calibers
Retinal microvascular calibers are considered markers of small vascular pathology, but also 
markers of vascular autoregulation13, 14, which we therefore stratified for. We assessed retinal 
microvascular calibers (arteriolar and venular calibers (in μm)) using fundus photographs 
and the Retinal Vessel Measurement System (Retinal Analysis, Optimate, WI; Department 
of Ophthalmology and Visual Science, University of Wisconsin-Madison)15 as previously 
described16, 17. Retinal microvascular calibers were assessed in a subset of 3219 individuals.
Assessment of small vessel and large vessel disease
For the lacunar infarcts and WMHs measurements on MRI scans, gray matter volume (GM), 
white matter volume (WM) and cerebrospinal fluid were quantified using an automated tis-
sue segmentation method, based on a k-nearest-neighbour brain tissue classifier algorithm18. 
This was extended with a custom-developed WMH (white matter hyperintensity) segmenta-
tion19. Segmentation results were visually inspected and if needed corrected manually. All 

















presence of lacunar infarcts (defined as focal lesions ≥3 and <15 mm in size with the same 
signal characteristics as cerebrospinal fluid on all sequences, and, if located supratentorially, 
with a hyperintense rim on the fluid attenuated inversion recovery sequence).
Markers of large vessel disease (intima-media thickness and carotid plaques) were mea-
sured as follows: Doppler ultrasound was used to measure carotid stenosis (≥50% stenosis). 
To measure carotid intima-media thickness and carotid plaques, ultrasonography of the 
common carotid artery, carotid bifurcation, and left and right internal carotid artery was 
performed with a 7.5-MHz linear-array transducer (ATL Ultra-Mark IV)20.
Stroke and TIA assessment
The definition of stroke was based on the WHO criteria21, describing a syndrome of rapidly 
developing symptoms of focal or global cerebral dysfunction lasting 24 hours or longer or 
leading to death, with apparent vascular cause. Prevalent stroke was assessed at baseline 
during interview and we verified these data with medical records. After study entry, we 
continuously monitored participants after enrollment for incident stroke through linkage 
of the study database with files from general practitioners. Files of nursing home physi-
cian’s and files from general practitioners of participants who moved out of the district were 
also checked. We obtained additional information from hospital records. When potential 
strokes were found, they were reviewed by research physicians and verified by an experienced 
neurologist. We then categorized strokes into ischemic or haemorrhagic on the basis of 
neuro-imaging reports. If neuroimaging was missing and we could not differentiate the type 
of stroke according to the symptoms, the stroke was classified as unspecified. Subarachnoid 
haemorrhages due to ruptured aneurysms were not considered stroke events. For this study, 
we were mainly interested in ischemic stroke as outcome. Follow-up for incident stroke was 
complete until January 1st 2016.
A similar work-up was performed to determine prevalent and incident TIA22. Transient 
neurological attacks (TNA) were defined as attacks of sudden neurological symptoms that 
completely resolved within 24 hours, with no clear evidence for the diagnosis of migraine, 
epilepsy, Meniere disease, hyperventilation, cardiac syncope, hypoglycemia, or orthostatic 
hypotension23. If only focal brain symptoms (hemiparesis, hemihypesthesia, dysphasia, dys-
arthria, amaurosis fugax, hemianopia, hemiataxia, diplopia, or vertigo) were reported, the 
event was classified as a focal TNA. If only nonfocal brain symptoms (decreased conscious-
ness, unconsciousness, confusion, amnesia, unsteadiness, nonrotatory dizziness, positive 
visual phenomena, cardiac or vegetative signs, paresthesias, bilateral weakness, and unwell 
feelings) were reported, the event was classified as nonfocal TNA. If both focal and nonfocal 
symptoms were reported for the same attack, a mixed TNA was diagnosed. For this study, we 










































Other measurements in the Rotterdam Study
Information on cardiovascular risk factors was obtained by interview, physical examination 
and blood sampling8. We assessed history of smoking (current, former, never), and use of 
antihypertensive, lipid-lowering and anti-thrombotic medication at baseline by interview. 
Body mass index was calculated as weight (kg)/length (m2). Diastolic and systolic blood 
pressures were measured twice on the right arm with a random-zero sphygmomanometer; 
for analyses the mean of these readings was used. Heart rate was measured during sitting 
blood pressure measurement. Total cholesterol and high-density lipoprotein (HDL) cho-
lesterol were measured by an automated enzymatic procedure. Diabetes mellitus type 2 was 
defined as the use of blood glucose-lowering medication at baseline or having a fasting serum 
glucose level of ≥126 mg/dL or ≥7.0 mmol/l24.
Statistical analysis
First, we investigated the association of global brain perfusion (per standard deviation 
decrease, and in tertiles) with the risk of TIA and ischemic stroke separately and combined 
(whichever came first) using Cox proportional hazards models. In model 1, we adjusted 
for age, sex and cohort. In model 2 we additionally adjusted for smoking status, systolic 
and diastolic blood pressure, blood pressure- and lipid lowering-medication, antithrombotic 
medication use, diabetes mellitus, BMI, carotid stenosis, total cholesterol, HDL and MRI-
defined lacunar infarcts. We censored for incident TIAs during follow-up in the analyses 
on ischemic stroke and for incident stroke in the analyses on TIA. We repeated the same 
analyses while not censoring for incident TIAs during follow-up in the analyses on stroke to 
compare what the effect is of brain perfusion when having a TIA before a stroke. For all Cox 
models, we tested the proportional hazard assumption using Schoenfeld residuals.
Second, we investigated potential effect modification by retinal vessel calibers, small and 
large vessel disease and finally blood pressure and heart rate on the association of brain 
perfusion with TIA and ischemic stroke. As markers of small vessel disease, we considered 
lacunar infarcts and WMH. While lacunar infarcts were dichotomized into yes versus no, 
we stratified WMH at their median (3.0 mL) and retinal calibers into tertiles. Regarding the 
association of blood pressure, lacunar infarcts and WMH with global brain perfusion we 
would like to point to the work of our colleagues in this same sample of community-dwelling 
people25, 26. As markers of large vessel disease, we considered carotid intima media thickness 
and carotid plaques. While we stratified carotid intima media thickness using a cut-off of 
1 mm, carotid plaques were dichotomized into presence and absence. As cardiovascular 
determinants we chose systolic and diastolic blood pressure and heart rate since these modify 
the diameter of blood vessels. Due to potential overfitting of the models, we only adjusted 
these analyses for age, sex and study cohort. In addition to these stratified analyses, we also 
tested for interaction on the multiplicative scale by adding interaction terms to the further 

















Third, since we defined TIA and ischemic stroke as clinical diagnoses, we assessed the 
effect of brain infarction on MRI by performing a sensitivity analysis in which we excluded 
participants with the presence of cortical infarcts on brain MRI. Finally, we excluded people 
with a carotid stenosis at baseline to preclude the effect of carotid stenosis on the association 
between global brain perfusion and TIA or ischemic stroke.
Missing data on covariables (maximum 10.3%) were imputed using 5-fold multiple 
imputation based on determinant, outcome and covariables with 20 iterations for each im-
putation. Distribution of covariables was similar in the imputed versus non-imputed dataset.
Analyses were done using RStudio version 1.0.153 (2009-2017 RStudio, Inc).
RESULTS
Of the 5289 stroke-free participants at baseline, mean age was 64.3 years, (standard devia-
tion 10.6) with 55.6% women and a mean global brain perfusion of 56.2 ml/min per 100 
mL brain (standard deviation 9.7; Table 1). During a median follow-up of 7.2 years (36,103 
person-years), 137 suffered a TIA (mean global brain perfusion 52.7) and 137 a stroke (mean 
global brain perfusion 53.3), whichever came first (incidence rate for both events: 3.8 per 1000 
person-years). Within the stroke group, 108 participants developed ischemic stroke (mean 
global brain perfusion 53.4), 20 participants developed haemorrhagic stroke and 9 participants 
developed a stroke which was not further specified. Among participants who developed TIA, 
93 participants had only focal symptoms and 44 participants had a mix of focal and non-focal 
symptoms. The majority developed a single TIA, while 22 participants had multiple attacks. 
We found that global brain perfusion at baseline associated with a higher risk of TIA 
(adjusted hazard ratio (aHR), 95% confidence interval (CI), per standard deviation decrease: 
1.30; 1.07–1.57) and not of ischemic stroke (aHR, 1.06; 95% CI, 0.87–1.30); Table 2. 
Effect estimates were higher for the risk of ischemic stroke when not censoring for previous 
TIA (aHR 1.09; 95% CI, 0.90 – 1.33). Results for the association for lower global brain 
perfusion with risk of TIA or any stroke combined are shown in Table 3. The proportional 
hazard assumption was met for all models.
After stratifying the analyses on retinal vessel diameter, lower global brain perfusion was 
associated more prominently with TIA across strata of wider arteriolar and wider venular 
retinal vessel calibers compared to strata of smaller retinal vessel calibers (aHR, 2.04, 95% 
CI, 1.18–3.50 for arterioles and aHR, 2.30, 95% CI, 1.26–4.17 for venules in the widest 
strata). For ischemic stroke, there were no differences between strata of retinal vessels (aHR, 
1.15, 95% CI, 0.64 – 2.06 for arterioles and aHR, 1.07, 95% CI, 1.72–0.79 for venules 
in the widest strata); Figure 2. However, within strata of higher diastolic blood pressure, 
participants had an 51% increased risk of developing an ischemic stroke per SD decrease 










































whereas higher diastolic blood pressure did not modify the risk of TIA (p=0.444); Figure 
2. For other markers of small and large vessel disease, no significant differences were found 
across strata for the risk of TIA or ischemic stroke (data not shown).
We found no evidence for a change in effect of brain perfusion on TIA or ischemic stroke 
after exclusion of all persons with cortical infarcts (n=66) on the MRI scan (aHR, 1.31, 95% 
CI, 1.08 – 1.58 for TIA and aHR, 1.07, 95% CI, 0.87–1.31 for ischemic stroke). Finally, 
after excluding people with carotid stenosis (n=190), also no difference was found in effect 
of brain perfusion on TIA or ischemic stroke (aHR, 1.24, 95% CI, 1.02 – 1.51 for TIA and 
aHR, 1.06, 95% CI, 0.86 – 1.31 for ischemic stroke).










Systolic blood pressure, mmHg 139.4 (21.3)
Diastolic blood pressure, mmHg 82.6 (11.0)
Use of blood-pressure lowering medication 1787 (34.1)
Serum total cholesterol, mmol/l 5.6 (1.1)
Serum high-density lipoprotein cholesterol, mmol/l 1.5 (0.4)
Use of lipid-lowering medication 1227 (23.4)
Diabetes mellitus type 2 506 (9.8)
Body mass index, kg/m2 27.5 (4.2)
Carotid stenosis 141 (2.7)
Use of antithrombotic medication 878 (16.7)
Presence of lacunar infarcts 325 (6.2)
global brain perfusion, ml/min per 100 mL brain 56.2 (9.7)
Abbreviations: N = number of participants included in study.
Data presented as mean (standard deviation) for continuous variables and number (percentages) for 
categorical variables. Data represent original data without imputed values.
Number of missing values are 546 (10.3%) for smoking, 38 (0.7%) for systolic blood pressure, 38 
(0.7%) for diastolic blood pressure, 42 (0.8%) for use of blood-pressure lowering medication, 89 
(1.7%) for serum total cholesterol, 89 (1.7%) for serum high-density lipoprotein cholesterol, 42 
(0.8%) for use of lipid-lowering medication, 114 (2.2%) for diabetes mellitus type 2, 32 (0.6%) for 
body mass index, 89 (1.7%) for carotid stenosis, 42 (0.8%) for use of antithrombotic medication and 
















































































































































































































































































































































































































































































































































































































































































Table 3. Global brain perfusion and the risk of TIA or ischemic stroke combined.
TIA or ischemic stroke
n/N Model I Model II
HR, 95% CI HR, 95% CI
global brain perfusion (per SD decrease) 246/5289 1.22, 1.06 – 1.40 1.18, 1.03 – 1.36
Tertile 1 (19 - 52) 108/1716 1.55, 1.10 – 2.17 1.49, 1.06 – 2.09
Tertile 2 (52 - 59) 84/1762 1.46, 1.03 – 2.05 1.45, 1.03 – 2.05
Tertile 3 (59 - 154) 54/1811 1 (reference) 1 (reference)
Total brain perfusion tertiles presented as lowest, middle, highest (mL/min per 100 mL).
Abbreviations: n = number of cases; N = number of persons at risk; HR = hazard ratio; CI = confidence interval.
Cox regression model I: Adjusted for sex, age and study cohort.
Cox regression model II: As model I, additionally adjusted for systolic blood pressure, diastolic blood 
pressure, blood pressure lowering medication, serum total cholesterol, serum high-density lipoprotein 
cholesterol, lipid-lowering medication, smoking, diabetes mellitus type 2, body mass index, carotid 





Figure 2. Assessment of effect measure modification between global brain perfusion per SD decrease 
and various cardiovascular determinants on the risk of TIA and ischemic stroke.
Assessing effect measure modification by stratification and interaction terms between global brain perfu-
sion per SD decrease and markers of microvascular disease (arteriolar and venular retinal diameter), and 
cardiovascular determinants (systolic and diastolic blood pressure and heart rate). P-value indicates p-
value for interaction. Abbreviations: μm = micrometer; mmHg = millimetre of mercury; b/m = beats per 
minute; n = number of cases; N = number of persons at risk, which may differ per stratified analyses de-
pending on the availability of data within the study population. Cox regression model I: Adjusted for sex, 


















In this population-based study, we observed that lower global brain perfusion was associated 
with a higher risk of TIA but not of ischemic stroke.
Previous studies have assessed the association between global brain perfusion and the risk 
of TIA or stroke among patient-based samples27, 28. A meta-analysis showed that lower brain 
perfusion is associated with increased risk of ischemic events in patients with symptomatic 
or asymptomatic carotid stenosis or occlusion7. In this meta-analysis, the odds ratio (OR) for 
stroke was 3.87 (95% CI 1.99-7.48) and for TIA and stroke combined 4.65 (95% CI 2.65-
8.14). Interestingly, we found no association of lower brain perfusion with a higher risk of 
stroke, even when censoring for previous TIA, which is in contrast with these earlier clinical 
studies. An important explanation for this may be the differences in study population. All 
of the prior findings were based on patients with carotid artery stenosis, whereas our study 
population comprised of asymptomatic community-dwelling elderly. A study population 
comprising of patients with carotid stenosis will have more comorbidity, thereby increasing 
the risk of developing a TIA or stroke.
Surprisingly, we found that the effect of lower global brain perfusion was more pro-
nounced for TIA than ischemic stroke. This implies that lower global brain perfusion is more 
likely a hemodynamic risk factor for focal transient ischemia than permanent ischemia. It is 
known that a reduction in global cerebral blood flow may give focal worsening of an existing 
neurological deficit in the brain, i.e. after TIA or stroke29. However, in people with lower 
global brain perfusion without history of TIA or stroke, probably the combination of a short 
disruption of global brain perfusion with impaired autoregulatory vasodilation leads to a 
TIA, while the presence of cardiovascular risk factors are necessary to cause a longer drop 
in global brain perfusion sufficient to lead to an ischemic stroke. An explanation could be 
that within an individual, perfusion in the cerebral arteries and larger arterioles fluctuates 
with the cardiac cycle30. Given a lower mean brain perfusion, these fluctuations resulting 
in peaks and troughs, may during a trough drop below the critical ischemia point causing 
a mild and short ischemia in the brain and consequently a TIA, but not a stroke due to a 
fast recovery from this trough in this brain perfusion cycle31. Such a harmful drop in brain 
perfusion will especially occur when cerebral autoregulation is poor for example by impaired 
myogenic mechanisms32. Indeed, in the analyses in which we stratified by retinal vessel 
diameters, we found evidence that in participants with wider retinal calibers, the association 
between global brain perfusion and TIA was stronger, but did not modify the association 
with ischemic stroke (Figure 2). Myogenic autoregulation is widely distributed over vascular 
beds including the retina and brain33. Autoregulation of the retinal vessels may thus reflect 
autoregulation in the small brain vessels. If arterioles are already fully vasodilated, they may 
not be able to widen any further in response to a drop in perfusion. Thus, our findings of 










































tory response to be an important contributing factor for TIA in the general population. 
For ischemic stroke to occur, however, it is likely that more is needed than a drop in global 
brain perfusion, namely the presence of cardiovascular risk factors. This is supported by 
our finding that participants with higher diastolic blood pressure show an increased risk 
for developing ischemic stroke per decrease of global brain perfusion. Another possibility is 
that a longer drop in global brain perfusion is needed to develop a stroke, for which a lower 
global brain perfusion in the general population is not a risk factor alone. Although TIA and 
ischemic stroke share many risk factors, specifically with regard to the role of global brain 
perfusion our study also suggests the existence of specific etiological differences. Further 
studies are needed to determine to which factors the lack of effect of global brain perfusion 
on ischemic stroke in the general population are attributable, for instance collateral circula-
tion in the brain.
Limitations of our study include the following. First, we used single global brain perfu-
sion measurements in relation to the risk of TIA or stroke. We could not perform analyses 
on repeated measurements of brain perfusion, due to small numbers at this moment. Hence, 
we could not assess fluctuations in perfusion or display changes of perfusion over a longer 
period of time. In addition, more advanced imaging techniques such as arterial spin labelling 
tend to have lower and slightly less variable absolute perfusion measures due to post process-
ing with a single value deconvolution model, compared to phase contrast imaging measures 
of perfusion, where overestimation of brain perfusion can particularly occur in aged brains 
due to usage of a max slope model34. But such a systematic deviation would not influence 
obtained relative risks and a larger variability would only lead to dilution of effect estimates. 
It is important to acknowledge that using our phase-contrast method we obtain a measure of 
blood flow in major brain arteries  which is  assumed to represent homogeneous flow in the 
entire brain under normal conditions. This directly highlights that  potentially interesting 
inhomogeneities of perfusion among different brain regions  cannot be taken into account. 
There may be compensation on other brain regions and these hypo- and hyperperfusion 
regions may average out in the carotid and basilar arterial flow.  Second, the vast majority of 
our population is of European ancestry, limiting generalizability to other ethnicities. More 
specifically, it is known that the impact of small vessel and large vessel disease on stroke is 
different between ethnic groups, where in Caucasians stroke is more often associated with 
large vessel disease (carotid stenosis) compared to small vessel disease (lacunar infarcts) in 
Africans and Asians35. Further study is needed to confirm that these findings indeed apply to 
other ethnicities and geographical regions. 
Strengths of our study are the population-based setting and the thorough assessment and 
follow-up for stroke and TIA. Another strength is the amount of stroke and TIA cases, which 
allowed us to investigate the association with brain perfusion for these outcomes separately. 

















population, although we found no effect modification of the association between brain 
perfusion and risk of ischemic stroke or TIA by sex in our study (data not shown).
In conclusion, impaired global brain perfusion increases the risk of TIA but not of 
ischemic stroke in this community-dwelling population. These findings support a role of 
global brain perfusion as a hemodynamic risk factor for developing a TIA. Further stud-
ies are warranted to unravel mechanisms in relation to compensatory mechanisms such 
as autoregulatory vasodilation and collateral circulation in the brain. Also more detailed 
regional changes that cannot be detected by phase-contrast imaging are important to take 
into consideration in order to assess the potential of global brain perfusion as a target for 
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FINDINgS IN PERSPECTIVE AND 
METHODOLOgICAL CONSIDERATIONS
Neurodegenerative and vascular pathologies interact, which is clinically shown in the fre-
quent co-occurrence of dementia and stroke. Therefore, widespread prevention measures 
of both dementia and stroke are becoming an inevitable necessity.1,2 While stroke is an 
acute disorder with the key clinical feature of sudden onset of a focal neurological deficit, 
Alzheimer’s disease (AD) is a progressive disorder, with blood-based biomarkers becom-
ing increasingly important for the diagnosis and prognosis of AD. In the past, the only 
validated biomarkers for AD were amyloid and neurofibrillary tangles.3 I aimed to uncover 
new promising biomarkers for AD in chapters 2 and 4 using a population-based approach, 
with a focus on the role of immunity and inflammation.
I studied the balance between innate versus adaptive immunity in relation to the risk of 
dementia using blood cell counts in chapter 2.1 and found that biomarkers reflecting this 
balance were associated with an increased dementia risk. I also found in chapter 4.2 that 
these immune biomarker levels differ in APOE haplotype, which remains the risk factor with 
the largest effect for developing sporadic AD. 
IMMUNITy AND DEMENTIA
To support the role of immunity in AD, I tried to triangulate our findings of chapter 2.1 by 
performing a two-sample Mendelian Randomization (MR) Study (chapter 2.2). This study 
suggests however that lifelong elevated circulating immune biomarkers are not associated 
with AD risk or hippocampal volume. So is immunity then really playing a role in AD? Let 
us have a closer look at the findings in chapter 2.1. There I find that especially an increase 
of platelets over time leads to an increased risk of all-cause dementia, even when censoring 
for stroke. These estimates are higher for Alzheimer’s disease and even higher for vascular 
dementia as outcomes. Therefore, I expected to find an association between platelets and 
Alzheimer’s disease risk using MR. There are several potential methodological explanations 
as why I did not find this association with MR as outlined in chapter 2.2. However, it 
could also be that an increase in platelets solely is not causally related to AD, and that a 
larger immunity disruption is needed to cause AD, such as an additional disruption in the 
adaptive immune system. Indeed, I find in chapter 2.2 that CD4 cell counts, important 
players of the adaptive immune system, show the strongest suggestive association with AD. 
This notion is supported by the findings in chapter 2.1 where I show that a doubling in 
PLR, reflecting an imbalance in platelets and lymphocytes, is also significantly associated 
with AD and that a doubling of lymphocytes displays a protective effect for AD especially 
















Several mechanisms could explain these associations. First, the classical vision on the 
innate immune system that it is merely the immediate mediator of host resistance and 
inflammation is switching into the notion that it also holds a memory similar to the adap-
tive immune system.4 Although primarily a protective response by increasing resistance to 
reinfection, under predisposing conditions innate memory may endorse human diseases 
characterized by excessive inflammation.5 Moreover, emerging evidence suggests that mi-
croglia are able to sense inflammatory signaling molecules originating outside the brain.4,6 
Thus, circulating innate immune myeloid cells could participate in the long-lasting dysregu-
lated AD immune response by acting either directly when recruited to brain, or indirectly 
through the release of soluble mediators.4,7 Second, regarding adaptive immunity, a study 
found that genetic ablation of peripheral immune cell populations significantly accelerates 
amyloid pathogenesis, worsens neuroinflammation, and alters microglial activation state.8 
They show that loss of IgG-producing B cells impairs microglial phagocytosis, thereby 
exacerbating amyloid deposition. Replacement of IgGs via direct injection or bone marrow 
transplantation reversed these effects and reduced Aβ pathology. Together, these results sup-
port the importance of the adaptive immune system and its interactions with microglia in 
the pathogenesis of AD.
But what triggers this imbalance in innate and adaptive immunity? A proposed new 
model suggests that infections of the brain, and infection elsewhere in the body that activates 
the immune system in the brain could be a potential trigger.9 Particularly agents capable of 
producing an ineradicable infection, like herpesviruses, theoretically could trigger chronic 
neuroinflammation. In chapter 2.4 I therefore linked herpes simplex virus type 1 (HSV-1) 
to AD, but found only an association between HSV-1 and risk of dementia within younger 
individuals. Several other microbes also have been linked to AD, including Helicobacter 
pylori (H. pylori), which we also investigated (chapter 2.3). Similar to HSV-1, I found no 
association between H. pylori and AD risk in the total population, however risk estimates 
were higher in older participants, possibly due to exposure to more virulent strains in ear-
lier years. Despite the null-findings considering infection and AD within the Rotterdam 
Study population, it is still plausible that infection leads to the formation of β-amyloid. 
For some investigators have suggested the “antimicrobial protection hypothesis”, arguing 
that β-amyloid is capable of functioning as a natural antimicrobial peptide that is effective 
against not only viruses but also bacteria and fungi.10 However, these smaller, soluble forms 
(oligomers) of β-amyloid are not only potential antimicrobials, they are also still neurotoxic. 
These neurotoxic effects typically become apparent only after age 60 years, potentially ex-
plaining its conservation throughout evolution for its beneficial effects earlier in life, at times 
where life expectancy was shorter and infectious diseases were important hazards.9 
To assess causality of immune mechanisms with AD, several study designs were consid-
ered in chapter 2, with each having its own strengths and limitations. In chapters 2.3 and 
















Limitations include reverse causation and residual confounding. In contrast to using a Cox 
regression model, the studies described in chapters 2.1 and 3.1 again used the prospective 
cohort design but now using repeated measurements for the determinant using joint models. 
This statistical model is in particular useful here since the internal covariates (blood cell 
counts) are intermittently measured (biomarker levels are only known for the specific time 
points the participant visited the study center), and because they also contain measurement 
error, their complete path up to any time point  t  is not fully observed.11 An important 
strength of the joint model is thus that we can successfully reconstruct the complete lon-
gitudinal history by postulating a suitable mixed-effects model to describe subject-specific 
time evolutions. The mixed model then accounts for the measurement error problem by 
postulating that the observed level of the blood cell count measurements equals the true level 
of the blood cell count measurements plus a random error term. However, since the survival 
function S depends on the whole history of the true marker levels (M), it is important to 
obtain a good estimate of M for an accurate estimation of S.12 Thus, careful examination 
of data is important since effects could be for instance non-linear, as in chapters 5.2 and 
4.3. Finally, we performed an MR study (chapter 2.2), a design in which genetic variants 
are used as ‘instrumental variables’ for a putative causal factor, theoretically minimizing the 
possible influence of confounding or reverse causality. If we seek to assess whether there 
is a causal effect of trait A (e.g. immune cells) on outcome B (AD), but not to provide an 
estimate of a causal effect parameter, then only the three instrumental variable assumptions 
listed in Figure 1 are required. To estimate a causal effect parameter, further assumptions are 
required, namely 1) linearity of the risk factor-outcome association, and 2) the stable unit 
treatment value assumption (the value of the outcome for each individual depends on the 
value of the risk factor, and not on the mechanism by which the risk factor was intervened 
on). MR studies are often compared to randomized controlled trials (RCTs), but the causal 
effect estimate from an MR study should not be interpreted literally as the expected outcome 
of an intervention on the risk factor of interest. In almost all cases, we can only make infer-
ences on the direction of the effect from an MR study rather than estimating an effect size.13
 
 
Figure 1. Diagram illustrating causal relationships between genetic variants G, putative causal trait 
(risk factor) A, putative effect trait (outcome) B, and confounders U necessary for instrumental vari-
able assumptions to be satisfied.13 The three instrumental variable assumptions are: 1) The set of ge-
netic variants is associated with risk factor A; 2) Each genetic variant is independent of confounders 
U of the association between A and B; 3) If the risk factors were kept constant, intervention on the 

















Besides the role of immunity in dementia, immunity disruption also seems to play a role 
in stroke development (chapter 3). Using a similar approach as in chapter 2.1, I studied 
how immune biomarkers relate to ASCVD risk since stroke shares many risk factors with 
other cardiovascular diseases although their relative importance varies (chapter 3.1).14 In 
contrast to chapter 2.1, where an increase of platelets leads to the highest dementia risk, 
I found in chapter 3.1 that granulocytes are the most important immune biomarkers for 
ASCVD risk, although platelets were still borderline significantly associated with a higher 
stroke risk, especially ischemic stroke. These findings suggest that immunity is indeed an 
overlapping mechanism between dementia and stroke, and that specifically platelets could 
form the bridge between the two diseases.15 Not only do platelets play a role in vessel oc-
clusion leading to stroke, they are also important players in inflammation.16 Moreover, they 
express the amyloid precursor protein (APP) and display the complete enzymatic machinery 
to process APP proteins into β-amyloid as mentioned earlier.17
In addition to the role of platelets, in chapter 3.1 I furthermore show that subclinical 
atherosclerosis as measured by carotid arterial calcifications potentially mediates the role of 
granulocytes in stroke risk. This suggests immunity-driven atherosclerosis as another impor-
tant common mechanism between dementia and stroke.18 Indeed, allelic variants in com-
mon genes including APOE predispose to both atherosclerosis and dementia.18 Moreover, 
I found that innate immunity was linked to larger plaques, whilst the adaptive immunity 
(lymphocytes) related to smaller plaques and a lower frequency of intraplaque hemorrhage 
(chapter 3.2). I found similar protective effects of lymphocytes on all-cause dementia risk 
in chapter 2.1. Taken together, these results suggest that an imbalance in innate and adap-
tive immunity does not only play a role in dementia risk, but also in stroke risk through 
increased vulnerability to carotid atherosclerosis rupture.
Several methodological issues warrant consideration regarding the findings in this 
chapter. First, the mediation analysis presented in chapter 3.1 presents large effect sizes, 
but they are not statistically significant. The assessed association between immunity and 
calcification is cross-sectional, is prone to measurement error and subject to reverse causality. 
I similarly used a cross-sectional design in chapter 3.2, highlighting that causality cannot 
be inferred solely based on these results. Second, multiple testing can be an issue because 
the more inferences are made, the more likely erroneous inferences are to occur. Several 
statistical techniques have been developed to deal with this issue, which generally require a 
stricter significance threshold for individual comparisons.19 An example is the usage of the 
false discovery rate (FDR) as I have done in chapter 2.2 when applying MR on multiple 
exposures or the usage of a Bonferroni correction as I have done in chapter 4.2.19 However, 
in chapters 3.1 and 3.2 I similarly perform multiple tests, where I associate multiple im-
















testing. This is because reducing the type I error for null associations also increases the type II 
error for those associations that are not null. Therefore, some researchers prefer not making 
adjustments for multiple comparisons because it will lead to fewer errors of interpretation 
when the data under evaluation are not random numbers but actual observations on nature, 
thereby avoiding the possibility of missing important findings.20
IMMUNITy: THE CONNECTION BETWEEN 
DEMENTIA AND STROKE
In chapter 4.1 I have investigated how plasma β-amyloid and NfL relate to the risk of stroke 
within the Rotterdam Study and I found that higher levels of β-amyloid 40 were related to 
higher stroke risk in APOE ε4 carriers and within younger participants. Furthermore, higher 
levels of plasma NfL at baseline were associated with a higher risk of incident stroke in the 
total population. Interestingly, in chapter 4.2, I found that β-amyloid 40 and NfL were 
elevated in participants with higher immune biomarker levels, especially within APOE allele 
4 carriers, suggesting that immunity disruption may be the trigger of β-amyloid 40 deposi-
tion in the vessel wall. In contrast to β-amyloid, blood NfL concentrations are non-specific, 
reflecting only underlying neuronal or axonal damage. This further underscores an early role 
of the immune system in neuronal damage, potentially inducing dementia and stroke.
An important methodological consideration is the validity of immune biomarker mea-
surements in this thesis. The question is whether blood cell counts truly reflect the balance 
between innate versus adaptive immunity. Indeed, the immune system is extremely complex, 
and consists of many more components than blood cells. For instance, glial cells, more 
specifically microglia, are important players as immune cells of the central nervous system. 
However, there is not a paradigm for studying microglia within the Rotterdam Study. 
Therefore, I provide suggestions as to which biomarkers could additionally be measured to 
have a better reflection of the balance between innate and adaptive immunity in the Future 
Research section of the Discussion.
Another important consideration is the relative relevance of the findings in this thesis. For 
instance, in chapter 4.2 the innate immunity phenotypes were related to higher Aβ, most 
strongly with a doubling in GLR leading to a 1.9% higher Aβ42 (95% confidence interval 
[95% CI] 0.4 to 3.3%) and 3.2% higher Aβ40 (95% CI 2.0 to 4.3%). These estimates, 
although statistically significant, are not very high. A valid question is therefore to what 
extent the immune system contributes to the onset of AD, or stroke, compared to other risk 
factors. The failures of several dementia prevention trials illustrates that identifying strong 
risk factors as potential targets for intervention is a field-wide problem. These trials have 
mainly focussed on reducing Aβ. Assuming the innate immune system and consequently the 
















prevent or treat AD. Regulating the more downstream effects of Aβ, however, could be more 
feasible considering the mere detrimental consequences of tau pathogenesis leading to tau-
mediated neurodegeneration.21 Thus, although effect sizes are generally small in this thesis, 
they do provide directions for further research, coming closer to successful interventions. 
At the end of this Findings in perspective and methodological considerations section, I 
therefore propose an updated model for AD pathogenesis, adding immunity to the other 
risk factors.
BRAIN PATHOLOgy
Another changing biomarker is tau, which is also assessed using blood-based assays within 
the Rotterdam Study. Total-tau has been previously assessed in association with dementia 
risk within the Rotterdam Study, where a J-shaped association was found. Similarly, in 
chapter 4.1 we show a J-shaped association between this same biomarker and stroke risk 
within the Rotterdam Study. Interestingly, I found within chapter 4.2 only an association 
between the platelet-to-lymphocyte ratio (PLR) and lower plasma total-tau levels within the 
same study population. This suggests a less clear role of the immune system in relation to 
tau, and suggests that tau changes are probably a consequence of β-amyloid abnormalities 
rather than being directly affected by the immune system. Since the PLR is only associated 
with higher β-amyloid and NfL within APOE allele 4 carriers, whereas these biomarkers are 
not altered in participants homozygous for APOE allele 3 and even lower within APOE allele 
2 carriers, it could be that a lower plasma total-tau indeed reflects tau abnormalities within 
the brain when PLR is elevated. The reason that I only find a relation between the PLR and 
plasma total-tau, and not between the other immune biomarkers, could be because platelets 
are the primary source of β-amyloid in human blood (~90%)22, and this secreted peptide is 
similar to those found in the senile plaques of Alzheimer’s patients.23
Cognitive impairment is another important biomarker in the progression towards AD. 
Cognitive functions are mediated by specialized areas of neocortex distributed across the 
cerebral hemisphere in an orderly arrangement.24 The cortex of each cerebral hemisphere is a 
continuous sheet of gray matter, which can be damaged by toxic peptides such as β-amyloid 
or by loss of neuronal integrity by the phosphorylation of tau. These aging-related processes 
can lead to cognitive impairment. Telomere length is an important biomarker for such 
aging-related processes, because telomeres shorten not only with each cell division, but also 
with aging and oxidative stress, both important factors in cognitive function.25,26 As such, it 
has been found that community resident elders with longer telomere length exhibited less 
decline in global cognitive functioning over 7 years relative to elders with short or medium 
telomere length.25 In contrast, another study has found that longer telomeres related to worse 
















findings, I found in chapter 4.3 that telomere length has a U-shaped association with AD 
risk, especially within APOE allele 4 carriers. However, telomere length seems to be related 
differently to stroke risk. I performed a preliminary analysis within the Rotterdam Study 
showing that telomere length is linearly associated with stroke, such that lower telomere 
length increases stroke risk. It could thus be that shorter telomere length reflects vascular 
pathology, while longer telomere length reflects more the AD-related brain pathology, the 
latter either through the upregulation of telomerase27, or survival bias since shorter telomere 
length also increases risk of all-cause mortality (Figure 2).
An important methodological issue needs to be taken into consideration, which is selec-
tion bias. This form of bias can be an issue in cohort studies, where informative censoring 
often takes place.28 Informative censoring occurs when participants are lost to follow-up 
due to reasons related to the study. Figure 2b shows a scenario that is possible in cohort 
studies, where an unmeasured cause of death and dementia can be present. When I would 
only include survivors in the analyses, this would lead to a biased estimate for the telomere 
length – dementia relationship. However, when I would also include the non-survivors or 
a.  
b.  
Figure 2a. Effect of telomere length (E) on survival (D1) and dementia (D2). Suppose the effect of 
exposure (longer telomere length) on D1 is protective. Then the hazard at time 2 is the probability of 
dementia at time 2 among those who survived past time 1, i.e. D1=0 (square around D1 indicates this 
conditioning). The lack of an arrow from E to D2 indicates that, although the exposure E has a direct 
protective effect (decreases the risk of death) at time 1, it has no direct effect on dementia at time 2. 
Exposure E would only have a protective effect on dementia at time 2 when there would be a direct 
arrow from E to D2 as now drawn. Figure 2b. In the presence of an unmeasured shared cause of death 
and dementia, then the hazard ratio at time 2 is a biased estimate of the direct effect of exposure on 
dementia at time 2 from E to D2 through D1 and U. Modified from Hernán, Miguel A.; Hernández-
















‘censored’ participants in the analyses by using their drop-out or mortality event as a study 
end-point (i.e. not conditioning on D1), then the issue of informed censoring would be 
solved by closing the non-causal path from E to D2 through D1 and U as shown in Figure 2. 
I have correctly done so in chapter 4.3.
BRAIN HEMODyNAMICS
Changes in brain vasculature are one of the earliest changing biomarkers leading to AD 
progression. Indeed, a multifactorial data-driven analysis using the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) data suggested that vascular dysregulation is an early step 
that leads to late-onset AD.29 These data are supported by a study within the Rotterdam 
cohort showing that low global brain perfusion precedes cognitive impairment.30 Since a 
large proportion of dementias can be prevented by preventing stroke1, it is important to 
maximize our understanding of risk factors for stroke, moving beyond atherosclerosis and 
thromboembolism. While a reduced global brain perfusion is a risk factor for transient 
ischemic attack (TIA) in the general population (chapter 5.1), results in chapter 5.1 also 
suggest that a reduced brain perfusion is only a risk factor for ischemic stroke within indi-
viduals with elevated diastolic blood pressure. These findings can be translated to a causal 
pie (Figure 3), where a reduction in global brain perfusion is sufficient to cause a TIA in 
middle- and older aged individuals, while an extra slice (i.e. component cause) is needed for 






Figure 3. A TIA and  stroke consist of a variety of overlapping component causes. Component causes 
A-C add up to sufficient cause for TIA and component causes A-D add up to sufficient cause for 
stroke. In this example component A may consist of a variety of cardiovascular risk factors, and com-
ponent B of genetic risk. The findings from our study suggest that the addition of component cause 
C, in this case lowered brain perfusion, completes the causal pie for a TIA (i.e. leads to a TIA) whereas 
















Moreover, since a reduced global brain perfusion seems to be a shared risk factor of 
dementia and stroke, it is of utmost importance to identify individuals that are at increased 
hemodynamic risk for developing these brain diseases. In chapter 5.2 I showed that thyroid 
function acts as a promising determinant to intervene on brain perfusion. 
The still hypothetical nature of brain perfusion mechanisms in AD and stroke highlights 
the impact of several methodological issues that slow the understanding of brain hemo-
dynamic deficits in these brain diseases. First and foremost, the assessment of global brain 
perfusion using phase-contrast imaging within this population-based setting has limitations 
in comparison to other methodologies such as arterial spin labelling31 or radioactive water 
perfusion measurements using PET.32 There may be meaningful inhomogeneities of perfu-
sion among brain regions that is not reflected by the average perfusion of the carotid and 
basilar arteries as measured by phase-contrast imaging. The lack of association between 
global brain perfusion and ischemic stroke thus remains to be confirmed. Second, I used 
retinal vessels as proxy for the brain microvasculature. If this can be extrapolated to the entire 
brain microvasculature remains an open question in the field, but over the years, it has been 
thought that these structures provide a direct measure for the vascular and neuronal status of 
the brain.33 Reduced blood flow following Poiseuille’s equation can be produced by altering 
vessel diameter, reducing viscosity and altering vessel length. I found an inverted U-shaped 
association between free thyroxine and arteriolar retinal vessel diameter, similar to global 
brain perfusion in chapter 5.2. Therefore, in the context of brain perfusion, I used retinal 
vessel diameter in this chapter as additional parameter of brain hemodynamics, although the 
effect is only within the retina and static, whereas with true autoregulation vessel diameter 
is naturally dynamic. Third, although most ischaemic stroke is due to embolism, there are 
also other major causes of stroke such as small vessel disease or other arterial diseases.14 
Unfortunately I was not able to further study ischemic stroke subtypes by stroke etiology 
due to the heterogeneous assessment of etiology within hospitals and due to a lack of power 
of stroke etiological subtypes.
Taking all these findings including their methodological considerations together, I 
propose a hypothetical updated Jack model of AD biomarkers to include the role of the 
immune system in addition to the more established roles of brain vasculature, amyloid PET, 
CSF β-amyloid and tau in AD (Figure 4). This model proposes that immunity is one of 
the changing biomarkers that leads to AD progression, but its exact position remains to be 
clarified. In the following sections, I will discuss how future research could shed more light 

















To increase our knowledge on the mechanisms underlying dementia and stroke, the most 
obvious approach is to fi rst reveal the order in which the diff erent components of brain 
pathology occur, and in particular when infl ammation and immunity changes occur. A 
statistical technique that can be used for this purpose is an event-based model (EBM), 
which is a class of interpretable disease progression models that estimate the timeline of 
neuropathologic change during AD progression.34,35 A specifi c EBM technique, namely 
discriminative event based model (DEBM), allows inferring the order in which biomarkers 
for a disease become abnormal based on cross-sectional data, taking into account disease 
heterogeneity to a larger extent as compared to existing EBM methods.35 But in order to use 
this model, it is important to test the assumptions of the DEBM. I propose a method for 
doing so in Box 1. I tested the assumption of a constant increase or decrease of markers over 
time by constructing a linear mixed model with random slope and intercept and observing 
if the slopes of the prevalent and incident AD subjects go up or remain constant (Box 1). 
As an example, I show that the assumptions are only met for innate immunity markers. 
Nevertheless, DEBM provides a useful tool for estimating ordering of biomarker changes 
provided that the assumptions are met. For this, using more specifi c adaptive immunity 
markers that show a constant increase or decrease over time is crucial.
 
 
Figure 4. Hypothetical updated Jack model of Alzheimer’s disease biomarkers to include the role 
of immunity. Hypothetical model of AD biomarker changes illustrating that immune changes may 
contribute to the initial stages of AD pathophysiological progression from NCI to MCI to AD. Abbre-
viations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; NCI, no cognitive impairment. 
Modifi ed from Hachinski V, Einhaupl K, Ganten D, et al. Special topic section: linkages among cerebrovas-
cular, cardiovascular, and cognitive disorders: Preventing dementia by preventing stroke: Th e Berlin Mani-
















Within this thesis, I have mainly used easily obtainable measures of immunity, which 
allow for repeated measurements in large samples. However, these measures are fairly gross 
and simplify the complexity of the immune system. This is especially the case for the adap-
tive immune system, for which I used lymphocyte count as proxy measure. But lymphocytes 
include natural killer cells, T cells, and B cells, and thus form a heterogeneous group with 
distinct functions.37 Of these lymphocyte subsets, T cells seem the most promising target for 
AD as well as atherosclerosis so far.38,39 T cells are involved in cell-mediated immunity, with 
T helper cells producing cytokines that direct the immune response, while cytotoxic T cells 
produce toxic granules.40 A first step thus would be to measure lymphocyte subsets, with 
a special focus on T cells and further T cell subtyping. More specifically, in this thesis I 
suggest in chapter 4.2 that in particular CD4 T cells are worthwhile exploring further. A 





Box 1. Testing the model assumptions of a discriminative event based model.
Conflicting data on the ordering of a disruption in the innate and adaptive immune system in amy-
loid metabolism have been reported, and remains limited to experimental studies.36 I aimed to use a 
novel method for estimating central ordering of events, using the discriminative event-based model 
applied within the Rotterdam Study.35 As markers of the innate immunity I used platelet counts and 
granulocyte counts and for the adaptive immunity we used lymphocyte counts. In order to use this 
model, the assumption of a constant increase or decrease of immune markers over time must be met. 
I tested this assumption by building a linear mixed model with non-AD subjects only to predict the 
effect of age and sex for granulocyte counts (1). Next, I found the residuals in demented subjects by 
running a model where I substracted the predicted granulocyte counts from model 1 from the raw 
granulocyte counts. (2). As a last step I would fit the residuals in a linear mixed model with time to 
dementia as the exposure variable (3). Results for innate and adaptive immunity markers are shown 
















in turn affects neuronal synapse maturation41, and another study showed that plaques from 
symptomatic patients (recent stroke or transient ischemic attack) were characterized by a 
distinct subset of CD4+ T cells.39 The old-fashioned notion that the brain is cut off from the 
peripheral immune system by the blood-brain-barrier (immune privileged) is being recon-
sidered to the idea that there is truly immune surveillance of the brain.42 There is promising 
evidence that temporarily reducing immunosuppressive mechanisms helps release effector T 
cell activity43, and at the same time, maintains a sufficient number of anti-inflammatory cells 
in the periphery.44 This allows trafficking of inflammation-resolving cells to the sites of brain 
pathology, in which they play an essential role.45
As mentioned earlier, also the measures used for the innate immune system could be 
expanded. For instance, translocator protein 18 kDa is a marker of activated glial cell re-
sponse and could be measured using positron emission tomography in a population-based 
setting.46-49 Measuring markers for glial cells that could be detected by imaging therefore 
may serve as a solution for measuring innate immunity in the CNS. 
In addition to targeting T cells and glial cells, the antimicrobial hypothesis of AD poses 
that long-lasting infections lead to β-amyloid accumulation, so another approach is to target 
infections or pathogens to prevent chronic neuroinflammation. Another rationale for this is 
that there has been a decline in dementia incidence across Western high-income countries.50 
This decline could partly be explained by favorable trends in vascular risk factors. Concomi-
tantly, there has been a decline of mortality by infectious diseases during the 20th century, 
which could be attributed to improved socio-economic indicators, or use of antibiotics.51 
There has been one randomized controlled trial to study the effect of antibiotics on the 
progressive decline of cognitive function in patients with AD. Combination antimicrobial 
therapy with doxycycline and rifampicin significantly reduced cognitive worsening after 6 
months but not after 12 months.52 Future researchers could investigate the hypothesis that 
certain antibiotics have a protective effect on the development of dementia.
To further reveal the order in which the different components of brain pathology occur, 
and in particular the position of inflammation and immunity changes, is by studying the 
relation between brain circulation and the immune system. Within the Rotterdam Study, 
there are ongoing efforts to add arterial spin labelling as a noninvasive measurement of 
regional cerebral blood flow (CBF).53 The possibility of taking these regional variations in 
CBF into account will allow for studying CBF physiology in relation to immunity and 
inflammation within a population-based setting. In addition, it facilitates disentangling the 
effect of regional CBF on brain outcomes and the determinants that cause regional CBF 
changes.54
Eventually, the goal is to prevent dementia and stroke by understanding pathophysiol-
ogy and determining clinical relevance of newly discovered pathways, such as the role of 
















stroke researchers, epidemiologists, neuroscientists, infection & immunity experts and 
geneticists. This is crucial for facilitating translational research.
CONCLUSION
In this thesis, I have shown that immunity and inflammation play a crucial role in dementia 
and stroke. Furthermore, I describe how future research can build upon this work. The 
prevention of dementia and stroke can be boosted by enhancing our understanding of the 
order in which different components of brain pathology and hemodynamic changes occur. 
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The etiological similarity between dementia and stroke was already suggested in Alois 
Alzheimer’s first major article on dementia, describing that those cases of atrophy without 
recognizable infarcts were due to microscopic infarcts. The similarity between dementia 
and stroke has been further confirmed by the evidence of substantial drops of dementia 
in high-income countries where stroke incidence and mortality has declined substantially. 
But what the exact underlying mechanism is of these two diseases is yet unknown. In this 
thesis, I examine immunity and inflammation as potential common mechanisms connecting 
dementia and stroke.
In the first part of this thesis, I demonstrate the role of an imbalance in the immune sys-
tem towards innate immunity in the pathogenesis of dementia by showing that an increase 
of components of innate immunity increase dementia risk and an increase of components of 
adaptive immunity is protective for dementia risk in the general population (chapter 2.1). 
In chapter 2.2 I did not find evidence to support associations of circulating biomarkers of 
immunity and inflammation with Alzheimer’s disease (AD) and hippocampal volume, but 
CD4 count, an important player of adaptive immunity, showed the strongest suggestive 
association with AD. In chapters 2.3 and 2.4 I found no evidence of Helicobacter pylori or 
herpes simplex type 1 infections to be associated with dementia risk in the general popula-
tion.
Focussing next on the role of immunity and inflammation in stroke, I show in chapter 
3.1 that an increased granulocyte count reflecting innate immunity was associated with a 
higher risk of atherosclerotic cardiovascular disease (ASCVD) in the general population. 
Moreover, higher levels of granulocytes were associated with larger volumes of arterial 
calcification, with a mediation analysis suggesting that arterial calcifications may explain 
a proportion of the link between granulocytes and ASCVD. A causal relationship is sup-
ported by effects of granulocytes and other immune markers on plaque thickness and plaque 
components in chapter 3.2, suggesting that an imbalance in innate and adaptive immunity 
may play a role in the vulnerability of the carotid atherosclerotic plaque.
Chapter 4.1 further connects dementia and stroke by finding that participants with 
higher total-tau and neurofilament light chain at baseline as markers of AD-related brain 
pathology had a higher risk of stroke. In addition, higher levels of plasma amyloid-β (Aβ) 
40 were associated with an increased stroke risk in APOE-ε4 carriers only. Supporting the 
role of accumulating brain pathology from an immunity and inflammation perspective in 
the etiology of dementia and stroke, I found in chapter 4.2 that higher levels of immunity 
markers were associated with higher Aβ in plasma. I further show that participants with 
a higher genetic predisposition to AD had higher immunity markers, where these effects 
were mainly driven by APOE-ε4. In contrast to the more traditional markers of AD-related 




















chapter 4.3, where I found a U-shaped association between telomere length and risk of AD 
in the general population and even more strongly so in APOE-ε4 carriers.
In chapter 5, I shift focus to brain hemodynamics. I found in chapter 5.1 that lower 
global brain perfusion was associated with a higher risk of transient ischemic attack, but 
not with the risk of ischemic stroke, in the general population. This association may be 
modified by wider arteriolar and venular retinal calibers for transient ischemic attack and 
elevated blood pressure for ischemic stroke. To identify a potentially amendable determinant 
to intervene on global brain perfusion, we studied thyroid function in chapter 5.2 and we 
found that global brain perfusion was lower in middle-aged and elderly with lower as well as 
higher FT4 levels. Furthermore, arteriolar retinal vessel diameters were narrower in elderly 
with higher TSH and TPO levels.
To conclude, I discuss in chapter 6 these main findings where I have shown that im-
munity and inflammation play a crucial role in dementia and stroke in light of published 
literature, and provide methodological considerations. Furthermore, I describe how future 
research can build upon this work by proposing that the prevention of dementia and stroke 
can be boosted by enhancing our understanding of the order in which different components 
of brain pathology and hemodynamic changes occur. Also the position of immunity and 










De etiologische gelijkenis tussen dementie en hersenberoertes kwam al naar voren in Al-
ois Alzheimer’s eerste grote artikel over dementie, waarin hij beschrijft dat patiënten met 
hersenatrofie zonder duidelijke infarcten waarschijnlijk microscopische infarcten hebben. 
De gelijkenis tussen dementie en hersenberoertes kwam verder naar voren bij de zichtbare 
afname van dementie in welvarende landen waar de incidentie van hersenberoertes en mor-
taliteit substantieel is afgenomen. Wat echter het exacte onderliggende mechanisme is van 
deze twee fascinerende aandoeningen is nog onduidelijk. In dit proefschrift beschouw ik het 
immuunsysteem en inflammatie als potentiële overlappende mechanismen die dementie en 
hersenberoertes kunnen verbinden.
In het eerste deel van dit proefschrift demonstreer ik de rol van een disbalans in het 
immuunsysteem richting het aangeboren immuunsysteem in de pathogenese van dementie 
door te laten zien dat een toename van componenten van het aangeboren immuunsysteem 
het risico op dementie verhogen terwijl een toename van componenten van het aangel-
eerde immuunsysteem beschermend is tegen het krijgen van dementie (hoofdstuk 2.1). In 
hoofdstuk 2.2 heb ik geen bewijs gevonden die het verband tussen het immuunsysteem 
en Alzheimer ondersteunen, maar CD4 cellen, belangrijke spelers van het aangeleerde im-
muunsysteem, laten de sterkste suggestieve associatie zien met Alzheimer. Kijkend naar de 
rol van infectieziekten in het ontstaan van dementie, vond ik in hoofdstukken 2.3 en 2.4 
geen associatie tussen de maagbacterie Helicobacter pylori of het virus herpes simplex type 1 
en dementie in de normale bevolking.
De focus verleggend naar de rol van het immuunsysteem en inflammatie in hersen-
beroertes, laat ik in hoofdstuk 3.1 zien dat een toename van granulocyten, die het aangebo-
ren immuunsysteem weerspiegelen, geassocieerd is met een hoger risico op het krijgen van 
cardiovasculaire aandoeningen. Via een mediatie analyse laat ik zien dat dit verband mogelijk 
voor een groot deel door de vorming van aderverkalking wordt veroorzaakt. Een causaal 
verband wordt ondersteund door te kijken naar de effecten van onder andere granulocyten 
op de dikte van aderverkalking en losse componenten van aderverkalking in hoofdstuk 3.2. 
Deze resultaten suggereren dat een disbalans in het aangeboren en aangeleerde immuunsys-
teem een rol zouden kunnen spelen in de kwetsbaarheid van aderverkalking om te scheuren.
Hoofdstuk 4.1 legt verder de verbinding tussen dementie en hersenberoertes door de 
bevinding dat mensen met meer total-tau en neurofilament light chain (biomarkers van 
Alzheimer-gerelateerde hersenpathologie) een hoger risico hebben op het ontwikkelen van 
hersenberoertes. Daarnaast zijn hogere spiegels van plasma amyloid-β (Aβ) 40 geassocieerd 
met een verhoogd risico op het krijgen van hersenberoertes in APOE-ε4 dragers. Kijkend 
vanuit het perspectief van het immuunsysteem, heb ik verder in hoofdstuk 4.2 gevonden 
dat hogere immuun- en inflammatiewaardes geassocieerd zijn met hogere Aβ in plasma. 




















ook verhoogde immuun- en inflammatiewaardes. Deze effecten worden vooral gedreven 
door APOE-ε4. In tegenstelling tot de meer traditionele markers van Alzheimer-gerelateerde 
breinpathologie heb ik ook telomeerlengte bestudeerd als een potentiële biomarker in 
hoofdstuk 4.3, waarbij ik heb gevonden dat er een U-vormige associatie is tussen telomeer-
lengte en het risico op het ontwikkelen van Alzheimer, waarbij deze associatie nog sterker is 
in APOE-ε4 dragers.
In hoofdstuk 5 verleg ik de aandacht naar breinhemodynamica. Ik heb in hoofdstuk 
5.1 gevonden dat een lagere algehele breinperfusie geassocieerd is met een hoger risico op het 
krijgen van een transient ischemic attack, ofwel een TIA, maar dat het risico niet verhoogd 
is op het krijgen van een ischemische hersenberoerte. Deze associatie werd gemodificeerd 
door wijdere retinale arteriolen en venulen voor het krijgen van een TIA en door een ho-
gere bloeddruk voor het krijgen van een ischemische hersenberoerte. Om een potentiële 
modificeerbare determinant te vinden om algehele breinperfusie te beïnvloeden, hebben 
we gekeken naar schildklierfunctie in hoofdstuk 5.2 en heb ik gevonden dat de algehele 
breinperfusie lager was in ouderen met lagere alsook hogere FT4 spiegels. Verder waren de 
retinale arteriolen ook smaller in ouderen met hogere TSH en TPO spiegels.
Tot slot bediscussieer ik in hoofdstuk 6 de bevindingen waarin ik laat zien dat het 
immuunsysteem en inflammatie een cruciale rol spelen in de ontwikkeling van dementie 
en hersenberoertes met inachtneming van de gepubliceerde literatuur en bespreek ik 
methodologische overwegingen en factoren. Ik beschrijf verder hoe toekomstig onderzoek 
kan bouwen op dit werk door voor te stellen dat de preventie van dementie en hersen-
beroertes een boost kan krijgen door te bestuderen wat de volgorde is van het veranderen 
van verschillende componenten van brein pathologie en hemodynamica. Wat de positie is 
van immuunsysteem- en inflammatieveranderingen in deze cascade is een cruciale vraag om 
door toekomstige onderzoekers beantwoord te worden.
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5th European Stroke Organisation Conference (ESOC). Milan, 
Italy
2019 2.0




CoSTREAM consortium meeting. Cambridge, UK 2017 1.0
Institute for Stroke and Dementia Research (ISD) - LMU 
Klinikum, Ludwig-Maximilians-University in Munich, germany
2020
2. Teaching Year ECTS
Teaching assistance
SPSS and/or R computer practicals of the one-week 
Biostatistical Methods I 2019
0.5

















Master’s project: Vitamin D Status and Risk of Stroke 2019 1.5
Master’s project: HSV1 and risk of dementia 2020 1.5
3. Other activities
Peer-review 2018-2020 2.5
Scan appraisal for incidental findings in population imaging 2018-2020 2.0
Stroke data collection of the Rotterdam Study 2017-2020 4.0




Physician at ERgO centre performing exit interview 2017-2020 3.0
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